

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

How, in what contexts, and why do quality dashboards lead to improvements in care quality? Protocol for a realist feasibility evaluation

Journal:	BMJ Open
Manuscript ID	bmjopen-2019-033208
Article Type:	Protocol
Date Submitted by the Author:	25-Jul-2019
Complete List of Authors:	Randell, Rebecca; University of Leeds, School of Healthcare Alvarado, Natasha; University of Leeds, School of Healthcare McVey, Lynn; University of Leeds, School of Healthcare Greenhalgh, Joanne; University of Leeds, Sociology and Social Policy West, Robert; University of Leeds, Leeds Institute of Health Sciences Farrin, Amanda; University of Leeds, Clinical Trials Research Unit Gale, Chris; University of Leeds, Leeds Institute if Genetics, Health and Therapeutics Keen, Justin; University of Leeds, Leeds Institute of Health Sciences Elshehaly, Mai; University of Leeds, School of Computing Ruddle, Roy; University of Leeds, School of Computing Lake, Julia; Leeds Teaching Hospitals NHS Trust Mamas, Mamas; Royal Stoke University Hospital Feltbower, Richard; University of Leeds, Dowding, Dawn; University of Manchester
Keywords:	AUDIT, Health informatics < BIOTECHNOLOGY & BIOINFORMATICS, Clinical audit < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, QUALITATIVE RESEARCH

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez on

Title: How, in what contexts, and why do quality dashboards lead to improvements in care quality? Protocol for a realist feasibility evaluation Authors Corresponding author: Rebecca Randell, School of Healthcare, University of Leeds, Leeds, UK, r.randell@leeds.ac.uk Natasha Alvarado, of Healthcare, University of Leeds, Leeds, UK, n.alvarado@leeds.ac.uk Lynn McVey, School of Healthcare, University of Leeds, Leeds, UK, I.mcvey@leeds.ac.uk Joanne Greenhalgh, School of Sociology and Social Policy, University of Leeds, Leeds, UK, j.greenhalgh@leeds.ac.uk Robert West, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK, r.m.west@leeds.ac.uk Amanda Farrin, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK, a.j.farrin@leeds.ac.uk Chris P. Gale, School of Medicine, University of Leeds, Leeds, UK, c.p.gale@leeds.ac.uk Roger Parslow, School of Medicine, University of Leeds, Leeds, UK, r.c.parslow@leeds.ac.uk Justin Keen, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK, j.keen@leeds.ac.uk Mai Elshehaly, School of Computing, University of Leeds, Leeds, UK, m.h.elshehaly@leeds.ac.uk Roy A. Ruddle, School of Computing, University of Leeds, Leeds, UK, r.a.ruddle@leeds.ac.uk Julia Lake, Leeds Teaching Hospitals NHS Trust, Leeds, UK, julia.lake3@nhs.net Mamas A. Mamas, Royal Stoke Hospital, Stoke on Trent, UK, mamasmamas1@yahoo.co.uk Richard Feltbower, School of Medicine, University of Leeds, Leeds, UK, r.g.feltbower@leeds.ac.uk Dawn Dowding, School of Health Sciences, University of Manchester, Manchester, UK, dawn.dowding@Imanchester.ac.uk

BMJ Open

 I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in our licence.

10 The Submitting Author accepts and understands that any supply made under these terms is made by 11 BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a 12 postgraduate student of an affiliated institution which is paying any applicable article publishing charge 13 ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on 14 an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access 15 shall be governed by a Creative Commons licence – details of these licences and which Creative 16 Commons licence will apply to this Work are set out in our licence referred to above.

ABSTRACT

Introduction: National audits are used to monitor care quality and safety and are anticipated to reduce unexplained variations in quality by stimulating quality improvement. However, variation within and between providers in the extent to which they engage with national audits mean that the potential for national audit data to inform quality improvement is not being realised. This study aims to undertake a feasibility evaluation of QualDash, a quality dashboard designed to support clinical teams and managers to explore data from two national audits, the Myocardial Ischaemia National Audit Project (MINAP) and the Paediatric Intensive Care Audit Network (PICANet).

Methods and analysis: Realist evaluation, which involves building, testing, and refining theories of how an intervention is supposed to work, provides an overall framework. Realist hypotheses that describe how, in what contexts, and why QualDash is expected to provide benefit will be tested across five hospitals. A controlled interrupted time series analysis will investigate impacts of QualDash using key MINAP and PICANet measures. Ethnographic observations and interviews over 12 months will provide insight into contexts and mechanisms that lead to those impacts. Feasibility outcomes include the extent to which MINAP and PICANet data are used, data completeness in the audits, and the extent to which participants perceive QualDash to be useful and express the intention to continue using it after the study period.

Ethics and dissemination: The study has been approved by University of Leeds School of Healthcare Research Ethics Committee. Study results will provide an initial understanding of how, in what contexts, and why quality dashboards may lead to improvements in care quality. These will be disseminated to academic audiences, study participants, hospital IT departments, and national audits. If results show a trial of QualDash is feasible, we will disseminate the QualDash software through a stepped wedge cluster randomised trial.

- Trial registration: ISRCTN18289782
- Keywords: Dashboard, audit and feedback, quality improvement, realist evaluation
 - Word count: 3,984

ARTICLE SUMMARY

Strengths and limitations of this study

- This study combines a controlled interrupted time series study with a qualitative multi-site case study in order to provide an understanding of not only whether use of a quality dashboard leads to guality improvement but also how, in what contexts, and why.
- In addition to assessing the feasibility of a trial, the study will determine the components of QualDash to be preserved in a definitive trial, appropriate outcome measures, and the contexts in which a definitive trial should be undertaken.
 - The study will contribute to understanding of how realist methods can contribute to feasibility studies and the design of trials.

INTRODUCTION

National clinical audits (NCAs), which provide comparative data on the performance of healthcare providers, are one means by which health systems around the world monitor care quality and safety. In England, a programme of over 60 NCAs is managed by the Healthcare Quality Improvement Partnership (HQIP) and all healthcare providers that contribute to delivery of the National Health Service (NHS) are required to participate. Such audits are anticipated to reduce unexplained variations in healthcare quality by stimulating quality improvement (QI) [1 2]. While there is evidence of positive impacts of NCAs [3-5], variation within and between providers in the extent to which they engage with NCAs mean that the potential for NCA data to inform QI is not being realised [67].

Quality dashboards are a form of audit and feedback (A&F) that provide visualisations of audit data with the aim of informing QI efforts [8]. Healthcare providers are increasingly using quality dashboards. For example, use of quality dashboards has been reported in Canada [9], the UK [10], and the Netherlands [11]. While quality dashboards have been shown to have positive effects on some performance indicators [9], empirical evidence regarding their impact remains limited [12].

1 QualDash

QualDash is an interactive web-based quality dashboard designed to support clinical teams and managers to explore data from two national audits, the Myocardial Ischaemia National Audit Project (MINAP) and the Paediatric Intensive Care Audit Network (PICANet), for the purpose of QI (Fig. 1). Information used to inform the design of QualDash was collected using a combination of methods, including: interviews, with 50 clinicians and managers across five NHS Trusts (providers) and four healthcare commissioners, that explored what supports and constrains their use of NCA data for QI; observations of meetings at different levels of the Trusts where audit data are discussed; a workshop with suppliers of NCAs; and two co-design workshops with clinicians and managers from one Trust.

Fig. 1: Prototype of main dashboard view for the Paediatric Intensive Care Audit Network (usingsimulated data).

13 [Figure 1 should go approximately here]

The interviews revealed that use of NCA data is largely at the clinical team level, with more limited use of NCA data at divisional and corporate (Board and sub-committees that report to the Board, such as Quality and Safety Committees) levels. At all levels, a key constraint in use of NCA data for QI is lack of access to timely data. QualDash seeks to overcome this constraint, providing users with a means to visualise their own data which they upload to the NCAs, rather than having to wait for data to be returned from the NCAs. There is also variation between Trusts in the extent to which NCA data are currently used, often related to resources; Trusts that make greater use of NCA data tend to have local databases from which they can generate visualisations of the data (e.g. bar charts) and audit support staff who have the time and skills to be able to generate such visualisations. Therefore, QualDash provides visualisations of key metrics, each metric being represented within a 'QualCard' (Fig. 2), enabling Trusts to use NCA data for QI, regardless of existing resources. Sites are also able to create additional QualCards, to reflect local priorities. However, the benefits perceived from using QualDash may vary between sites, with under-resourced sites that previously made little use of NCA data for QI perceiving greater impact than those sites that already have the means to use NCA data for this purpose. There are also constraints on use of NCA data for QI that it may be difficult for QualDash to address. For example, in some Trusts, clinical team members perceive that the relevant managers will not agree to

BMJ Open

3 4	1	provide the resources necessary for QI initiatives, which reduces motivation to engage with NCA data
5 6	2	and may affect the extent to which QualDash is used. However, QualDash provides means for
7	3	visualisations to be downloaded and incorporated into presentations and reports, which may support
8 9	4	clinical teams in making a stronger case for QI initiatives.
10 11	5	
12 13	6	Fig. 2: Prototype of main dashboard view for the Paediatric Intensive Care Audit Network with the
14 15	7	Mortality QualCard expanded (using simulated data).
16 17	8	[Figure 2 should go approximately here]
18 19	9	
20 21	10	In this paper, we describe the methods for a realist feasibility evaluation of QualDash, informed by our
22 23	11	understanding of how, in what contexts, and why NCA data are used and our expectations of how, in
24 25	12	what contexts, and why QualDash will be used. The objectives of the study are:
26 27	13	1. To understand how, in what contexts, and why use of QualDash leads to QI; and
28 29	14	2. To assess the feasibility of conducting a randomised controlled trial (RCT) of QualDash.
30	15	As no checklists exist for the reporting of realist evaluation protocols, in presenting this protocol we
31 32	16	draw on the RAMESES II reporting standards for realist evaluations [13] (Additional file 1).
33 34	17	METHODS AND ANALYSIS
35 36	18	
37 38	19	METHODS AND ANALYSIS
39 40	20	Study design
41 42	21	Use of theory is needed for design and evaluation of A&F interventions [14-16], and QI initiatives more
43 44	22	generally [17-19]. This project draws on Realist Evaluation (RE), which involves building, testing, and
45 46	23	refining the underlying assumptions or theories of how an intervention is supposed to work [20]. These
47 48	24	theories are expressed in the form of Context Mechanism Outcome (CMO) configurations, where
49 50	25	C+M=O, reflecting the realist understanding that it is recipients' reasoning about and responses to the
50 51 52	26	resources that the intervention provides (the intervention mechanisms) that determine the impact of the
53	27	intervention, and such responses are highly influenced by context [21]. Consequently, RE seeks to
54 55	28	answer not only the question of 'what works?' but 'what works for whom, in what circumstances, and
56 57 58 59	29	why?' [22]. It is concerned with both intended and unintended outcomes. RE is recommended for

studying QI [23] and has been used successfully for studying the implementation and impact of large-scale QI programmes [24].

There is increasing interest in use of realist methods in feasibility evaluations [25-27]. By understanding the relationship between contexts, mechanisms, and outcomes, we aim to identify those components of QualDash associated with mechanisms that produce the desired outcomes in order for them to be preserved in a definitive trial, whereas other components may be adapted to suit the local context. By understanding both intended and unintended consequences, appropriate outcome measures can also be determined. Additionally, findings regarding contexts can be used to inform the decision about contexts in which the definitive trial should be undertaken, in terms of level of the organisation (clinical team, division, and/or corporate) and clinical area. This understanding will consequently inform which NCAs will be included in the trial.

We have drawn on a range of sources to develop CMO configurations which describe how, in what contexts, and why use of QualDash is anticipated to lead to QI (see Additional file 2). Data generated from the interviews, observations, and workshops described above have been essential to this, as have discussions with the designers of QualDash (ME and RAR) who, drawing on their expertise in information visualisation, have their own literature-informed theories regarding why certain features of QualDash will provide benefit to users [28 29]. We have also drawn on substantive theories regarding how A&F lead to QI at the individual micro level (Contextual Feedback Intervention Theory [30] and the model of actionable feedback [31]), the organisational meso level (Van Helden and Tilemma's model of benchmarking [32]), and the macro level (institutional theory [33 34]). The CMO configurations focus on use of QualDash by clinical teams, as this is where NCA data are most actively used, but also suggest how outputs produced via QualDash may become integrated in division and corporate quality monitoring processes.

Data collection is designed to enable testing of the CMO configurations. Outcome data, in the form of key MINAP and PICANet measures, will be collected and analysed in a controlled interrupted time series (CITS) study, while a multi-site case study [35] will provide insight into the contexts and mechanisms that lead to those outcomes, as well as providing data on intermediate outcomes such as increased use of

BMJ Open

NCA data. A&F interventions, and QI interventions more generally, require longitudinal evaluation to
allow sufficient time for staff to implement changes and incorporate them into their practice [36-38].
Similarly, evaluation of health IT (HIT) should allow time for staff to integrate the technology into their
practices and evolve those practices to take advantage of the functionality offered by the technology [39].
Therefore, data will be collected over a 12 month period, from August 2019.

7 Public and patient involvement

A Lay Advisory Group has been established, who have contributed to the design of QualDash by reviewing the topic guide for the interviews that were conducted, providing their perspective on the findings of the interview study, and participating in the usability evaluation of QualDash. For the realist feasibility evaluation, they have provided advice on aspects to pay attention to when undertaking observations. They will contribute to analysis of a sample of the qualitative data, to provide a patient perspective. They will advise on dissemination of findings to relevant interest groups and will contribute to the creation of outputs by reviewing them for comprehensibility.

) 15

16 Setting/context

QualDash will be evaluated in the five NHS acute Trusts in which the interview study that informed the design of QualDash was undertaken. Three Trusts are teaching hospitals that participate in both MINAP and PICANet and have been selected to ensure variation in key outcome measures (MINAP: 30-day mortality for patients hospitalised with ST-elevation myocardial infarction; PICANet: risk adjusted standardised mortality ratio). Two Trusts are District General Hospitals (DGHs) that participate in MINAP but do not have a PICU and so do not participate in PICANet. These have been selected to ensure variation in the same key MINAP measure.

25 Multi-site case study

In the multi-site case study, data will be collected through ethnographic observation and interviews.
Ethnographic methods, such as non-participant observation, have been argued as essential for
studying the implementation of QI interventions [19] and the introduction of HIT [40]. Ethnography is
well suited to RE because it involves observing phenomena in context, supporting understanding of
how context influences the response to an intervention [41]. We will follow the Biography of Artefacts

approach [42], which is concerned with capturing the way in which particular contexts and
appropriations of a technology lead to different processes and generate different outcomes, a parallel
to RE's concern with contexts, mechanisms, and outcomes [43]. It involves longitudinal 'strategic
ethnography' [42], where data collection is guided by a provisional understanding of the moments and
locales in which a technology and associated practices evolve [43].

7 Data collection

In the three teaching hospitals, we will undertake a minimum of 24 periods of observation per Trust, to be split across activities related to cardiology and the PICU, and in the two DGHs we will undertake a minimum of 12 periods of observation per Trust, to be spent observing activities related to cardiology. Each period of observation will be a minimum of four hours (total n=384 hours). While the researchers will return to each Trust monthly, to understand how use of QualDash changes over time, more time will be spent in the first few months following the introduction of QualDash, because this is when users are most likely to engage with and explore the affordances of QualDash and establish new practices around it, generating information with implications for system enhancement [43]. Observations will be scheduled to take place at different times of day and on different days of the week, to ensure that the account of what is observed is as complete and representative as possible [44].

At each case site, an initial phase of general observation will provide an opportunity for researchers to become familiar with the setting and for those in the setting to become familiar with the presence of the researchers. Following a previous study of dashboards [10], observations will be undertaken in clinical areas to understand clinical teams' working practices and capture 'corridor committees' where issues of quality and safety are discussed more informally [45]. In the PICUs, initial observations will take place on the PICU, for example with the researchers positioning themselves by the nurses' station, as well as observing handovers, safety huddles, and ward rounds. Because activities related to cardiology tend to be more dispersed across hospitals, researchers will first shadow clinical team members (consultant cardiologists and acute chest pain nurses) to determine where it is most appropriate to conduct subsequent observations. These initial observations will also provide the opportunity to record general details of the setting that may influence use of QualDash, such as staffing levels and availability of computers.

BMJ Open

After this initial phase, observation will be guided by the CMO configurations under investigation. In addition to observing formal meetings where quality and safety are discussed, predominantly at ward level but also at divisional and corporate level, observation will involve shadowing staff members as they undertake particular activities: collection and entry of NCA data, to see if and how this changes over time; accessing and interrogating NCA data, whether using QualDash or some other means; preparation of reports and/or presentations using NCA data, again whether using QualDash or some other means. Where visualisations from QualDash are incorporated into presentations and written reports, we will follow the path of those documents, to identify staff members who may not use QualDash directly but are receiving QualDash outputs. Attention will be paid to how, in what contexts, and why QualDash and QualDash outputs are used or not, understood in the context of broader practices and use of other sources of information for monitoring care quality, and how this changes over time. We will also follow local QI initiatives, recording data on, for example, when and how the need for the QI initiative was identified, contextual factors that appear to support and constrain its introduction, how the impact of the QI initiative is monitored, and other contextual factors that appear to influence the metric that the QI initiative is targeting.

18 Researchers will record observations in fieldnotes. The scope of the notes will be kept wide on the basis 19 that what previously seemed insignificant may come to take on new meaning in light of subsequent 20 events [44]. In addition, the researchers will record incidents of observer effects (e.g. participants asking 21 'What are you writing?') to allow analysis of whether participants' awareness of the researchers' 22 presence changed over time [46]. Fieldnotes will be written up in detail as soon after data collection as 23 possible.

Brief interviews will be undertaken opportunistically during the course of conducting observations to clarify aspects of practice that are not immediately intelligible to an observer, with participant responses recorded in fieldnotes [47]. As data collection progresses, longer semi-structured interviews will be used to discuss revisions to our CMO configurations. These interviews will be undertaken using a particular approach from RE, referred to as the teacher-learner cycle, whereby the theories under investigation are made explicit to the interviewee so that the interviewee can use their experiences to refine the researcher's understanding [48]. Additionally, being concerned with the reasoning of intervention recipients, mechanisms are often not observable [21] and so these longer interviews will also provide the opportunity to explore staff reasoning about QualDash. These longer interviews will be audio recorded and transcribed verbatim.

Logfiles are widely used to evaluate visualisation tools [49] and with QualDash will record information about a user (job title, etc.), data used (audit, year, variables displayed, etc.), overall time spent using QualDash, functionality used, and whether the user downloaded the QualDash visualisations. In addition to providing important data regarding extent of QualDash use, how QualDash is used and by whom (e.g. whether the most frequent users are nurses, consultants, or audit support staff), and how this changes over time, information from logfiles will be used to inform qualitative data collection (e.g. asking in interviews why participants use particular QualCards and not others).

At the end of the data collection period, we will ask participants to complete a questionnaire based on the Technology Acceptance Model, using well validated items that have been used in numerous evaluations of HIT [50], including dashboards [51]. This will provide participants' perceptions of the usefulness of QualDash and data on whether they intend to continue using QualDash after the study period.

20 Analysis

An iterative approach to data collection and analysis will be taken, to enable: ongoing testing and refinement of the CMO configurations; gathering of further data in light of such revisions; and refinement of QualDash in response to participants' feedback. Fieldnotes and interview transcripts will be entered into NVivo 11. Narrative analysis will be undertaken to develop a 'biography' of QualDash, which will describe use of QualDash and its outputs by a range of stakeholders at different levels (clinical team, divisional, and corporate) and the interconnections between them [10]. Narrative analysis is consistent with a realist approach due to its emphasis on preserving connections within the data, thereby helping to understand causality [52]. This analysis will be supplemented with analysis of the logfiles and questionnaire data. Findings will be compared with the CMO configurations, to determine whether they support, refute, or suggest a revision or addition to the CMO configurations.

7

1

2	
3	
4	
5	
6 7	
8	
9	
10	
11 12	
12 13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27 28	
20 29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44 45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58 50	
59 60	
00	

2 Controlled interrupted time series study

CITS studies provide a robust method of assessing the effect of an intervention and have been used to
assess the effectiveness of a variety of complex interventions [53]. Data will be collected across the five
Trusts, with two control Trusts per intervention Trust. Control Trusts will be matched according to their
size and outcomes pre-intervention.

8 Given the study intention to determine the feasibility of and inform the design of a trial, a range of 9 measures will be considered. Initially, we selected two process measures, one for MINAP and one for 10 PICANet. For MINAP, we selected the composite process measure Cumulative Missed Opportunities for Care (CMOC). This has nine components (pre-hospital ECG, acute use of aspirin, timely perfusion, 11 12 referral for cardiac rehabilitation, and prescription at hospital discharge of what are considered to be 13 the gold standard drugs – aspirin, thienopyridine inhibitor, ACE-inhibitor, HMG-CoA reductase inhibitor, 14 and beta blockers) and is inversely associated with mortality [54]. As some of these components, such 15 as pre-hospital ECG, are outside the direct control of the Trust, we will also explore the impact of 16 QualDash on the individual measures that make up CMOC. On the basis of the measures that 17 cardiology clinicians described in the interview study as being important for measuring care quality, we 18 will also look at the percentage of patients who receive an angiogram within 72 hours from first 19 admission to hospital, which is part of the Best Practice Tariff financial incentive scheme, and, for those 20 hospitals that provide percutaneous coronary intervention (PCI), the proportion of patients who have a door-to-balloon time (the time from arrival at the hospital to PCI) of less than 60 minutes. Our CMO 21 22 configurations (Additional file 2) suggest that improvement will be seen in measures if: clinical teams 23 perceive them as being important indicators of care and/or they relate to financial incentives; 24 performance is not in line with expectations; they perceive the measure as being within their control; 25 and the team is resourced to introduce QI initiatives in relation to these measures. 26

For PICANet, we initially selected use of non-invasive ventilation first for patients requiring ventilation, which has been shown to be associated with reduced mortality [55]. However, this was not raised as an area of concern in our interviews with PICU clinicians. On the basis of this and two additional considerations – it would require loading additional data into QualDash which would reduce the

> performance of QualDash in terms of speed and it requires computation of the data, while the focus of QualDash is on visualising the data – a QualCard has not been created for this metric. Therefore, we do not hypothesise that this measure will change, unless other sources of information, such as the PICANet annual report, draw a PICU team's attention to it. However, accidental extubation was identified in our interviews with PICU clinicians as being an important indicator of care quality; QualDash includes a QualCard for accidental extubation, which displays the number of patients receiving invasive ventilation, and we will include this as a measure. Unplanned readmission within 48 hours was also identified in our interviews as being an important indicator of care quality, so a QualCard for this has been created and we will include this as a measure. On the basis of our CMO configurations (Additional file 2), we would expect to see an improvement in these measures in sites where performance is not in line with expectations, if the team is resourced to introduce QI initiatives in relation to these measures.

13 Sample size considerations

A CITS study requires data for a minimum of three time points pre-intervention and three time points post-intervention and must also allow for any seasonal effect on the outcomes [56]. Monthly data will be obtained for 24 months pre-intervention and 12 months post-intervention. Consequently, for each intervention Trust, there will be 72 data points prior to introduction (24 for the intervention Trust and 48 for the control Trusts) and 36 data points post intervention (12 for the intervention Trust and 24 for the control Trusts).

21 Analysis

Monthly MINAP and PICANet data will be extracted to spreadsheets for analysis with R software [57]. For both NCAs, each outcome will be regressed upon time and the intervention. The time component will include a seasonal effect (quarterly effect) and will allow for a (linear) time trend. To account for clustering of monthly observations within hospitals a random intercept will be fitted, although a fixed effect for hospital as a sensitivity analysis will be explored. Although the intervention is abrupt, its impact may well be 'phased in' over a few months, perhaps three. The timing of the bedding in of the intervention will be reported from the multi-site case study. Then a partial effect can be considered for this period with the interaction effect stepping up in a linear fashion.

 BMJ Open

The results of the CITS analysis will be incorporated into the biography of QualDash, the analysis of
 the data from the multi-site case study describing how contextual factors shape the evolution of
 practices around QualDash and how this leads to the resulting outcome pattern.

5 Assessment of trial feasibility

Criteria for progression to an RCT are: (i) the number of people who engage with either MINAP or PICANet data (via QualDash or some other means) is the same or higher than the number of people who engaged with either MINAP or PICANet data prior to QualDash's introduction; (ii) data completeness in the national audit improves or remains the same; (iii) 50% or more of participants in the questionnaire survey perceive QualDash to be useful and express the intention to continue using it after the study period. Criteria (i) and (ii) are concerned with ensuring that the intervention does not have unintended negative consequences which would affect the success of the intervention. Criterion (ii) is also concerned with the feasibility of outcome assessment. Criterion (iii) is concerned with acceptability and uptake of the intervention, and therefore has implications for recruitment to a trial, as well as being concerned with participants' perceptions of the impact of QualDash on care. While not formally assessed as part of the progression criteria, the impact of QualDash on processes of care as identified in the CITS will also be considered in determining whether a future cluster randomised controlled trial is justified. A traffic light system will be used to determine if a trial is feasible (green), feasible with modifications to QualDash (amber), or not feasible (red) [58 59].

40 20 42 21 ETHICS AND DISSEMINATION

Ethics approval has been received from the University of Leeds School of Healthcare Research Ethics
Committee (Approval no.HREC16-044). Written consent will be obtained from participants for interviews
and for meeting observations.

Study results will provide an initial understanding of how, in what contexts, and why quality dashboards
may lead to improvements in care quality. We will disseminate these results to academic audiences,
study participants, hospital IT departments, and National Clinical Audits. If the results show a trial of
QualDash is feasible, we will design a stepped wedge cluster randomised trial, which will, in addition to

Page 16 of 32

BMJ Open

providing further understanding of the impact of quality dashboards on care quality, result in wider
 dissemination of the QualDash software.

Acknowledgements

This research is funded by the National Institute for Health Research (NIHR) Health Services and Delivery Research (HS&DR) Programme (project number 16/04/06). The views and opinions expressed are those of the presenter and do not necessarily reflect those of the HS&DR programme, NIHR, NHS or the Department of Health.

10 Data statement

The qualitative data gathered during the course of this evaluation will be kept until June 2030 and can be accessed by other researchers during this time, subject to the necessary ethical approvals being obtained. Requests for access to this data should be addressed to the corresponding author.

15 Authors' contributions

16 RR is Principal Investigator for the study. She conceived, designed, and secured funding for the study 17 in collaboration with JG, RW, AF, CPG, RP, JK, RAR, JL, MM, and DD. NA and LM led the qualitative 18 data collection and analysis that informed the design of QualDash and the design of evaluation. ME 19 developed the QualDash software and contributed to the design of the evaluation. RP and RF provided 20 data for the testing of QualDash and provided significant feedback on its design. All authors provided 21 input into various aspects of the evaluation design and revised drafts of the protocol. RR led the writing 22 of this protocol manuscript. All authors read and approved the final manuscript.

24 Funding statement

This research is funded by the National Institute for Health Research (NIHR) Health Services and
Delivery Research (HS&DR) Programme (project number 16/04/06).

2		
3	1	Competing interests statement
4 5 6	2	Chris Gale is a member of the MINAP Academic and Steering Groups. Richard Feltbower is Principal
6 7	3	Investigator for PICANet and Roger Parslow was previously Principal Investigator for PICANet. The
8 9	4	authors have no other competing interests to declare.
10 11	5	
12 13	6	Additional files
14 15	7	Additional file 1: Checklist of RAMESES II reporting standards for realist evaluations (PDF)
16 17	8	Additional file 2: Context Mechanism Outcome configurations to be tested in the realist feasibility
18 19	9	evaluation (PDF)
20 21	10	
22 23	11	REFERENCES
24	12	1. Phekoo KJ, Clements J, Bell D. National Clinical Audit Quality Assessment - Overview of the self-
25 26	13	assessment survey: "audit of audits". London: Healthcare Quality Improvement Partnership,
20 27	14	2014.
28	15	2. Miller T, Leatherman S. The National Quality Forum: a'me-too'or a breakthrough in quality
29	16	measurement and reporting? Health Aff. (Millwood) 1999; 18 (6):233-37.
30	17	3. Birkhead JS, Walker L, Pearson M, Weston C, Cunningham AD, Rickards AF. Improving care for
31	18	patients with acute coronary syndromes: initial results from the National Audit of Myocardial
32 33	19	Infarction Project (MINAP). Heart 2004;90(9):1004-09.
33 34	20	4. Bridgewater B, Grayson AD, Brooks N, et al. Has the publication of cardiac surgery outcome data
35	21	been associated with changes in practice in northwest England: an analysis of 25 730 patients
36	22	undergoing CABG surgery under 30 surgeons over eight years. Heart 2007; 93 (6):744-48.
37	23	5. Neuburger J, Currie C, Wakeman R, et al. The Impact of a National Clinician-led Audit Initiative on
38	24 25	Care and Mortality after Hip Fracture in England: An External Evaluation using Time Trends in Non-audit Data. Med. Care 2015; 53 (8):686-91.
39 40	25	6. Allwood D. Engaging Clinicians in Quality Improvement through National Clinical Audit. London:
41	20	Healthcare Quality Improvement Partnership, 2014.
42	28	7. Taylor A, Neuburger J, Walker K, Cromwell D, Groene O. How is feedback from national clinical
43	29	audits used? Views from English National Health Service trust audit leads. J. Health Serv. Res.
44	30	Policy 2016; 21 (2):91-100.
45 46	31	8. Pauwels K, Ambler T, Clark BH, et al. Dashboards as a Service Why, What, How, and What Research
40 47	32	Is Needed? Journal of Service Research 2009; 12 (2):175-89.
48	33	9. Weiss D, Dunn SI, Sprague AE, et al. Effect of a population-level performance dashboard
49	34	intervention on maternal-newborn outcomes: an interrupted time series study. BMJ Quality
50	35	& Safety 2018; 27 (6):425-36.
51	36	10. Keen J, Nicklin E, Long A, et al. Quality and safety between ward and board: a biography of artefacts
52 53	37	study. Health Services and Delivery Research 2018;6(22).
55 54	38	11. Weggelaar-Jansen AMJWM, Broekharst DSE, de Bruijne M. Developing a hospital-wide quality and
55	39	safety dashboard: a qualitative research study. BMJ Quality & amp; Safety 2018.
56	40	12. Dowding D, Randell R, Gardner P, et al. Dashboards for improving patient care: Review of the
57	41	literature. International Journal of Medical Informatics 2015; 84 (2):87-100.
58 50	42	13. Wong G, Westhorp G, Manzano A, Greenhalgh J, Jagosh J, Greenhalgh T. RAMESES II reporting
59 60	43	standards for realist evaluations. BMC Med. 2016; 14 (1):96.

- 14. Foy R, Eccles MP, Jamtvedt G, Young J, Grimshaw JM, Baker R. What do we know about how to do audit and feedback? Pitfalls in applying evidence from a systematic review. BMC Health Serv. Res. 2005;5:50.
- 15. Ivers NM, Grimshaw JM, Jamtvedt G, et al. Growing Literature, Stagnant Science? Systematic Review, Meta-Regression and Cumulative Analysis of Audit and Feedback Interventions in Health Care. J. Gen. Intern. Med. 2014;29(11):1534-41.
 - 16. Ivers NM, Sales A, Colquhoun H, et al. No more 'business as usual' with audit and feedback interventions: towards an agenda for a reinvigorated intervention. Implementation Science 2014;9(1):1-8.
 - 17. Grol RPTM, Bosch MC, Hulscher MEJL, Eccles MP, Wensing M. Planning and Studying Improvement in Patient Care: The Use of Theoretical Perspectives. Milbank Q. 2007;85(1):93-138.
- 18. Davidoff F, Dixon-Woods M, Leviton L, Michie S. Demystifying theory and its use in improvement. BMJ Quality & Safety 2015.
- 19. Dixon-Woods M, Bosk CL, Aveling EL, Goeschel CA, Pronovost PJ. Explaining Michigan: Developing an Ex Post Theory of a Quality Improvement Program. Milbank Q. 2011;89(2):167-205.
- 20. Pawson R, Tilley N. Realistic Evaluation. London: SAGE Publications, 1997.
- 21. Dalkin S, Greenhalgh J, Jones D, Cunningham B, Lhussier M. What's in a mechanism? Development of a key concept in realist evaluation. Implementation Science 2015;10(1):49.
 - 22. Pawson R. The science of evaluation: a realist manifesto. London: SAGE, 2013.
 - 23. Robert G, Fulop N. The role of context in successful improvement. Perspectives on context. A selection of essays considering the role of context in successful quality improvement. London: Health Foundation 2014;31.
 - 24. Greenhalgh T, Humphrey C, Hughes J, Macfarlane F, Butler C, Pawson R. How Do You Modernize a Health Service? A Realist Evaluation of Whole-Scale Transformation in London. Milbank Q. 2009;87(2):391-416.
 - 25. Fletcher A, Jamal F, Moore G, Evans RE, Murphy S, Bonell C. Realist complex intervention science: Applying realist principles across all phases of the Medical Research Council framework for developing and evaluating complex interventions. Evaluation 2016;22(3):286-303.
 - 26. Brand SL, Quinn C, Pearson M, et al. Building programme theory to develop more adaptable and scalable complex interventions: Realist formative process evaluation prior to full trial. Evaluation 2019;25(2):149-70.
 - 27. Randell R, Honey S, Hindmarsh J, et al. A realist process evaluation of robot-assisted surgery: integration into routine practice and impacts on communication, collaboration and decisionmaking. Health Services and Delivery Research 2017;5(20).
 - 28. Andrienko N, Andrienko G. Exploratory analysis of spatial and temporal data: a systematic approach: Springer Science & Business Media, 2006.
 - 29. Brehmer M, Munzner T. A multi-level typology of abstract visualization tasks. IEEE transactions on visualization and computer graphics 2013;19(12):2376-85.
 - 30. Sapyta J, Riemer M, Bickman L. Feedback to clinicians: Theory, research, and practice. J. Clin. Psychol. 2005;61(2):145-53.
- 31. Hysong SJ, Best RG, Pugh JA. Audit and feedback and clinical practice guideline adherence: Making feedback actionable. Implementation Science 2006;1(1):1-10.
- 32. Van Helden GJ, Tillema S. In Search of a Benchmarking Theory for the Public Sector. Financial Accountability & Management 2005;21(3):337-61.
- 33. Scott RW. Institutions and Organizations. 2nd Edition ed. London: Sage, 2001.
- 34. Furusten S. Institutional Theory and Organizational Change. Cheltenham, UK: Edward Elgar, 2013.
- 35. Yin RK. Case study research: design and methods. 3rd ed. Thousand Oaks, California: SAGE, 2003.
- 36. Øvretveit J, Gustafson D. Evaluation of quality improvement programmes. Quality and Safety in Health Care 2002;**11**(3):270-75.

2		
3	1	37. Ramsay AIG, Turner S, Cavell G, et al. Governing patient safety: lessons learned from a mixed
4	2	methods evaluation of implementing a ward-level medication safety scorecard in two English
5	3	NHS hospitals. BMJ Quality & Safety 2013; 23 :136-46.
6	4	38. Benn J, Burnett S, Parand A, Pinto A, Iskander S, Vincent C. Studying large-scale programmes to
7	5	improve patient safety in whole care systems: Challenges for research. Soc. Sci. Med.
8 9	6	2009; 69 (12):1767-76.
9 10	7	39. Hyysalo S. Health technology development and use: from practice-bound imagination to evolving
11	8	impacts. New York: Routledge, 2010.
12	9	40. Greenhalgh T, Swinglehurst D. Studying technology use as social practice: the untapped potential
13	10	of ethnography. BMC Med. 2011; 9 (1):45.
14	10	41. Dainty KN, Golden BR, Hannam R, et al. A realist evaluation of value-based care delivery in home
15		
16	12	care: The influence of actors, autonomy and accountability. Soc. Sci. Med. 2018; 206 :100-09.
17	13	42. Pollock N, Williams R. Software and organisations: The biography of the enterprise-wide system or
18	14	how SAP conquered the world. New York: Routledge, 2008.
19 20	15	43. Pollock N, Williams R. e-Infrastructures: How Do We Know and Understand Them? Strategic
20	16	Ethnography and the Biography of Artefacts. Computer Supported Cooperative Work (CSCW)
22	17	2010; 19 (6):521-56.
23	18	44. Hammersley M, Atkinson P. <i>Ethnography: principles in practice</i> . London: Routledge, 1995.
24	19	45. Waring J. Adaptive regulation or governmentality: patient safety and the changing regulation of
25	20	medicine. Sociol. Health Illn. 2007; 29 (2):163-79.
26	21	46. McDonald S. Studying actions in context: a qualitative shadowing method for organizational
27	22	research. Qualitative Research 2005;5(4):455-73.
28	23	47. Goodwin D, Pope C, Mort M, Smith A. Access, boundaries and their effects: legitimate participation
29	24	in anaesthesia. Sociol. Health Illn. 2005; 27 (6):855-71.
30	25	48. Pawson R. Theorizing the Interview. The British Journal of Sociology 1996;47(2):295-314.
31 32	26	49. Harrison DG, Efford ND, Fisher QJ, Ruddle RA. PETMiner—A Visual Analysis Tool for Petrophysical
32 33	27	Properties of Core Sample Data. IEEE transactions on visualization and computer graphics
34	28	2017; 24 (5):1728-41.
35	29	50. Holden RJ, Karsh B-T. The Technology Acceptance Model: Its past and its future in health care.
36	30	Journal of Biomedical Informatics 2010; 43 (1):159-72.
37	31	51. Lee K, Jung SY, Hwang H, et al. A novel concept for integrating and delivering health information
38	32	using a comprehensive digital dashboard: An analysis of healthcare professionals' intention to
39	33	adopt a new system and the trend of its real usage. Int. J. Med. Inform. 2017; 97 :98-108.
40	34	52. Maxwell JA. A realist approach for qualitative research. London: SAGE Publications, 2012.
41	35	53. Hu Y. Stepped wedge, natural experiments and interrupted time series analysis designs. In:
42 43	36	Richards DA, Hallberg IR, eds. Complex interventions in health: An overview of research
44	37	methods. Abingdon: Routledge, 2015:200-12.
45	38	54. Simms AD, Baxter PD, Cattle BA, et al. An assessment of composite measures of hospital
46	39	performance and associated mortality for patients with acute myocardial infarction. Analysis
47	40	of individual hospital performance and outcome for the National Institute for Cardiovascular
48	41	Outcomes Research (NICOR). European Heart Journal: Acute Cardiovascular Care 2013;2(1):9-
49	42	18.
50	43	55. Morris JV, Ramnarayan P, Parslow RC, Fleming SJ. Outcomes for Children Receiving Noninvasive
51	44	Ventilation as the First-Line Mode of Mechanical Ventilation at Intensive Care Admission: A
52 53	45	Propensity Score-Matched Cohort Study. Crit. Care Med. 2017.
55 54	46	56. Cochrane Effective Practice and Organisation of Care Group (EPOC). What study designs should be
55	47	inlcuded in an EPOC review and what should they be called? Oslo: Norwegian Knowledge
56	48	Centre for the Health Services, 2013.
57	49	57. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R
58	50	Foundation for Statistical Computing, 2014.
59		
60		

c

- 58. Bugge C, Williams B, Hagen S, et al. A process for Decision-making after Pilot and feasibility Trials (ADePT): development following a feasibility study of a complex intervention for pelvic organ prolapse. Trials 2013;**14**(1):353.
- 59. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res. Methodol. 2010;**10**(1):1-10.

to beet teries only

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml





Fig. 1: Prototype of main dashboard view for the Paediatric Intensive Care Audit Network (using simulated data).

161x74mm (300 x 300 DPI)

BMJ Open: first published as 10.1136/bmjopen-2019-033208 on 25 February 2020. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright.

BMJ Open: first published as 10.1136/bmjopen-2019-033208 on 25 February 2020. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright.



57 58 59

60



Fig. 2: Prototype of main dashboard view for the Paediatric Intensive Care Audit Network with the Mortality QualCard expanded (using simulated data).

161x85mm (300 x 300 DPI)

Page 23 of 32

BMJ Open How, in what contexts, and why do quality dashboards lead to improvements in care quality? Protocol for a realist feasibility evaluation (Randell et al.) Additional file 2

#	Context	+	Me	echanism g	=	Outcome
			Resource	Response 5		
1.	Teams previously constrained in their	+	QualDash offers easy access to	Teams are able to see whether the	=	Improvement in data
	ability to use NCA data for monitoring		key metrics	data displayed are timely, accurate,		quality in terms of
	service performance because data not			and/or complete and, wher $\stackrel{oldsymbol{arepsilon}}{oldsymbol{arepsilon}}$ they are		timeliness, accuracy, a
	considered to be timely, accurate, and/or			not, adjust their data collection		completeness – as da
	complete			processes in order to benet		quality improves, use
				QualDash		QualDash increases
				Teams use QualDash to endbed NCA	=	Increased routine use
				data within their monitoring		NCA data in performa
				e.g. in clinical governance		monitoring, providing
				where data is presented visionally via		opportunities for its us
				screens.		quality improvement
2.	Teams previously using NCA data to	+	QualDash visualises key	Teams use QualDash to fagilitate their	=	Reduced time spent in
	monitor service performance routinely by		metrics in ways that clearly	existing processes for monigoring		accessing, and prepar
	extracting raw data and producing		show whether service	service performance using BCA data		visualisations of, NCA
	reports for review in meetings and by		performance is within an	April 16,		data
	individuals		expected range and provides	1 <u>6</u> ,		
			functions to interrogate that data	2024		
				t by		
				gues		
				ל. די		
				otec		
				ted t		
				by guest. Protected by copyright		
				y pyri		
				-		
	For pe	er rev	iew only - http://bmjopen.bmj.com/si	ite/about/guidelines.xhtml		

Page 24 of 32

3 4

24

			BMJ Open		miopen-		Page 24
#	Context	+	M	echanism	2019	=	Outcome
			Resource	Response	9-03:		
3.	Teams who want to use NCA data but	+	QualDash provides functions	Teams will use these funct	Bens to	=	Introduction of QI
	were previously constrained by data		that enable users to interact	interrogate anomalies in the	gdata,		initiatives in relation to
	quality and existing systems did not		with NCA data and explore	which will help them to und	erstand		metrics that teams
	provide functions to easily access and		relationships between variables	what has impacted perform	gince,		consider important and
	interact with the data			thereby enabling them to ic	entify		where performance is not
				appropriate strategies for ir	N Peproving		in line with expectations
				performance	0 0		
					Downloaded		Over time, improvement in
					oade		metrics that QI initiatives
					ed fro		target
4.	Performance in key metrics, such as the	+	QualDash offers teams the	Teams add new QualCards	to be able	=	Introduction of QI
	Best Practice Tariff, is in line with		ability to quickly and easily add	to monitor and interrogate	etrics they		initiatives in relation to
	expectations		new QualCards (within NCA	have chosen as important ,	/bmi		metrics shown on new
			parameters)		oper		QualCards when
	Relevant audit/IT support staff have time			Э.	i.bm		performance is not in line
	and willingness to support use of						with expectations
	QualDash			have chosen as important	n∕ or		
				O_{h}	Apr		Over time, improvement in
					1 1 1 0		metrics that QI initiatives
					. 2024		target
					< qu		
					est.		
					Prot		
					ecte		
					d by		
					COD		
					by quest. Protected by copyright.		2
					it.		

Page 25	of	32
---------	----	----

3 4

33 34

44 45

#	Context +	+	M	echanism	-201	=	Outcome
			Resource	Response			
5.	Teams who previously did not, or were +	• (QualDash provides quick and	Teams will become aware	ć.s	=	Introduction of QI
	not able to, monitor key metrics routinely	e	easy access to key metrics	discrepancies between per	Byrmance		initiatives in relation to ke
				and targets in key metrics,			metrics
	Performance is not in line with			will take action to address	ebru		
	expectations in key metrics				Jarv		Over time, improvement i
				will take action to address	2020		those metrics
	Teams are resourced to make practice				D		
	changes				wnlo		
6.	Teams are asked to produce reports and </td <td>+ C</td> <td>QualDash offers easy access to</td> <td>Teams will use QualDash t</td> <td>produce</td> <td>=</td> <td>Reduced time spent in</td>	+ C	QualDash offers easy access to	Teams will use QualDash t	produce	=	Reduced time spent in
	recommendations for managers and	N	ICA data and visualisations	performance reports reque	sted by		report preparation
	other groups about service performance,	t	hat can be exported into	other groups	m ht		
	e.g. at the time of publication of NCA	r	eports		tp://t		Increased use of NCA
	annual report				omio		data at divisional and
					pen.		corporate levels via
),	bmi.		outputs produced by
					com.		QualDash
			eports		http://bmiopen.bmi.com/ on April 16. 2024 by qu		
				<i>b</i>	April		Over time, use of
					16.		QualDash at divisional
					2024		and/or corporate levels,
					4 bv		due to increased
					ques		awareness of NCA data
					<u>ያ</u> ተ 		
					rotected		
					ted T		
					by copyright.		
				:	VQC		
					<u>.</u> .		

Page 26 of 32

3 4

24

#	Context +	Μ	o o h o u i o uo	mionen-20		Outcome
#	Context +	Resource	Response	019-	=	Outcome
7.	Teams receive data requests from +	QualDash can be easily	Service managers will use	ວັ ອັບລlDash to	=	Streamlines the use of
	service managers	accessed via the web by	access the information they	<u>5</u> 0	-	NCA data for clinical
	Service managers	multiple users				managers
		multiple users				managers
				February 2020		Reduced time spent by
				< >0		audit support staff/clinica
				20		team in producing data
				Dow		
	Transa and to evidence their	QualDack viewaliana	Tanana will wan than a found			reports for managers
8.	Teams need to evidence their	QualDash visualises	Teams will use these functi	P	=	Other Trust groups, who
	performance to managers and other	performance metrics, which can	evidence service performar	2		are able to offer addition
	groups in order to support a case for	also be exported into reports	to convince other Trust gro	tps that		resource to teams, are
	practice change e.g. in business	and presentations	change is needed	5.//h		convinced of the need for
	meetings with managers or in the NCA		?h 00/	//hmiopen hmi com/ on April 16		change based on the
	annual report summary					evidence provided.
				<u><u> </u></u>		However, this is likely to
			· N,	Š.		be where those outputs
			0			are clearly associated w
				Δpril		Trust priorities, e.g.
				10		relating to Trust reputati
				2024 by cu		or avoiding
				1 by		penalties/gaining
						incentives.
				<u>א</u> ד		
				Protected by convright		
			-			
			ú	inht		
	For peer re	view only - http://bmjopen.bmj.com/s				

RAMESES II reportin	g standards for realist evaluations		omjopen-2019-033208	
How, in what contexts, and why do quality dashboards lead to improvements in care quality? Protocol for a realist feasibility evaluation		Reported in document Y/N/NA	Page(s) in document	Comment
1	In the title, identify the document as a	**	1 2020.	
	realist evaluation). Do	
SUMMARY OR	ABSTRACT Opp		wnlo	
2	Journal articles will usually require an abstract, while reports and other forms of publication will usually benefit from a short summary. The abstract or summary should include brief details on: the policy, programme or initiative under evaluation; programme setting; purpose of the evaluation; evaluation question(s) and/or objective(s); evaluation strategy; data collection, documentation and analysis methods; key findings and conclusions Where journals require it and the	en 0,	wnloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected b	

		BMJ Open		mjopen-201	
		evaluation and recruitment and sampling processes may also be included Sufficient detail should be provided to identify that a realist approach was used and that realist programme theory was developed and/or refined		omjopen-2019-033208 on 25 February 2020. Downloade	
	TRODUCTION Detionals for	Further the number of the such stirt	Y		
3	Rationale for evaluation	Explain the purpose of the evaluation and the implications for its focus and design	1	om http://b	
4	Programme theory	Describe the initial programme theory (or theories) that underpin the programme, policy or initiative	Y	7-8 and Additional file 1 <u>bi</u> 6 April 16	Placed in body of article, rather than Introduction, as more appropriate fo protocol
5	Evaluation questions, objectives and focus	State the evaluation question(s) and specify the objectives for the evaluation. Describe whether and how the programme theory was used to define the scope and focus of the evaluation	Y	2024 by guest.	
6	Ethical approval	State whether the realist evaluation required and has gained ethical approval from the relevant	Y	Protected by copyright	Stated under declarations as required by journal

Page 2	29 of 32
--------	----------

		BMJ Open		Jobeu	
				2019-03 -03	
		authorities, providing details as appropriate. If ethical approval was deemed unnecessary, explain why		a	
ME	THODS			Diua	
7	Rationale for using realist evaluation	Explain why a realist evaluation approach was chosen and (if relevant) adapted	Y	7 2020.	
8	Environment surrounding the evaluation	Describe the environment in which the evaluation took place	Y	8 0000	
9	Describe the programme policy, initiative or product evaluated	Provide relevant details on the programme, policy or initiative evaluated	Y	4-5 7-14	Description of intervention placed in Background as this seemed more appropriate in providing the conte for the protocol
10	Describe and justify the evaluation design	A description and justification of the evaluation design (i.e. the account of what was planned, done and why) should be included, at least in summary form or as an appendix, in the document which presents the main findings. If this is not done, the omission should be justified and a reference or link to the evaluation	Y	7-14 70 guest. Frotected by cupyright	

 omjopen-2019

Page	30	of 32	
rage	50	01.52	

		design given. It may also be useful to publish or make freely available (e.g. online on a website) any original evaluation design document or protocol, where they exist		208 on 25 February 20	
11	Data collection methods	Describe and justify the data collection methods – which ones were used, why and how they fed into developing, supporting, refuting or refining programme theory Provide details of the steps taken to enhance the trustworthiness of data collection and documentation	Y	9-033208 on 25 February 2020. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright.	
12	Recruitment process and sampling strategy	Describe how respondents to the evaluation were recruited or engaged and how the sample contributed to the development, support, refutation or refinement of programme theory	Y	mj.com/ on April 16, 2024 by	Sampling of sites, rather than individuals, is described; Recruitment will be described when reporting the results of the study
13	Data analysis	Describe in detail how data were analysed. This section should include information on the constructs that were identified, the process of	Y	guest. Protected b	

Page	31	of	32
------	----	----	----

 omjopen-2

		analysis, how the programme theory was further developed, supported, refuted and refined, and (where relevant) how analysis changed as the evaluation unfolded		2019-033208 on 25 February 2020.	
	SULTS		NT A		Protocol so no
14	Details of participants	Report (if applicable) who took part in the evaluation, the details of the data they provided and how the data was used to develop, support, refute or refine programme theory	NA	ownloaded from http	results to report
15	Main findings	Present the key findings, linking them to contexts, mechanisms and outcome configurations. Show how they were used to further develop, test or refine the programme theory	NA	Downloaded from http://bmjopen.bmj.com/ on	Protocol so no results to report
DIS	SCUSSION			Apri	
16	Summary of findings	Summarise the main findings with attention to the evaluation questions, purpose of the evaluation, programme theory and intended audience	NA	16,	Protocol so no results to report
17	Strengths, limitations and future directions	Discuss both the strengths of the evaluation and its limitations. These should include (but need not be	NA	2024 by guest. Protected by copyright.	Discussion of the strengths and limitations will be covered when

		BMJ Open		njopen-2	
				2019-03	
		limited to): (1) consideration of all the steps in the evaluation processes; and (2) comment on the adequacy, trustworthiness and value of the explanatory insights which emerged In many evaluations, there will be an expectation to provide guidance on future directions for the programme, policy or initiative, its implementation and/or design. The particular implications arising from the realist nature of the findings should be		omjopen-2019-033208 on 25 February 2020. Downloaded from http://bmjopen.t	reporting the result of the study
18	Comparison with existing literature	reflected in these discussions Where appropriate, compare and contrast the evaluation's findings with the existing literature on similar programmes, policies or initiatives	NA	mj.com/ on April	Protocol so no results to compare with existing literature
19	Conclusion and recommendations	List the main conclusions that are justified by the analyses of the data. If appropriate, offer recommendations consistent with a realist approach	NA	16, 2024 by guest.	Protocol so no results on which to base recommendations
20	Funding and conflict of interest	State the funding source (if any) for the evaluation, the role played by the	Y	16 Protected	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 33 of 32	BMJ Open g
1 2	BMJ Open -2019-2019-2019-2019-2023
3 4 5	funder (if any) and any conflicts of
6 7	interests of the evaluators
8 9	
10 11 12 13 14 15 16	interests of the evaluators
17 18 19 20 21	from http://bmj
22 23 24 25	ppen.bmj.com/
26 27 28 29 30	on April 16, 2
31 32 33 34	024 by guest
35 36 37	Prote
38 39	cted by
40 41 42	Protected by copyright
42 43 44 45	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
46	

How, in what contexts, and why do quality dashboards lead to improvements in care quality in acute hospitals? Protocol for a realist feasibility evaluation

Journal:	BMJ Open
Manuscript ID	bmjopen-2019-033208.R1
Article Type:	Protocol
Date Submitted by the Author:	21-Oct-2019
Complete List of Authors:	Randell, Rebecca; University of Leeds, School of Healthcare Alvarado, Natasha; University of Leeds, School of Healthcare McVey, Lynn; University of Leeds, School of Healthcare Greenhalgh, Joanne; University of Leeds, Sociology and Social Policy West, Robert; University of Leeds, Leeds Institute of Health Sciences Farrin, Amanda; University of Leeds, Clinical Trials Research Unit Gale, Chris; University of Leeds, Leeds Institute if Genetics, Health and Therapeutics Keen, Justin; University of Leeds, Leeds Institute of Health Sciences Elshehaly, Mai; University of Leeds, School of Computing Ruddle, Roy; University of Leeds, School of Computing Lake, Julia; Leeds Teaching Hospitals NHS Trust Mamas, Mamas; Royal Stoke University Hospital Feltbower, Richard; University of Leeds, Dowding, Dawn; University of Manchester
Primary Subject Heading :	Health informatics
Secondary Subject Heading:	Health services research
Keywords:	AUDIT, Health informatics < BIOTECHNOLOGY & BIOINFORMATICS, Clinical audit < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, QUALITATIVE RESEARCH

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

R. O.

2									
3 4	1	Title: How, in what contexts, and why do quality dashboards lead to improvements in care							
5 6	2	quality in acute hospitals? Protocol for a realist feasibility evaluation							
7 8	3								
8 9 10	4	Authors							
10 11 12	5	Corresponding author: Rebecca Randell, School of Healthcare, University of Leeds, Leeds, UK,							
13 14	6	r.randell@leeds.ac.uk							
15	7	Natasha Alvarado, of Healthcare, University of Leeds, Leeds, UK, n.alvarado@leeds.ac.uk							
16 17	8	Lynn McVey, School of Healthcare, University of Leeds, Leeds, UK, I.mcvey@leeds.ac.uk							
18 19	9	Joanne Greenhalgh, School of Sociology and Social Policy, University of Leeds, Leeds, UK,							
20 21	10	j.greenhalgh@leeds.ac.uk							
22 23	11	Robert West, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK, r.m.west@leeds.ac.uk							
24 25	12	Amanda Farrin, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK,							
26 27	13	a.j.farrin@leeds.ac.uk							
28 29	14	Chris P. Gale, School of Medicine, University of Leeds, Leeds, UK, c.p.gale@leeds.ac.uk							
30 31	15	Roger Parslow, School of Medicine, University of Leeds, Leeds, UK, r.c.parslow@leeds.ac.uk							
32 33	16	Justin Keen, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK, j.keen@leeds.ac.uk							
34 35	17	Mai Elshehaly, School of Computing, University of Leeds, Leeds, UK, m.h.elshehaly@leeds.ac.uk							
36 37	18	Roy A. Ruddle, School of Computing, University of Leeds, Leeds, UK, r.a.ruddle@leeds.ac.uk							
38	19	Julia Lake, Leeds Teaching Hospitals NHS Trust, Leeds, UK, julia.lake3@nhs.net							
39 40	20	Mamas A. Mamas, Royal Stoke Hospital, Stoke on Trent, UK, mamasmamas1@yahoo.co.uk							
41 42	21	Richard Feltbower, School of Medicine, University of Leeds, Leeds, UK, r.g.feltbower@leeds.ac.uk							
43 44	22	Dawn Dowding, School of Health Sciences, University of Manchester, Manchester, UK,							
45 46	23	dawn.dowding@Imanchester.ac.uk							
47 48	24								
49 50	25								
51									
52									
53									
54									
55 56									
56 57									
57 58									
59									
60									
		1							

BMJ Open

 I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in our licence.

10 The Submitting Author accepts and understands that any supply made under these terms is made by 11 BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a 12 postgraduate student of an affiliated institution which is paying any applicable article publishing charge 13 ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on 14 an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access 15 shall be governed by a Creative Commons licence – details of these licences and which Creative 16 Commons licence will apply to this Work are set out in our licence referred to above.

ABSTRACT

Introduction: National audits are used to monitor care quality and safety and are anticipated to reduce unexplained variations in quality by stimulating quality improvement. However, variation within and between providers in the extent to which they engage with national audits mean that the potential for national audit data to inform quality improvement is not being realised. This study aims to undertake a feasibility evaluation of QualDash, a quality dashboard designed to support clinical teams and managers to explore data from two national audits, the Myocardial Ischaemia National Audit Project (MINAP) and the Paediatric Intensive Care Audit Network (PICANet).

Methods and analysis: Realist evaluation, which involves building, testing, and refining theories of how an intervention is supposed to work, provides an overall framework. Realist hypotheses that describe how, in what contexts, and why QualDash is expected to provide benefit will be tested across five hospitals. A controlled interrupted time series analysis will investigate impacts of QualDash using key MINAP and PICANet measures. Ethnographic observations and interviews over 12 months will provide insight into contexts and mechanisms that lead to those impacts. Feasibility outcomes include the extent to which MINAP and PICANet data are used, data completeness in the audits, and the extent to which participants perceive QualDash to be useful and express the intention to continue using it after the study period.

Ethics and dissemination: The study has been approved by University of Leeds School of Healthcare Research Ethics Committee. Study results will provide an initial understanding of how, in what contexts, and why quality dashboards may lead to improvements in care quality. These will be disseminated to academic audiences, study participants, hospital IT departments, and national audits. If results show a trial of QualDash is feasible, we will disseminate the QualDash software through a stepped wedge cluster randomised trial.

- Trial registration: ISRCTN18289782

Keywords: Dashboard, audit and feedback, quality improvement, realist evaluation

Word count: 4,078

1	ARTICLE SUMMARY
---	-----------------

Strengths and limitations of this study

- This study combines a controlled interrupted time series study with a qualitative multi-site case study in order to provide an understanding of not only whether use of a quality dashboard leads to guality improvement but also how, in what contexts, and why.
- In addition to assessing the feasibility of a trial, the study will determine the components of QualDash to be preserved in a definitive trial, appropriate outcome measures, and the contexts in which a definitive trial should be undertaken.
 - The study will contribute to understanding of how realist methods can contribute to feasibility studies and the design of trials.
 - Issues of data quality may be a limitation of the CITS; data completeness, and whether this changes over the course of the study, will be assessed,

INTRODUCTION

National clinical audits (NCAs), which provide comparative data on the performance of healthcare providers, are one means by which health systems around the world monitor care quality and safety. In England, a programme of over 30 NCAs is managed by the Healthcare Quality Improvement Partnership (HQIP) and all healthcare providers that contribute to delivery of the National Health Service (NHS) are required to participate. Such audits are anticipated to reduce unexplained variations in healthcare quality by stimulating quality improvement (QI) [1 2]. While there is evidence of positive impacts of NCAs [3-5], variation within and between providers in the extent to which they engage with NCAs mean the potential for NCA data to inform QI is not being realised [6 7].

Quality dashboards are a form of audit and feedback (A&F) that provide visualisations of audit data with the aim of informing QI efforts [8]. Healthcare providers are increasingly using quality dashboards. For example, quality dashboard use has been reported in Canada [9], the UK [10], and the Netherlands [11]. While quality dashboards have been shown to have positive effects on some performance indicators [9], empirical evidence regarding their impact remains limited [12].

1		
2 3	1	
4 5		
6 7	2	QualDash
8 9	3	QualDash is an interactive web-based quality dashboard designed to support clinical teams and
10 11	4	managers to explore data from two national audits, the Myocardial Ischaemia National Audit Project
12 13	5	(MINAP) and the Paediatric Intensive Care Audit Network (PICANet), for the purpose of QI (Fig. 1).
14 15	6	Information used to inform design of QualDash was collected through interviews with 50 clinicians and
16 17	7	managers across five NHS Trusts (providers) and four healthcare commissioners, observations of
18 19	8	meetings where audit data are discussed, a workshop with NCA suppliers, and two co-design
20	9	workshops with clinicians and managers from one Trust.
21 22	10	
23 24	11	Fig. 1: Prototype of main dashboard view for the Paediatric Intensive Care Audit Network (using
25 26	12	simulated data).
27 28	13	[Figure 1 should go approximately here]
29 30	14	
31 32	15	The interviews revealed that use of NCA data is largely at the clinical team level, with more limited use
33 34	16	at divisional and corporate (Board and sub-committees that report to the Board, such as Quality and
35	17	Safety Committees) levels. At all levels, a key constraint in use of NCA data for QI is lack of access to
36 37	18	timely data; there was consensus among interviewees that data should not be more than three months
38 39	19	old. QualDash seeks to improve access to timely data, providing users with a means to visualise the
40 41	20	data they collect for the NCAs, without having to wait for data to be returned to them from the NCAs.
42 43	20	There is variation between Trusts in the extent to which NCA data are used, often related to resources,
44 45	21	
46 47	22	which in turn impacts on timeliness of data; Trusts that make greater use of NCA data tend to have
48		local databases from which they can generate visualisations of the data (e.g. bar charts) and audit
49 50	24	support staff who have the time and skills to be able to generate such visualisations. In contrast, where
51 52	25	such resources are not available, Trusts rely on the NCA annual reports, where data may be 15 months
53 54	26	old (e.g. one annual report published in June 2017 reported data from April 2015 to March 2016).
55 56	27	QualDash provides visualisations of key metrics, each metric being represented within a 'QualCard'
57 58	28	(Fig. 2), enabling Trusts to use NCA data for QI, regardless of existing resources. QualCards for MINAP
58 59 60	29	and PICANet are listed in Table 1; while there is only one set of QualCards for PICANet, for MINAP an
00		

- additional QualCard is provided for teaching hospitals, as discussions with sites revealed that the
 - metrics of interest are different between teaching hospitals and District General Hospitals (DGHs). Sites
 - are also able to create additional QualCards, to reflect local priorities.

- Fig. 2: Prototype of main dashboard view for the Paediatric Intensive Care Audit Network with the
- Mortality QualCard expanded (using simulated data).
 - [Figure 2 should go approximately here]

Table 1: QualCards

	Metric			
MINAP – all	Mortality			
sites	Door (arrival in Accident and Emergency) to angiogram time			
	Gold standard drugs on discharge			
	Referral for cardiac rehabilitation			
	Acute use of aspirin			
MINAP -	Call (by patient/relative to emergency services) to balloon (percutaneous			
teaching	teaching coronary intervention) time			
hospital specific				
PICANet – all	Mortality			
sites 48 hour unplanned readmission				
Bed days and accidental extubation				
Specialty case mix				
Data quality (number of records with a missing value)				
Patient dependency				

To load new data into QualDash, NCA data are either extracted from the site's database or downloaded from the NCA website and then fed to a small script (written in R), which in turn updates the dashboard. Users can add new data as often as they want, but at a minimum they will load data into QualDash at the same time as uploading to the NCAs (typically every three months).

The benefits perceived from using QualDash may vary between sites, with under-resourced sites that previously made little use of NCA data for QI perceiving greater impact than those that already have the means to use NCA data for QI. There are also constraints on use of NCA data for QI that it may be difficult for QualDash to address. For example, in some Trusts, clinical team members perceive that relevant managers will not agree to provide the resources necessary for QI initiatives, which reduces motivation to engage with NCA data and may affect the extent to which QualDash is used. However, QualDash provides means for visualisations to be downloaded and incorporated into presentations and

reports, which may support clinical teams in making a stronger case for QI initiatives. Another constraint on use of NCA data for QI relates to clinicians' trust in the quality of the data. Interviews revealed variations across sites in processes for ensuring data quality. However, some interviewees also suggested that having the means to make more use of NCA data via QualDash would motivate them to improve their processes for ensuring data quality, although this will be dependent on local resources.

In this paper, we describe the methods for a realist feasibility evaluation of QualDash. The study
objectives are:

9 1. To understand how, in what contexts, and why use of QualDash leads to QI; and

10 2. To assess the feasibility of conducting a trial of QualDash.

11 As no checklists exist for reporting of realist evaluation protocols, in presenting this protocol we draw

12 on the RAMESES II reporting standards for realist evaluations [13] (Additional file 1).

14 METHODS AND ANALYSIS

15 Study design

Use of theory is needed for design and evaluation of A&F interventions [14-16], and QI initiatives more generally [17-19]. This project draws on Realist Evaluation (RE), which involves building, testing, and refining theories about how an intervention is supposed to work [20]. These theories are expressed in the form of Context Mechanism Outcome (CMO) configurations, where C+M=O, reflecting the realist understanding that it is recipients' responses to the resources that an intervention provides (the intervention mechanisms) that determine the impact of the intervention, and such responses are highly influenced by context [21]. Consequently, RE seeks to answer not only the guestion of 'what works?' but 'what works for whom, in what circumstances, and why?' [22]. It is concerned with both intended and unintended outcomes. RE is recommended for studying QI [23] and has been used for studying the implementation and impact of large-scale QI programmes [24]. There is increasing interest in use of realist methods in feasibility evaluations [25-27].

We have drawn on a range of sources to develop CMO configurations which describe how, in what contexts, and why use of QualDash is anticipated to lead to QI (see Additional file 2). Data generated from the interviews, observations, and workshops described above have been essential to this, as have

BMJ Open

discussions with the designers of QualDash (ME and RAR) who, drawing on their expertise in
 information visualisation, have their own literature-informed theories regarding why certain features of
 QualDash will provide benefit to users [28 29]. We have also drawn on substantive theories regarding
 how A&F lead to QI at the micro [30 31], meso [32], and macro level [33 34].

Data collection is designed to enable testing of the CMO configurations. Outcome data, in the form of key MINAP and PICANet measures, will be collected and analysed in a controlled interrupted time series (CITS) study, while a multi-site case study [35] will provide insight into the contexts and mechanisms that lead to those outcomes, as well as providing data on intermediate outcomes such as increased use of NCA data. A&F interventions, and QI interventions more generally, require longitudinal evaluation to allow sufficient time for staff to implement changes and incorporate them into their practice [36-38]. Similarly, evaluation of health IT (HIT) should allow time for staff to integrate the technology into their practices and evolve those practices to take advantage of the functionality offered by the technology [39]. Therefore, data will be collected over a 12 month period, from August 2019.

)

Public and patient involvement

A Lay Advisory Group has been established, which has contributed to the design of QualDash by reviewing the topic guide for the interviews that were conducted, providing their perspective on the findings of the interview study, and participating in the usability evaluation of QualDash. For the realist feasibility evaluation, they have provided advice on aspects to pay attention to when undertaking observations. They will contribute to analysis of a sample of the qualitative data, to provide a patient perspective. They will advise on dissemination of findings to relevant interest groups and will review outputs for comprehensibility.

25 Setting/context

QualDash will be evaluated in the five NHS acute Trusts in which the interview study that informed the
design of QualDash was undertaken. Three Trusts are teaching hospitals that participate in both MINAP
and PICANet and have been selected to ensure variation in key outcome measures (MINAP: 30-day
mortality for patients hospitalised with ST-elevation myocardial infarction; PICANet: risk adjusted
standardised mortality ratio). Two Trusts are DGHs that participate in MINAP but do not have a PICU

and so do not participate in PICANet. These have been selected to ensure variation in the same key
 MINAP measure.

4 Multi-site case study

In the multi-site case study, data will be collected through ethnographic observation and interviews. Ethnographic methods have been argued as essential for studying implementation of QI interventions [19] and introduction of HIT [40]. Ethnography is well suited to RE because it involves observing phenomena in context, supporting understanding of how context influences the response to an intervention [41]. We will follow the Biography of Artefacts approach [42], which is concerned with capturing how particular contexts and appropriations of a technology lead to different processes and generate different outcomes, a parallel to RE's concern with contexts, mechanisms, and outcomes [43]. It involves longitudinal 'strategic ethnography' [42], where data collection is guided by a provisional understanding of the moments and locales in which a technology and associated practices evolve [43].

15 Data collection

In the three teaching hospitals, we will undertake a minimum of 24 periods of observation per Trust, to be split across activities related to cardiology and the PICU, and in the two DGHs we will undertake a minimum of 12 periods of observation per Trust, to be spent observing activities related to cardiology. Each period of observation will be a minimum of four hours (total n=384 hours). While researchers will return to each Trust monthly, to understand how use of QualDash changes over time, more time will be spent in the first few months following the introduction of QualDash, because this is when users are most likely to engage with and explore the affordances of QualDash and establish new practices around it, generating information with implications for system enhancement [43]. Observations will be scheduled to take place at different times of day and on different days of the week, to ensure the account of what is observed is as complete and representative as possible [44].

At each case site, an initial phase of general observation will provide an opportunity for researchers to
 become familiar with the setting and for those in the setting to become familiar with the presence of the
 researchers. Following a previous study of dashboards [10], observations will be undertaken in clinical
 areas to understand clinical teams' working practices and capture 'corridor committees' where issues

BMJ Open

of quality and safety are discussed more informally [45]. In the PICUs, initial observations will take place on the PICU, e.g. with the researchers positioning themselves by the nurses' station, as well as observing handovers, safety huddles, and ward rounds. Because activities related to cardiology tend to be more dispersed across hospitals, researchers will first shadow clinical team members (consultant cardiologists and acute chest pain nurses) to determine where it is most appropriate to conduct subsequent observations. These initial observations will also be used to record general details of the setting that may influence QualDash use, such as staffing levels and availability of computers.

After this initial phase, observation will be guided by the CMO configurations under investigation. In addition to observing formal meetings where quality and safety are discussed, predominantly at ward level but also at divisional and corporate level, observation will involve shadowing staff members as they undertake particular activities: collection and entry of NCA data, to see if and how this changes over time; accessing and interrogating NCA data, whether using QualDash or some other means; preparation of reports and/or presentations using NCA data, again whether using QualDash or some other means. Where visualisations from QualDash are incorporated into presentations and written reports, we will follow the path of those documents, to identify staff members who may not use QualDash directly but are receiving QualDash outputs. Attention will be paid to how, in what contexts, and why QualDash and QualDash outputs are used or not, understood in the context of broader practices and use of other sources of information for monitoring care quality, and how this changes over time. We will also follow local QI initiatives, recording data on, for example, when and how the need for the QI initiative was identified, contextual factors that appear to support and constrain its introduction, how the impact of the QI initiative is monitored, and other contextual factors that appear to influence the metric that the QI initiative is targeting. Researchers will record observations in fieldnotes, which will be written up in detail as soon after data collection as possible.

Brief interviews will be undertaken opportunistically during the course of conducting observations to
clarify aspects of practice that are not immediately intelligible to an observer, with participant responses
recorded in fieldnotes [46]. As data collection progresses, longer semi-structured interviews will be used
to discuss revisions to our CMO configurations. These will be undertaken using a particular approach
from RE, referred to as the teacher-learner cycle, whereby the theories under investigation are made

explicit to the interviewee so that the interviewee can use their experiences to refine the researcher's
understanding [47]. Being concerned with the reasoning of intervention recipients, mechanisms are
often not observable [21], so these longer interviews will also provide the opportunity to explore staff
reasoning about QualDash. These longer interviews will be audio recorded and transcribed verbatim.

Logfiles are widely used to evaluate visualisation tools [48]. QualDash logfiles will record information about the user (job title, etc.), data used (audit, year), overall time spent using QualDash, time spent interacting with different QualCards (including new QualCards that have been created), functionality used, and whether QualDash visualisations were downloaded. In addition to providing data regarding extent of QualDash use, how QualDash is used and by whom, and how this changes over time, information from logfiles will be used to inform qualitative data collection (e.g. asking in interviews why participants use particular QualCards and not others and the motivation behind the creation of new QualCards).

 At the end of the data collection period, we will ask participants to complete a questionnaire based on the Technology Acceptance Model, using well validated items that have been used in numerous evaluations of HIT [49], including dashboards [50]. This will provide participants' perceptions of the usefulness of QualDash and data on whether they intend to continue using QualDash after the study period.

21 Analysis

An iterative approach to data collection and analysis will be taken, to enable: ongoing testing and refinement of the CMO configurations; gathering of further data in light of such revisions; and refinement of QualDash in response to participants' feedback. Fieldnotes and interview transcripts will be entered into NVivo 11. Narrative analysis will be undertaken to develop a 'biography' of QualDash, which will describe use of QualDash and its outputs by a range of stakeholders at different levels (clinical team, divisional, and corporate) and the interconnections between them [10]. Narrative analysis is consistent with a realist approach due to its emphasis on preserving connections within the data, thereby helping to understand causality [51]. This analysis will be supplemented with analysis of the logfiles and

BMJ Open

questionnaire data. Findings will be compared with the CMO configurations, to determine whether they
 support, refute, or suggest a revision or addition to the CMO configurations.

4 Controlled interrupted time series study

Interrupted time series studies provide a robust method of assessing the effect of an intervention and have been used to assess effectiveness of a variety of complex interventions [52]. In a CITS, the addition of a control group enhances causal inference because the presence of seasonal trends and other potential time-varying confounders can be assessed [53]. Data will be collected across the five Trusts, with two control Trusts per intervention Trust, providing a total of 10 control Trusts. Control Trusts will be matched according to their size and outcomes pre-intervention. Having more than one control site per intervention site increases power but, as the number of control sites per intervention site increases, guality of matching decreases. Therefore, we have chosen to have two control Trusts per intervention Trust to increase power while maintaining quality of the matching.

Given the study intention to determine the feasibility of and inform the design of a trial, a range of measures will be considered. Initially, we selected two process measures, one for MINAP and one for PICANet. For MINAP, we selected the composite process measure Cumulative Missed Opportunities for Care (CMOC). This has nine components (pre-hospital ECG, acute use of aspirin, timely perfusion, referral for cardiac rehabilitation, and prescription at hospital discharge of what are considered to be the gold standard drugs – aspirin, thienopyridine inhibitor, ACE-inhibitor, HMG-CoA reductase inhibitor, and beta blockers) and is inversely associated with mortality [54]. As some of these components, such as pre-hospital ECG, are outside the direct control of the Trust, we will also explore the impact of QualDash on the individual measures that make up CMOC. On the basis of the measures that cardiology clinicians described in the interviews as being important for measuring care quality, we will also look at the percentage of patients who receive an angiogram within 72 hours from first admission to hospital, which is part of the Best Practice Tariff financial incentive scheme, and, for those hospitals that provide percutaneous coronary intervention (PCI), the proportion of patients who have a door-to-balloon time (the time from arrival at the hospital to PCI) of less than 60 minutes. Our CMO configurations (Additional file 2) suggest improvement will be seen in measures if: clinical teams perceive them as being important indicators of care and/or they relate to financial incentives;

performance is not in line with expectations; they perceive the measure as being within their control; and the team is resourced to introduce QI initiatives in relation to these measures.

> For PICANet, we initially selected use of non-invasive ventilation first for patients requiring ventilation, which has been shown to be associated with reduced mortality [55]. However, this was not raised as an area of concern in our interviews with PICU clinicians. On the basis of this and two additional considerations - it would require loading additional data into QualDash which would reduce the performance of QualDash in terms of speed and it requires computation of the data, while the focus of QualDash is on visualising the data – a QualCard has not been created for this metric. Therefore, we do not hypothesise that this measure will change, unless other sources of information, such as the PICANet annual report, draw a PICU team's attention to it. However, accidental extubation and unplanned readmission within 48 hours were identified in our interviews with PICU clinicians as being important indicators of care quality, so we will include these two measures in the CITS. On the basis of our CMO configurations (Additional file 2), we would expect to see an improvement in these measures in sites where performance is not in line with expectations, if the team is resourced to introduce QI 1.6 initiatives in relation to these measures.

Sample size considerations

A CITS study requires data for a minimum of three time points pre-intervention and three time points post-intervention and must also allow for any seasonal effect on the outcomes [56]. Monthly data will be obtained for 24 months pre-intervention and 12 months post-intervention. Consequently, for each intervention Trust, there will be 72 data points prior to introduction (24 for the intervention Trust and 48 for the control Trusts) and 36 data points post intervention (12 for the intervention Trust and 24 for the control Trusts). Sample size calculations were undertaken based on our two initial measures, CMOC for MINAP and use of non-invasive ventilation first for patients requiring ventilation for PICANet; full details are provided in Additional file 3.

Analysis

Monthly MINAP and PICANet data will be extracted to spreadsheets for analysis with R software [57]. For both NCAs, each outcome will be regressed upon time and the intervention. The time component

BMJ Open

will include a seasonal effect (quarterly effect) and will allow for a (linear) time trend. To account for clustering of monthly observations within hospitals, a random intercept will be fitted, although a fixed effect for hospital as a sensitivity analysis will be explored. Although the intervention is abrupt, its impact may well be 'phased in' over a few months, perhaps three. The timing of the bedding in of the intervention will be reported from the multi-site case study. Then a partial effect can be considered for this period with the interaction effect stepping up in a linear fashion.

8 Results of the CITS analysis will be incorporated into the biography of QualDash, the analysis of the
9 data from the multi-site case study describing how contextual factors shape the evolution of practices
10 around QualDash and how this leads to the resulting outcome pattern.

12 Trial feasibility assessment and design

Our trial progression criteria are: (i) the number of people who engage with either MINAP or PICANet data (via QualDash or some other means) is the same or higher than the number of people who engaged with either MINAP or PICANet data prior to QualDash's introduction; (ii) data completeness in the national audit improves or remains the same; (iii) 50% or more of participants in the questionnaire survey perceive QualDash to be useful and express the intention to continue using it after the study period. Criteria (i) and (ii) are concerned with ensuring the intervention does not have unintended negative consequences which would affect success of the intervention. Criterion (ii) is also concerned with feasibility of outcome assessment. Criterion (iii) is concerned with acceptability and uptake of the intervention, and therefore has implications for recruitment to a trial, as well as being concerned with participants' perceptions of the impact of QualDash on care. While not formally assessed as part of the progression criteria, the impact of QualDash on care as identified in the CITS will be considered in determining whether a future trial is justified. A traffic light system will be used to determine if a trial is feasible (green), feasible with modifications to QualDash (amber), or not feasible (red) [58 59].

If the results show a trial of QualDash is feasible, we will design a stepped wedge cluster randomised
trial. Data from the CITS will be used to inform the selection of NCAs to be included in the trial (MINAP
and/or PICANet) and will provide information about variability of outcomes and about how long a trial
intervention period would need to be. Findings from the multi-site case study will be used to inform the

selection of categories of user to be included in the trial and, associated with this, the level of randomisation (Trust, hospital, or ward). Using the understanding of the relationship between contexts, mechanisms, and outcomes provided by the study, we will identify QualDash components associated with mechanisms that produce the desired outcomes in order for them to be preserved in the trial, while other components can be adapted to suit the local context.

ETHICS AND DISSEMINATION

Ethics approval has been received from the University of Leeds School of Healthcare Research Ethics Committee (Approval no.HREC16-044). Written consent will be obtained from participants for interviews and for meeting observations.

> Study results will provide initial understanding of how and in what contexts quality dashboards may lead to improvements in care quality. We will disseminate these results to academic audiences, study participants, hospital IT departments, and NCAs. If we progress to a trial, in addition to providing further understanding of the impact of quality dashboards on care quality, this will result in wider dissemination of the QualDash software. 4.0

Acknowledgements

This research is funded by the National Institute for Health Research (NIHR) Health Services and Delivery Research (HS&DR) Programme (project number 16/04/06). The views and opinions expressed are those of the presenter and do not necessarily reflect those of the HS&DR programme, NIHR, NHS or the Department of Health.

Data statement

The qualitative data gathered during the course of this evaluation will be kept until June 2030 and can be accessed by other researchers during this time, subject to the necessary ethical approvals being obtained. Requests for access to this data should be addressed to the corresponding author.

Ζ.		
- 3 4	1	Authors' contributions
5	2	RR is Principal Investigator for the study. She conceived, designed, and secured funding for the study
7	3	in collaboration with JG, RW, AF, CPG, RP, JK, RAR, JL, MM, and DD. NA and LM led the qualitative
8 9	4	data collection and analysis that informed the design of QualDash and the design of evaluation. ME
10 11	5	developed the QualDash software and contributed to the design of the evaluation. RP and RF provided
12 13	6	data for the testing of QualDash and provided significant feedback on its design. All authors provided
14 15	7	input into various aspects of the evaluation design and revised drafts of the protocol. RR led the writing
16 17	8	of this protocol manuscript. All authors read and approved the final manuscript.
18 19	9	
20 21	10	Funding statement
22 23	11	This research is funded by the National Institute for Health Research (NIHR) Health Services and
24 25	12	Delivery Research (HS&DR) Programme (project number 16/04/06).
26	13	
27 28	14	Competing interests statement
29 30	15	Chris Gale is a member of the MINAP Academic and Steering Groups. Richard Feltbower is Principal
31 32	16	Investigator for PICANet and Roger Parslow was previously Principal Investigator for PICANet. The
33 34	17	authors have no other competing interests to declare.
35 36	18	
37 38	19	Additional files
39 40	20	Additional file 1: Checklist of RAMESES II reporting standards for realist evaluations (PDF)
41 42	21	Additional file 2: Context Mechanism Outcome configurations to be tested in the realist feasibility
43 44	22	evaluation (PDF)
45 46	23	Additional file 3: Sample size calculations for controlled interrupted time series (PDF)
47 48	24	
49 50	25	REFERENCES
51	26	1. Phekoo KJ, Clements J, Bell D. National Clinical Audit Quality Assessment - Overview of the self-
52	27	assessment survey: "audit of audits". London: Healthcare Quality Improvement Partnership,
53	28	2014.
54		
55	29	2. Miller T, Leatherman S. The National Quality Forum: a'me-too'or a breakthrough in quality
56	30	measurement and reporting? Health Aff. (Millwood) 1999; 18 (6):233-37.
57	31	3. Birkhead JS, Walker L, Pearson M, Weston C, Cunningham AD, Rickards AF. Improving care for
58	32	patients with acute coronary syndromes: initial results from the National Audit of Myocardial
59	33	Infarction Project (MINAP). Heart 2004; 90 (9):1004-09.
60		

Page 18 of 33

BMJ Open

1 2

2		
3	1	4. Bridgewater B, Grayson AD, Brooks N, et al. Has the publication of cardiac surgery outcome data
4	2	been associated with changes in practice in northwest England: an analysis of 25 730 patients
5	3	undergoing CABG surgery under 30 surgeons over eight years. Heart 2007; 93 (6):744-48.
6 7	4	5. Neuburger J, Currie C, Wakeman R, et al. The Impact of a National Clinician-led Audit Initiative on
8	5	Care and Mortality after Hip Fracture in England: An External Evaluation using Time Trends in
9	6	Non-audit Data. Med. Care 2015; 53 (8):686-91.
10	7	6. Allwood D. Engaging Clinicians in Quality Improvement through National Clinical Audit. London:
11	8	Healthcare Quality Improvement Partnership, 2014.
12	9	7. Taylor A, Neuburger J, Walker K, Cromwell D, Groene O. How is feedback from national clinical
13	10	audits used? Views from English National Health Service trust audit leads. J. Health Serv. Res.
14	11	Policy 2016; 21 (2):91-100.
15	12	8. Pauwels K, Ambler T, Clark BH, et al. Dashboards as a Service Why, What, How, and What Research
16	13	Is Needed? Journal of Service Research 2009; 12 (2):175-89.
17	14	9. Weiss D, Dunn SI, Sprague AE, et al. Effect of a population-level performance dashboard
18 19	15	intervention on maternal-newborn outcomes: an interrupted time series study. BMJ Quality
20	16	& amp; Safety 2018; 27 (6):425-36.
20	10	10. Keen J, Nicklin E, Long A, et al. Quality and safety between ward and board: a biography of artefacts
22	18	study. Health Services and Delivery Research 2018;6(22).
23		11. Weggelaar-Jansen AMJWM, Broekharst DSE, de Bruijne M. Developing a hospital-wide quality and
24	19 20	safety dashboard: a qualitative research study. BMJ Quality & amp; Safety 2018.
25	20	
26	21	12. Dowding D, Randell R, Gardner P, et al. Dashboards for improving patient care: Review of the
27	22	literature. International Journal of Medical Informatics 2015; 84 (2):87-100.
28	23	13. Wong G, Westhorp G, Manzano A, Greenhalgh J, Jagosh J, Greenhalgh T. RAMESES II reporting
29 30	24	standards for realist evaluations. BMC Med. 2016; 14 (1):96.
31	25	14. Foy R, Eccles MP, Jamtvedt G, Young J, Grimshaw JM, Baker R. What do we know about how to do
32	26	audit and feedback? Pitfalls in applying evidence from a systematic review. BMC Health Serv.
33	27	Res. 2005; 5 :50.
34	28	15. Ivers NM, Grimshaw JM, Jamtvedt G, et al. Growing Literature, Stagnant Science? Systematic
35	29	Review, Meta-Regression and Cumulative Analysis of Audit and Feedback Interventions in
36	30	Health Care. J. Gen. Intern. Med. 2014; 29 (11):1534-41.
37	31	16. Ivers NM, Sales A, Colquhoun H, et al. No more 'business as usual' with audit and feedback
38	32	interventions: towards an agenda for a reinvigorated intervention. Implementation Science
39 40	33	2014; 9 (1):1-8.
40	34	17. Grol RPTM, Bosch MC, Hulscher MEJL, Eccles MP, Wensing M. Planning and Studying Improvement
42	35	in Patient Care: The Use of Theoretical Perspectives. Milbank Q. 2007; 85 (1):93-138.
43	36	18. Davidoff F, Dixon-Woods M, Leviton L, Michie S. Demystifying theory and its use in improvement.
44	37	BMJ Quality & Safety 2015.
45	38	19. Dixon-Woods M, Bosk CL, Aveling EL, Goeschel CA, Pronovost PJ. Explaining Michigan: Developing
46	39	an Ex Post Theory of a Quality Improvement Program. Milbank Q. 2011; 89 (2):167-205.
47	40	20. Pawson R, Tilley N. <i>Realistic Evaluation</i> . London: SAGE Publications, 1997.
48	41	21. Dalkin S, Greenhalgh J, Jones D, Cunningham B, Lhussier M. What's in a mechanism? Development
49 50	42	of a key concept in realist evaluation. Implementation Science 2015; 10 (1):49.
50 51	43	22. Pawson R. The science of evaluation: a realist manifesto. London: SAGE, 2013.
52	44	23. Robert G, Fulop N. The role of context in successful improvement. Perspectives on context. A
53	45	selection of essays considering the role of context in successful quality improvement. London:
54	46	Health Foundation 2014; 31 .
55	47	24. Greenhalgh T, Humphrey C, Hughes J, Macfarlane F, Butler C, Pawson R. How Do You Modernize a
56	48	Health Service? A Realist Evaluation of Whole-Scale Transformation in London. Milbank Q.
57	49	2009; 87 (2):391-416.
58		
59		
60		

17

¢

2		
3	1	25. Fletcher A, Jamal F, Moore G, Evans RE, Murphy S, Bonell C. Realist complex intervention science:
4	2	Applying realist principles across all phases of the Medical Research Council framework for
5	3	developing and evaluating complex interventions. Evaluation 2016; 22 (3):286-303.
6	4	26. Brand SL, Quinn C, Pearson M, et al. Building programme theory to develop more adaptable and
7	5	scalable complex interventions: Realist formative process evaluation prior to full trial.
8 9	6	Evaluation 2019; 25 (2):149-70.
9 10	7	27. Randell R, Honey S, Hindmarsh J, et al. A realist process evaluation of robot-assisted surgery:
11	8	integration into routine practice and impacts on communication, collaboration and decision-
12	° 9	
13		making. Health Services and Delivery Research 2017;5(20).
14	10	28. Andrienko N, Andrienko G. <i>Exploratory analysis of spatial and temporal data: a systematic</i>
15	11	approach: Springer Science & Business Media, 2006.
16	12	29. Brehmer M, Munzner T. A multi-level typology of abstract visualization tasks. IEEE transactions on
17	13	visualization and computer graphics 2013; 19 (12):2376-85.
18	14	30. Hysong SJ, Best RG, Pugh JA. Audit and feedback and clinical practice guideline adherence: Making
19	15	feedback actionable. Implementation Science 2006; 1 (1):1-10.
20	16	31. Sapyta J, Riemer M, Bickman L. Feedback to clinicians: Theory, research, and practice. J. Clin.
21	17	Psychol. 2005; 61 (2):145-53.
22	18	32. Van Helden GJ, Tillema S. In Search of a Benchmarking Theory for the Public Sector. Financial
23	19	Accountability & Management 2005; 21 (3):337-61.
24 25	20	33. Scott RW. Institutions and Organizations. 2nd Edition ed. London: Sage, 2001.
25	21	34. Furusten S. Institutional Theory and Organizational Change. Cheltenham, UK: Edward Elgar, 2013.
20	22	35. Yin RK. Case study research: design and methods. 3rd ed. Thousand Oaks, California: SAGE, 2003.
28	23	36. Øvretveit J, Gustafson D. Evaluation of quality improvement programmes. Quality and Safety in
29	24	Health Care 2002; 11 (3):270-75.
30	25	37. Ramsay AIG, Turner S, Cavell G, et al. Governing patient safety: lessons learned from a mixed
31	26	methods evaluation of implementing a ward-level medication safety scorecard in two English
32	27	NHS hospitals. BMJ Quality & Safety 2013; 23 :136-46.
33	28	38. Benn J, Burnett S, Parand A, Pinto A, Iskander S, Vincent C. Studying large-scale programmes to
34	28	improve patient safety in whole care systems: Challenges for research. Soc. Sci. Med.
35		
36	30	2009; 69 (12):1767-76.
37	31	39. Hyysalo S. Health technology development and use: from practice-bound imagination to evolving
38	32	impacts. New York: Routledge, 2010.
39 40	33	40. Greenhalgh T, Swinglehurst D. Studying technology use as social practice: the untapped potential
40 41	34	of ethnography. BMC Med. 2011; 9 (1):45.
42	35	41. Dainty KN, Golden BR, Hannam R, et al. A realist evaluation of value-based care delivery in home
43	36	care: The influence of actors, autonomy and accountability. Soc. Sci. Med. 2018; 206 :100-09.
44	37	42. Pollock N, Williams R. Software and organisations: The biography of the enterprise-wide system or
45	38	how SAP conquered the world. New York: Routledge, 2008.
46	39	43. Pollock N, Williams R. e-Infrastructures: How Do We Know and Understand Them? Strategic
47	40	Ethnography and the Biography of Artefacts. Computer Supported Cooperative Work (CSCW)
48	41	2010; 19 (6):521-56.
49	42	44. Hammersley M, Atkinson P. Ethnography: principles in practice. London: Routledge, 1995.
50	43	45. Waring J. Adaptive regulation or governmentality: patient safety and the changing regulation of
51	44	medicine. Sociol. Health Illn. 2007; 29 (2):163-79.
52 53	45	46. Goodwin D, Pope C, Mort M, Smith A. Access, boundaries and their effects: legitimate participation
53 54	46	in anaesthesia. Sociol. Health Illn. 2005; 27 (6):855-71.
54 55	47	47. Pawson R. Theorizing the Interview. The British Journal of Sociology 1996;47(2):295-314.
56	48	48. Harrison DG, Efford ND, Fisher QJ, Ruddle RA. PETMiner—A Visual Analysis Tool for Petrophysical
57	49	Properties of Core Sample Data. IEEE transactions on visualization and computer graphics
58	50	2017; 24 (5):1728-41.
59	20	
60		

c

- 49. Holden RJ, Karsh B-T. The Technology Acceptance Model: Its past and its future in health care.
 Journal of Biomedical Informatics 2010;43(1):159-72.
 - 50. Lee K, Jung SY, Hwang H, et al. A novel concept for integrating and delivering health information
 using a comprehensive digital dashboard: An analysis of healthcare professionals' intention to
 adopt a new system and the trend of its real usage. Int. J. Med. Inform. 2017;97:98-108.

6 51. Maxwell JA. *A realist approach for qualitative research*. London: SAGE Publications, 2012.

- 52. Hu Y. Stepped wedge, natural experiments and interrupted time series analysis designs. In:
 Richards DA, Hallberg IR, eds. Complex interventions in health: An overview of research
 methods. Abingdon: Routledge, 2015:200-12.
- 53. Handley MA, Lyles CR, McCulloch C, Cattamanchi A. Selecting and Improving Quasi-Experimental
 Designs in Effectiveness and Implementation Research. Annu. Rev. Public Health 2018;**39**(1):5 25.
- 54. Simms AD, Baxter PD, Cattle BA, et al. An assessment of composite measures of hospital
 performance and associated mortality for patients with acute myocardial infarction. Analysis
 of individual hospital performance and outcome for the National Institute for Cardiovascular
 Outcomes Research (NICOR). European Heart Journal: Acute Cardiovascular Care 2013;2(1):9 18.
 - 55. Morris JV, Ramnarayan P, Parslow RC, Fleming SJ. Outcomes for Children Receiving Noninvasive
 Ventilation as the First-Line Mode of Mechanical Ventilation at Intensive Care Admission: A
 Propensity Score-Matched Cohort Study. Crit. Care Med. 2017.
 - 56. Cochrane Effective Practice and Organisation of Care Group (EPOC). What study designs should be
 inlcuded in an EPOC review and what should they be called? Oslo: Norwegian Knowledge
 Centre for the Health Services, 2013.
 - 57. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014.
 - 58. Bugge C, Williams B, Hagen S, et al. A process for Decision-making after Pilot and feasibility Trials
 (ADePT): development following a feasibility study of a complex intervention for pelvic organ
 prolapse. Trials 2013;14(1):353.
 - 59. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res.
 Methodol. 2010;10(1):1-10.




Fig. 1: Prototype of main dashboard view for the Paediatric Intensive Care Audit Network (using simulated data).

161x74mm (300 x 300 DPI)

BMJ Open: first published as 10.1136/bmjopen-2019-033208 on 25 February 2020. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright.






Fig. 2: Prototype of main dashboard view for the Paediatric Intensive Care Audit Network with the Mortality QualCard expanded (using simulated data).

161x85mm (300 x 300 DPI)

Page 23	of 33
---------	-------

AMESES II reporting	standards for realist evaluations		omjopen-2019-033208 o	
lead to improv	contexts, and why do quality dashboards rements in care quality in acute hospitals? realist feasibility evaluation	Reported in document Y/N/NA	Page(s) in document	Comment
1	In the title, identify the document as a	Y	1 2020	
	realist evaluation		D	
SUMMARY OR A	ABSTRACT		wnlo	
2	Journal articles will usually require an abstract, while reports and other forms of publication will usually benefit from a short summary. The abstract or summary should include brief details on: the policy, programme or initiative under evaluation; programme setting; purpose of the evaluation; evaluation question(s) and/or objective(s); evaluation strategy; data collection, documentation and analysis methods; key findings and conclusions Where journals require it and the nature of the study is appropriate, brief details of respondents to the	Y	wnloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected b ຕາ	

		BMJ Open		omjopen-20	
		evaluation and recruitment and sampling processes may also be included Sufficient detail should be provided to identify that a realist approach was used and that realist programme theory was developed and/or refined		omjopen-2019-033208 on 25 February 2020. Downloade	
	FRODUCTION		X7	<u>a</u>	
3	Rationale for evaluation	Explain the purpose of the evaluation and the implications for its focus and design	Y	from http://t	
4	Programme theory	Describe the initial programme theory (or theories) that underpin the programme, policy or initiative	Y	8 and by Additional file 2 h	Placed in body of article, rather than Introduction, as more appropriate fo protocol
5	Evaluation questions, objectives and focus	State the evaluation question(s) and specify the objectives for the evaluation. Describe whether and how the programme theory was used to define the scope and focus of the evaluation	Y	n April 16, 2024 by guest. I	
6	Ethical approval	State whether the realist evaluation required and has gained ethical approval from the relevant	Y	15 Protected by copyright	

Page	25	of	33
------	----	----	----

		BMJ Open		lopen-z	5
				mjopen-zurie-usazue	
		authorities, providing details as appropriate. If ethical approval was deemed unnecessary, explain why		on 25 re	
ME	THODS			brua	
7	Rationale for using realist evaluation	Explain why a realist evaluation approach was chosen and (if relevant) adapted	Y	7-8 2020. Dow	
8	Environment surrounding the evaluation	Describe the environment in which the evaluation took place	Y	8-9 Red from	
9	Describe the programme policy, initiative or product evaluated	Provide relevant details on the programme, policy or initiative evaluated	Y	5-7 -14 April 16	Description of intervention placed in Introduction as this seemed more appropriate in providing the conte for the protocol
10	Describe and justify the evaluation design	A description and justification of the evaluation design (i.e. the account of what was planned, done and why) should be included, at least in summary form or as an appendix, in the document which presents the main findings. If this is not done, the omission should be justified and a reference or link to the evaluation	Y	7-14 Pril 16, 2024 by guest. Protected by copyright.	

		BMJ Open		omjopen-2	
		design given. It may also be useful to publish or make freely available (e.g. online on a website) any original evaluation design document or		omjopen-2019-033208 on 25 February 2020. Downloaded from http://bmjopen.tcmj.com/ on April 16. 9-11 9-11 8-9	
		protocol, where they exist	\$7	ary 202	
11	Data collection methods	Describe and justify the data collection methods – which ones were used, why and how they fed into developing, supporting, refuting or refining programme theory	Y	9-11 20. Downloaded from ht	
		Provide details of the steps taken to enhance the trustworthiness of data collection and documentation		tp://bmjopen.t	
12	Recruitment process and sampling strategy	Describe how respondents to the evaluation were recruited or engaged and how the sample contributed to the development, support, refutation or refinement of programme theory	Ŷ	2024	Sampling of sites, rather than individuals, is described; Recruitment will be described when reporting the results of the study
13	Data analysis	Describe in detail how data were analysed. This section should include information on the constructs that were identified, the process of	Y	by galactic by gal	
				/ copyright.	

Page	27	of	33
------	----	----	----

	BMJ Open		mjopen-2019-033208 on	
RESULTS	analysis, how the programme theory was further developed, supported, refuted and refined, and (where relevant) how analysis changed as the evaluation unfolded		25 February 2020.	
14 Details of participants	Report (if applicable) who took part in the evaluation, the details of the data they provided and how the data was used to develop, support, refute or refine programme theory	NA	Downloaded from http:/	Protocol so no results to report
15 Main findings	Present the key findings, linking them to contexts, mechanisms and outcome configurations. Show how they were used to further develop, test or refine the programme theory	NA	/bmjopen.bmj.com/ on	Protocol so no results to report
DISCUSSION		0)	Apri	
16 Summary of findings	Summarise the main findings with attention to the evaluation questions, purpose of the evaluation, programme theory and intended audience	NA	ii 16, 2024 by guest.	Protocol so no results to report
17 Strengths, limitations and future directions	Discuss both the strengths of the evaluation and its limitations. These should include (but need not be	4	t. Protected by copyright	Strengths and limitations of study design

3 4

	BMJ Open		njopen-2(
			019-03	
	 limited to): (1) consideration of all the steps in the evaluation processes; and (2) comment on the adequacy, trustworthiness and value of the explanatory insights which emerged In many evaluations, there will be an expectation to provide guidance on future directions for the programme, policy or initiative, its implementation and/or design. The particular implications arising from the realist 		omjopen-2019-033208 on 25 February 2020. Downloaded from http://bmjopen.t	
	nature of the findings should be reflected in these discussions			
18 Comparison with existing literature	Where appropriate, compare and contrast the evaluation's findings with the existing literature on similar programmes, policies or initiatives	NA	mj.com/ on April ,	Protocol so no results to compare with existing literature
19 Conclusion and recommendations	List the main conclusions that are justified by the analyses of the data. If appropriate, offer recommendations consistent with a realist approach	NA	16, 2024 by guest.	Protocol so no results on which to base recommendations
20 Funding and conflict	State the funding source (if any) for the evaluation, the role played by the	Y	16 Protected	

Page 29 of 33	BMJ Open	omiopen
1 2		miopen-2019-033
3 4	funder (if any) and any conflicts of	32008
5		<u>o</u>
6 7		
8		3brua
9 10		arv 2
11		0200.
12 13		Dow
13		
15		aded
16 17		from
18		from http://bmiopen.bmi.com/ on April 16. 2024 by au
19 20		5.//bn
21		
22 23		
24		<u>B</u>
25 26		om/
27		on A
28 29		
30		6. N
31		024
32 33		
34		uest.
35 36		Pro
37		
38 39		
40		Protected by copyright.
41 42		
42 43		h t
44	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	
45		
46		

BMJ Open How, in what contexts, and why do quality dashboards lead to improvements in care quality in acute hospitals? Protocol for a realist feasibility evaluation

#	Context	+	M	echanism 25	=	Outcome
			Resource	Response g		
1.	Teams previously constrained in their	+	QualDash offers easy access to	Teams are able to see whether the	=	Improvement in data
	ability to use NCA data for monitoring		key metrics	data displayed are timely, $a_{\rm gc}^{ m N}$ curate,		quality in terms of
	service performance because data not			and/or complete and, where they are		timeliness, accuracy
	considered to be timely, accurate, and/or			not, adjust their data collection		completeness – as c
	complete			processes in order to benet from		quality improves, us
				QualDash T		QualDash increases
				Teams use QualDash to endbed NCA	=	Increased routine us
				data within their monitoring processes		NCA data in perform
				e.g. in clinical governance		monitoring, providing
				where data is presented visually via		opportunities for its
				screens.		quality improvement
2.	Teams previously using NCA data to	+	QualDash visualises key	Teams use QualDash to fagilitate their	=	Reduced time spent
	monitor service performance routinely by		metrics in ways that clearly	existing processes for mone		accessing, and prep
	extracting raw data and producing		show whether service	service performance using ACA data		visualisations of, NC
	reports for review in meetings and by		performance is within an	116,		data
	individuals		expected range and provides	2024 by		
			functions to interrogate that data	4 by		
				gue		
				st. P		
				rotec		
				cted		
				by o		
				guest. Protected by copyright.		
				ight.		
	For pee	er rev	view only - http://bmjopen.bmj.com/s	ite/about/guidelines.xhtml		

44 45

#	Context	+	Me	echanism	=	Outcome
			Resource	Response မ္မ်		
3.	Teams who want to use NCA data but	+	QualDash provides functions	Teams will use these functions to	=	Introduction of QI
	were previously constrained by data		that enable users to interact	interrogate anomalies in the data,		initiatives in relation to
	quality and existing systems did not		with NCA data and explore	which will help them to und grstand		metrics that teams
	provide functions to easily access and		relationships between variables	what has impacted performence,		consider important and
	interact with the data			thereby enabling them to identify		where performance is no
				appropriate strategies for inproving		in line with expectations
				performance		
				penomance Downloaded		Over time, improvement
				oad		metrics that QI initiatives
				ed fr		target
4.	Performance in key metrics, such as the	+	QualDash offers teams the	Teams add new QualCards to be able	. =	Introduction of QI
	Best Practice Tariff, is in line with		ability to quickly and easily add	to monitor and interrogate detrics the	у	initiatives in relation to
	expectations		new QualCards (within NCA	have chosen as important	-	metrics shown on new
			parameters)	ope		QualCards when
	Relevant audit/IT support staff have time					performance is not in line
	and willingness to support use of					with expectations
	QualDash			have chosen as important on April 16, 2		·
				Ap r		Over time, improvement
				ni 16		metrics that QI initiatives
				3, 2024		target
				n6 A		
				est.		
				Prot		
				ecte		
				by guest. Protected by copyright		
				op Op		
				ýrig		

Page 32 of 33

3 4

24

			BMJ Open		omjopen		Page 3
#	Context	+				=	Outcome
			Resource	Response	2019-03:		
5.	Teams who previously did not, or were	+	QualDash provides quick and	Teams will become aware	<u>ଝ</u>	=	Introduction of QI
	not able to, monitor key metrics routinely		easy access to key metrics	discrepancies between per	Bormance		initiatives in relation to key
				and targets in key metrics,			metrics
	Performance is not in line with			will take action to address	ebru		
	expectations in key metrics				lary		Over time, improvement in
				will take action to address	2020		those metrics
	Teams are resourced to make practice				 Do		
	changes				wnlo		
6.	Teams are asked to produce reports and	+	QualDash offers easy access to	Teams will use QualDash	produce	=	Reduced time spent in
	recommendations for managers and		NCA data and visualisations	performance reports reque	Sted by		report preparation
	other groups about service performance,		that can be exported into	other groups	m ht		
	e.g. at the time of publication of NCA		reports		tp://t		Increased use of NCA
	annual report				mjo		data at divisional and
					pen.		corporate levels via
					bmj.		outputs produced by
					com/		QualDash
					http://bmjopen.bmj.com/ on April 16, 2024 by gu		
					April		Over time, use of
					16, 1		QualDash at divisional
					2024		and/or corporate levels,
					by		due to increased
					guest.		awareness of NCA data
					Protected by copyright.		
					ted b		
					e S		
					pyri		
					ght.		
	For peer	r rev	iew only - http://bmjopen.bmj.com/s	ite/about/guidelines.xhtml			

Page	33	of	33
------	----	----	----

# Context + Mechanism Resource = Outcome 7. Teams receive data requests from service managers + QualDash can be easily accessed via the web by multiple users Service managers will use gualDash to access the information theygneed = Streamlines the use of NCA data for clinical managers 8. Teams need to evidence their performance to managers and other groups in order to support a case for practice change e.g. in business meetings with managers or in the NCA annual report summary + QualDash visualises performance Teams will use these functions to evidence service performangers, in order to convince other Trust groups, who are able to offer addition resource to teams, are change is needed = Other Trust groups, who are able to offer addition resource to teams, are convinced of the need for evidence performangers, e.g.	3 of 33	BMJ Open BMJ Open								
7. Teams receive data requests from service managers + QualDash can be easily accessed via the web by multiple users Service managers will use gualDash to access the information theygneed quickly and easily = Streamlines the use of NCA data for clinical managers 8. Teams need to evidence their performance to managers and other groups in order to support a case for + QualDash visualises performance metrics, which can also be exported into reports Teams will use these functions to evidence their to convince other Trust groups that = Other Trust groups, who are able to offer addition resource to teams, are	-	#	Context	+	М			=	Outcome	
service managers accessed via the web by multiple users access the information they need quickly and easily Reduced time spent by audit support staff/clinicate team in producing data reports for managers and other groups in order to support a case for also be exported into reports also be exported into reports and other resource to teams, are					Resource	Response	9-03			
 multiple users quickly and easily Reduced time spent by audit support staff/clinicate team in producing data reports for managers Teams need to evidence their performance to managers and other groups in order to support a case for qualDash visualises performance metrics, which can also be exported into reports 	-	7.	Teams receive data requests from	+	QualDash can be easily	Service managers will use	gualDash to	=	Streamlines the use of	
8. Teams need to evidence their performance to managers and other groups in order to support a case for + QualDash visualises performance metrics, which can also be exported into reports Teams will use these functions to evidence service performance, in order to convince other Trust groups that = Other Trust groups, who are able to offer addition resource to teams, are			service managers		accessed via the web by	access the information the	gneed		NCA data for clinical	
8. Teams need to evidence their performance to managers and other groups in order to support a case for + QualDash visualises performance metrics, which can also be exported into reports Teams will use these functions to evidence service performance, in order to convince other Trust groups that = Other Trust groups, who are able to offer addition resource to teams, are					multiple users	quickly and easily	25 Fel		managers	
8. Teams need to evidence their performance to managers and other groups in order to support a case for + QualDash visualises performance metrics, which can also be exported into reports Teams will use these functions to evidence service performance, in order to convince other Trust groups that = Other Trust groups, who are able to offer addition resource to teams, are							oruary		Reduced time spent by	
8. Teams need to evidence their + QualDash visualises Teams will use these functions to = Other Trust groups, who are able to offer addition groups in order to support a case for also be exported into reports to convince other Trust groups that = Other Trust groups, who are able to offer addition							2020		audit support staff/clinica	
8. Teams need to evidence their performance to managers and other groups in order to support a case for + QualDash visualises performance metrics, which can also be exported into reports Teams will use these functions to evidence service performance, in order to convince other Trust groups that = Other Trust groups, who are able to offer addition resource to teams, are									team in producing data	
performance to managers and other performance metrics, which can evidence service performance, in order are able to offer addition groups in order to support a case for also be exported into reports to convince other Trust groups that resource to teams, are							ownl		reports for managers	
groups in order to support a case for also be exported into reports to convince other Trust groups that resource to teams, are	-	8.	Teams need to evidence their	+	QualDash visualises	Teams will use these funct	ions to	=	Other Trust groups, who	
			performance to managers and other		performance metrics, which can	evidence service performa	≝ ∰ce, in order		are able to offer additiona	
practice change e.g. in business and presentations change is needed convinced of the need for meetings with managers or in the NCA annual report summary evidence provided. However, this is likely to be where those outputs are clearly associated w Trust priorities, e.g. relating to Trust reputation or avoiding penalties/gaining incentives.			groups in order to support a case for		also be exported into reports	to convince other Trust gro	gps that		resource to teams, are	
meetings with managers or in the NCA annual report summary However, this is likely to be where those outputs are clearly associated w Trust priorities, e.g. relating to Trust reputation or avoiding penalties/gaining incentives.			practice change e.g. in business		and presentations	change is needed	ttp://		convinced of the need fo	
annual report summary evidence provided. However, this is likely to be where those outputs are clearly associated w Trust priorities, e.g. relating to Trust reputation or avoiding penalties/gaining incentives.			meetings with managers or in the NCA				bmjo		change based on the	
However, this is likely to be where those outputs are clearly associated w Trust priorities, e.g. relating to Trust reputation or avoiding penalties/gaining incentives.			annual report summary				open		evidence provided.	
be where those outputs are clearly associated w Trust priorities, e.g. relating to Trust reputation or avoiding penalties/gaining incentives.							.bm		However, this is likely to	
April 16, 2024 by gree to are clearly associated with a relating to Trust priorities, e.g. relating to Trust reputation or avoiding penalties/gaining incentives.							.con		be where those outputs	
April 16, 2024 by get Trust priorities, e.g. relating to Trust reputation or avoiding penalties/gaining incentives.							√ on		are clearly associated wi	
relating to Trust reputation or avoiding penalties/gaining incentives.							Apri		Trust priorities, e.g.	
by genalties/gaining incentives.							116,		relating to Trust reputation	
by penalties/gaining کو incentives.							202		or avoiding	
incentives.							4 by		penalties/gaining	
							gue		incentives.	
							rote			
							cted			
rotected							by c			
Protected by c							оруг			
rotected by copyr							ight.			
Protected by copyright.			For pe	er rev	iew only - http://bmjopen.bmj.com/s					
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml										

How, in what contexts, and why do quality dashboards lead to improvements in care quality in acute hospitals? Protocol for a realist feasibility evaluation (Randell et al.) Additional file 2

The average CMOC for patients on a ward will be averaged for each month, so that there are 36 observations clustered within each of 15 hospitals. Taking the intra-class correlation to be 0.15, this yields a design effect of 6.25. Hence the effective number of observations is 15*36/6.25=86.4. Using Cohen's approach to sample size calculation means an effect size of 0.17 can be estimated with 80% given that there are six parameters in the model (including the coefficient for QualDash). Converting this to the percentage of variation that can be explained by the model, this yields 20.5%. Translating this back to CMOC, currently 49.6% of patients are discharged from hospital without missing any of the nine opportunities for care, and we would be powered at the 80% level to detect an improvement from an average of 8.33 opportunities achieved to 8.46. Thus our study has good power to detect small but meaningful clinical improvements. For PICANet, 10% of the admitted population receive non-invasive ventilation first [1]. On average there are 5.25 ventilation cases per month per hospital. With a further design effect from patients clustered within hospitals, based on the reported intraclass correlation coefficient of 0.065 giving a design effect of 1.276, the actual anticipated number of patients is 1701 giving an effective number of 213: 71 exposed to QualDash and 142 controls. This yields 80% power to detect a change from 32% to 53%.

References

 Morris JV, Ramnarayan P, Parslow RC, Fleming SJ. Outcomes for Children Receiving Noninvasive Ventilation as the First-Line Mode of Mechanical Ventilation at Intensive Care Admission: A Propensity Score-Matched Cohort Study. Crit. Care Med. 2017.

How, in what contexts, and why do quality dashboards lead to improvements in care quality in acute hospitals? Protocol for a realist feasibility evaluation

Journal:	BMJ Open			
Manuscript ID	bmjopen-2019-033208.R2			
Article Type:	Protocol			
Date Submitted by the Author:	13-Dec-2019			
Complete List of Authors:	Randell, Rebecca; University of Leeds, School of Healthcare Alvarado, Natasha; University of Leeds, School of Healthcare McVey, Lynn; University of Leeds, School of Healthcare Greenhalgh, Joanne; University of Leeds, Sociology and Social Policy West, Robert; University of Leeds, Leeds Institute of Health Sciences Farrin, Amanda; University of Leeds, Clinical Trials Research Unit Gale, Chris; University of Leeds, Leeds Institute if Genetics, Health and Therapeutics Keen, Justin; University of Leeds, Leeds Institute of Health Sciences Elshehaly, Mai; University of Leeds, School of Computing Ruddle, Roy; University of Leeds, School of Computing Lake, Julia; Leeds Teaching Hospitals NHS Trust Mamas, Mamas; Royal Stoke University Hospital Feltbower, Richard; University of Leeds, Dowding, Dawn; University of Manchester			
Primary Subject Heading :	Health informatics			
Secondary Subject Heading:	Health services research			
Keywords:	AUDIT, Health informatics < BIOTECHNOLOGY & BIOINFORMATICS, Clinical audit < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, QUALITATIVE RESEARCH			

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

R. O.

2									
3 4	1	Title: How, in what contexts, and why do quality dashboards lead to improvements in care							
5 6	2	quality in acute hospitals? Protocol for a realist feasibility evaluation							
7 8	3								
8 9 10	4	Authors							
10 11 12	5	Corresponding author: Rebecca Randell, School of Healthcare, University of Leeds, Leeds, UK,							
13 14	6	r.randell@leeds.ac.uk							
15	7	Natasha Alvarado, of Healthcare, University of Leeds, Leeds, UK, n.alvarado@leeds.ac.uk							
16 17	8	Lynn McVey, School of Healthcare, University of Leeds, Leeds, UK, I.mcvey@leeds.ac.uk							
18 19	9	Joanne Greenhalgh, School of Sociology and Social Policy, University of Leeds, Leeds, UK,							
20 21	10	j.greenhalgh@leeds.ac.uk							
22 23	11	Robert West, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK, r.m.west@leeds.ac.uk							
24 25	12	Amanda Farrin, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK,							
26 27	13	a.j.farrin@leeds.ac.uk							
28 29	14	Chris P. Gale, School of Medicine, University of Leeds, Leeds, UK, c.p.gale@leeds.ac.uk							
30 31	15	Roger Parslow, School of Medicine, University of Leeds, Leeds, UK, r.c.parslow@leeds.ac.uk							
32 33	16	Justin Keen, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK, j.keen@leeds.ac.uk							
34 35	17	Mai Elshehaly, School of Computing, University of Leeds, Leeds, UK, m.h.elshehaly@leeds.ac.uk							
36 37	18	Roy A. Ruddle, School of Computing, University of Leeds, Leeds, UK, r.a.ruddle@leeds.ac.uk							
38	19	Julia Lake, Leeds Teaching Hospitals NHS Trust, Leeds, UK, julia.lake3@nhs.net							
39 40	20	Mamas A. Mamas, Royal Stoke Hospital, Stoke on Trent, UK, mamasmamas1@yahoo.co.uk							
41 42	21	Richard Feltbower, School of Medicine, University of Leeds, Leeds, UK, r.g.feltbower@leeds.ac.uk							
43 44	22	Dawn Dowding, School of Health Sciences, University of Manchester, Manchester, UK,							
45 46	23	dawn.dowding@Imanchester.ac.uk							
47 48	24								
49 50	25								
51									
52									
53									
54									
55 56									
56 57									
57 58									
59									
60									
		1							

BMJ Open

 I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in our licence.

10 The Submitting Author accepts and understands that any supply made under these terms is made by 11 BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a 12 postgraduate student of an affiliated institution which is paying any applicable article publishing charge 13 ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on 14 an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access 15 shall be governed by a Creative Commons licence – details of these licences and which Creative 16 Commons licence will apply to this Work are set out in our licence referred to above.

ABSTRACT

Introduction: National audits are used to monitor care guality and safety and are anticipated to reduce unexplained variations in quality by stimulating quality improvement. However, variation within and between providers in the extent of engagement with national audits mean that the potential for national audit data to inform quality improvement is not being realised. This study will undertake a feasibility evaluation of QualDash, a quality dashboard designed to support clinical teams and managers to explore data from two national audits, the Myocardial Ischaemia National Audit Project (MINAP) and the Paediatric Intensive Care Audit Network (PICANet).

Methods and analysis: Realist evaluation, which involves building, testing, and refining theories of how an intervention works, provides an overall framework for this feasibility study. Realist hypotheses that describe how, in what contexts, and why QualDash is expected to provide benefit will be tested across five hospitals. A controlled interrupted time series analysis, using key MINAP and PICANet measures, will provide preliminary evidence of the impact of QualDash, while ethnographic observations and interviews over 12 months will provide initial insight into contexts and mechanisms that lead to those impacts. Feasibility outcomes include the extent to which MINAP and PICANet data are used, data completeness in the audits, and the extent to which participants perceive QualDash to be useful and express the intention to continue using it after the study period.

Ethics and dissemination: The study has been approved by University of Leeds School of Healthcare Research Ethics Committee. Study results will provide an initial understanding of how, in what contexts, and why quality dashboards lead to improvements in care quality. These will be disseminated to academic audiences, study participants, hospital IT departments, and national audits. If results show a trial is feasible, we will disseminate the QualDash software through a stepped wedge cluster randomised trial.

Keywords: Dashboard, audit and feedback, quality improvement, realist evaluation

Trial registration: ISRCTN18289782

Word count: 4,218

1	ARTICLE SUMMARY	
---	-----------------	--

- Strengths and limitations of this study
- This study combines a controlled interrupted time series study with a qualitative multi-site case study in order to provide an initial understanding of not only whether use of a quality dashboard leads to quality improvement but also how, in what contexts, and why.
- In addition to assessing the feasibility of a trial, the study will determine the components of QualDash to be preserved in a definitive trial, appropriate outcome measures, and the contexts in which a definitive trial should be undertaken.
 - The study will contribute to understanding of how realist methods can contribute to feasibility studies and the design of trials.
 - Issues of data quality may be a limitation of the CITS; data completeness, and whether this changes over the course of the study, will be assessed,

INTRODUCTION

National clinical audits (NCAs), which provide comparative data on the performance of healthcare providers, are one means by which health systems around the world monitor care quality and safety. In England, a programme of over 30 NCAs is managed by the Healthcare Quality Improvement Partnership (HQIP) and all healthcare providers that contribute to delivery of the National Health Service (NHS) are required to participate. Such audits are anticipated to reduce unexplained variations in healthcare quality by stimulating quality improvement (QI) [1 2]. While there is evidence of positive impacts of NCAs [3-5], variation within and between providers in the extent to which they engage with NCAs mean the potential for NCA data to inform QI is not being realised [6 7].

Quality dashboards are a form of audit and feedback (A&F) that provide visualisations of audit data with the aim of informing QI efforts [8]. Healthcare providers are increasingly using quality dashboards. For example, quality dashboard use has been reported in Canada [9], the UK [10], and the Netherlands [11]. While quality dashboards have been shown to have positive effects on some performance indicators [9], empirical evidence regarding their impact remains limited [12].

1		
2 3	1	
4 5		
6 7	2	QualDash
8 9	3	QualDash is an interactive web-based quality dashboard designed to support clinical teams and
10 11	4	managers to explore data from two national audits, the Myocardial Ischaemia National Audit Project
12 13	5	(MINAP) and the Paediatric Intensive Care Audit Network (PICANet), for the purpose of QI (Fig. 1).
14 15	6	Information used to inform design of QualDash was collected through interviews with 50 clinicians and
16 17	7	managers across five NHS Trusts (providers) and four healthcare commissioners, observations of
18 19	8	meetings where audit data are discussed, a workshop with NCA suppliers, and two co-design
20	9	workshops with clinicians and managers from one Trust.
21 22	10	
23 24	11	Fig. 1: Prototype of main dashboard view for the Paediatric Intensive Care Audit Network (using
25 26	12	simulated data).
27 28	13	[Figure 1 should go approximately here]
29 30	14	
31 32	15	The interviews revealed that use of NCA data is largely at the clinical team level, with more limited use
33 34	16	at divisional and corporate (Board and sub-committees that report to the Board, such as Quality and
35	17	Safety Committees) levels. At all levels, a key constraint in use of NCA data for QI is lack of access to
36 37	18	timely data; there was consensus among interviewees that data should not be more than three months
38 39	19	old. QualDash seeks to improve access to timely data, providing users with a means to visualise the
40 41	20	data they collect for the NCAs, without having to wait for data to be returned to them from the NCAs.
42 43	20	There is variation between Trusts in the extent to which NCA data are used, often related to resources,
44 45	21	
46 47	22	which in turn impacts on timeliness of data; Trusts that make greater use of NCA data tend to have
48		local databases from which they can generate visualisations of the data (e.g. bar charts) and audit
49 50	24	support staff who have the time and skills to be able to generate such visualisations. In contrast, where
51 52	25	such resources are not available, Trusts rely on the NCA annual reports, where data may be 15 months
53 54	26	old (e.g. one annual report published in June 2017 reported data from April 2015 to March 2016).
55 56	27	QualDash provides visualisations of key metrics, each metric being represented within a 'QualCard'
57 58	28	(Fig. 2), enabling Trusts to use NCA data for QI, regardless of existing resources. QualCards for MINAP
58 59 60	29	and PICANet are listed in Table 1; while there is only one set of QualCards for PICANet, for MINAP an
00		

- additional QualCard is provided for teaching hospitals, as discussions with sites revealed that the
 - metrics of interest are different between teaching hospitals and District General Hospitals (DGHs). Sites
 - are also able to create additional QualCards, to reflect local priorities.

- Fig. 2: Prototype of main dashboard view for the Paediatric Intensive Care Audit Network with the
- Mortality QualCard expanded (using simulated data).
 - [Figure 2 should go approximately here]

Table 1: QualCards

	Metric			
MINAP – all	Mortality			
sites	Door (arrival in Accident and Emergency) to angiogram time			
	Gold standard drugs on discharge			
	Referral for cardiac rehabilitation			
	Acute use of aspirin			
MINAP –	Call (by patient/relative to emergency services) to balloon (percutaneous			
teaching	coronary intervention) time			
hospital specific				
PICANet – all	Mortality			
sites	48 hour unplanned readmission			
	Bed days and accidental extubation			
	Specialty case mix			
	Data quality (number of records with a missing value)			
Patient dependency				

To load new data into QualDash, NCA data are either extracted from the site's database or downloaded from the NCA website and then fed to a small script (written in R), which in turn updates the dashboard. Users can add new data as often as they want, but at a minimum they will load data into QualDash at the same time as uploading to the NCAs (typically every three months).

The benefits perceived from using QualDash may vary between sites, with under-resourced sites that previously made little use of NCA data for QI perceiving greater impact than those that already have the means to use NCA data for QI. There are also constraints on use of NCA data for QI that it may be difficult for QualDash to address. For example, in some Trusts, clinical team members perceive that relevant managers will not agree to provide the resources necessary for QI initiatives, which reduces motivation to engage with NCA data and may affect the extent to which QualDash is used. However, QualDash provides means for visualisations to be downloaded and incorporated into presentations and

reports, which may support clinical teams in making a stronger case for QI initiatives. Another constraint on use of NCA data for QI relates to clinicians' trust in the quality of the data. Interviews revealed variations across sites in processes for ensuring data quality. However, some interviewees also suggested that having the means to make more use of NCA data via QualDash would motivate them to improve their processes for ensuring data quality, although this will be dependent on local resources.

In this paper, we describe the methods for a realist feasibility evaluation of QualDash. The study objectives are:

1. To develop an initial understanding of how, in what contexts, and why use of QualDash leads to QI; and

2. To assess the feasibility of conducting a trial of QualDash.

As no checklists exist for reporting of realist evaluation protocols, in presenting this protocol we draw on the RAMESES II reporting standards for realist evaluations [13] (Additional file 1).

METHODS AND ANALYSIS

Study design

Use of theory is needed for design and evaluation of A&F interventions [14-16], and QI initiatives more generally [17-19]. This project draws on Realist Evaluation (RE), which involves building, testing, and refining theories about how an intervention is supposed to work [20]. These theories are expressed in the form of Context Mechanism Outcome (CMO) configurations, where C+M=O, reflecting the realist understanding that it is recipients' responses to the resources that an intervention provides (the intervention mechanisms) that determine the impact of the intervention, and such responses are highly influenced by context [21]. Consequently, RE seeks to answer not only the question of 'what works?' but 'what works for whom, in what circumstances, and why?' [22]. It is concerned with both intended and unintended outcomes. RE is recommended for studying QI [23] and has been used for studying the implementation and impact of large-scale QI programmes [24]. There is increasing interest in use of realist methods in feasibility evaluations [25-27].

We have drawn on a range of sources to develop CMO configurations which describe how, in what contexts, and why use of QualDash is anticipated to lead to QI (see Additional file 2). Data generated

BMJ Open

from the interviews, observations, and workshops described above have been essential to this, as have discussions with the designers of QualDash (ME and RAR) who, drawing on their expertise in information visualisation, have their own literature-informed theories regarding why certain features of QualDash will provide benefit to users [28 29]. We have also drawn on substantive theories regarding how A&F lead to QI at the micro [30 31], meso [32], and macro level [33 34].

Data collection is designed to enable testing of the CMO configurations. Outcome data, in the form of key MINAP and PICANet measures, will be collected and analysed in a controlled interrupted time series (CITS) study, while a multi-site case study [35] will provide an initial understanding of the contexts and mechanisms that lead to those outcomes, as well as providing data on intermediate outcomes such as increased use of NCA data. A&F interventions, and QI interventions more generally, require longitudinal evaluation to allow sufficient time for staff to implement changes and incorporate them into their practice [36-38]. Similarly, evaluation of health IT (HIT) should allow time for staff to integrate the technology into their practices and evolve those practices to take advantage of the functionality offered by the technology [39]. Therefore, data will be collected over a 12 month period, from August 2019.

17 Public and patient involvement

A Lay Advisory Group has been established, which has contributed to the design of QualDash by reviewing the topic guide for the interviews that were conducted, providing their perspective on the findings of the interview study, and participating in the usability evaluation of QualDash. For the realist feasibility evaluation, they have provided advice on aspects to pay attention to when undertaking observations. They will contribute to analysis of a sample of the qualitative data, to provide a patient perspective. They will advise on dissemination of findings to relevant interest groups and will review outputs for comprehensibility.

26 Setting/context

The feasibility study will be conducted in the five NHS acute Trusts in which the interview study that informed the design of QualDash was undertaken. Three Trusts are teaching hospitals that participate in both MINAP and PICANet and have been selected to ensure variation in key outcome measures (MINAP: 30-day mortality for patients hospitalised with ST-elevation myocardial infarction; PICANet: (MINAP: 30-day mortality for patients hospitalised with ST-elevation myocardial infarction; PICANet: risk adjusted standardised mortality ratio). Two Trusts are DGHs that participate in MINAP but do not
 have a PICU and so do not participate in PICANet. These have been selected to ensure variation in the
 same key MINAP measure.

5 Multi-site case study

 In the multi-site case study, data will be collected through ethnographic observation and interviews. Ethnographic methods have been argued as essential for studying implementation of QI interventions [19] and introduction of HIT [40]. Ethnography is well suited to RE because it involves observing phenomena in context, supporting understanding of how context influences the response to an intervention [41]. We will follow the Biography of Artefacts approach [42], which is concerned with capturing how particular contexts and appropriations of a technology lead to different processes and generate different outcomes, a parallel to RE's concern with contexts, mechanisms, and outcomes [43]. It involves longitudinal 'strategic ethnography' [42], where data collection is guided by a provisional understanding of the moments and locales in which a technology and associated practices evolve [43].

16 Data collection

In the three teaching hospitals, we will undertake a minimum of 24 periods of observation per Trust, to be split across activities related to cardiology and the PICU, and in the two DGHs we will undertake a minimum of 12 periods of observation per Trust, to be spent observing activities related to cardiology. Each period of observation will be a minimum of four hours (total n=384 hours). While researchers will return to each Trust monthly, to understand how use of QualDash changes over time, more time will be spent in the first few months following the introduction of QualDash, because this is when users are most likely to engage with and explore the affordances of QualDash and establish new practices around it, generating information with implications for system enhancement [43]. Observations will be scheduled to take place at different times of day and on different days of the week, to ensure the account of what is observed is as complete and representative as possible [44].

At each case site, an initial phase of general observation will provide an opportunity for researchers to become familiar with the setting and for those in the setting to become familiar with the presence of the researchers. Following a previous study of dashboards [10], observations will be undertaken in clinical

BMJ Open

areas to understand clinical teams' working practices and capture 'corridor committees' where issues of quality and safety are discussed more informally [45]. In the PICUs, initial observations will take place on the PICU, e.g. with the researchers positioning themselves by the nurses' station, as well as observing handovers, safety huddles, and ward rounds. Because activities related to cardiology tend to be more dispersed across hospitals, researchers will first shadow clinical team members (consultant cardiologists and acute chest pain nurses) to determine where it is most appropriate to conduct subsequent observations. These initial observations will also be used to record general details of the setting that may influence QualDash use, such as staffing levels and availability of computers.

After this initial phase, observation will be guided by the CMO configurations under investigation. In addition to observing formal meetings where quality and safety are discussed, predominantly at ward level but also at divisional and corporate level, observation will involve shadowing staff members as they undertake particular activities: collection and entry of NCA data, to see if and how this changes over time; accessing and interrogating NCA data, whether using QualDash or some other means; preparation of reports and/or presentations using NCA data, again whether using QualDash or some other means. Where visualisations from QualDash are incorporated into presentations and written reports, we will follow the path of those documents, to identify staff members who may not use QualDash directly but are receiving QualDash outputs. Attention will be paid to how, in what contexts, and why QualDash and QualDash outputs are used or not, understood in the context of broader practices and use of other sources of information for monitoring care quality, and how this changes over time. We will also follow local QI initiatives, recording data on, for example, when and how the need for the QI initiative was identified, contextual factors that appear to support and constrain its introduction, how the impact of the QI initiative is monitored, and other contextual factors that appear to influence the metric that the QI initiative is targeting. Researchers will record observations in fieldnotes, which will be written up in detail as soon after data collection as possible.

Brief interviews will be undertaken opportunistically during the course of conducting observations to
 clarify aspects of practice that are not immediately intelligible to an observer, with participant responses
 recorded in fieldnotes [46]. As data collection progresses, longer semi-structured interviews will be used
 to discuss revisions to our CMO configurations. These will be undertaken using a particular approach

> from RE, referred to as the teacher-learner cycle, whereby the theories under investigation are made explicit to the interviewee so that the interviewee can use their experiences to refine the researcher's understanding [47]. Being concerned with the reasoning of intervention recipients, mechanisms are often not observable [21], so these longer interviews will also provide the opportunity to explore staff reasoning about QualDash. These longer interviews will be audio recorded and transcribed verbatim.

> Logfiles are widely used to evaluate visualisation tools [48]. QualDash logfiles will record information about the user (job title, etc.), data used (audit, year), overall time spent using QualDash, time spent interacting with different QualCards (including new QualCards that have been created), functionality used, and whether QualDash visualisations were downloaded. In addition to providing data regarding extent of QualDash use, how QualDash is used and by whom, and how this changes over time, information from logfiles will be used to inform qualitative data collection (e.g. asking in interviews why participants use particular QualCards and not others and the motivation behind the creation of new QualCards).

At the end of the data collection period, we will ask participants to complete a questionnaire based on the Technology Acceptance Model, using well validated items that have been used in numerous evaluations of HIT [49], including dashboards [50]. This will provide participants' perceptions of the usefulness of QualDash and data on whether they intend to continue using QualDash after the study period.

22 Analysis

An iterative approach to data collection and analysis will be taken, to enable: ongoing testing and refinement of the CMO configurations; gathering of further data in light of such revisions; and refinement of QualDash in response to participants' feedback. Fieldnotes and interview transcripts will be entered into NVivo 11. Narrative analysis will be undertaken to develop a 'biography' of QualDash, which will describe use of QualDash and its outputs by a range of stakeholders at different levels (clinical team, divisional, and corporate) and the interconnections between them [10]. Narrative analysis is consistent with a realist approach due to its emphasis on preserving connections within the data, thereby helping to understand causality [51]. This analysis will be supplemented with analysis of the logfiles and

BMJ Open

questionnaire data. Findings will be compared with the CMO configurations, to determine whether they
 support, refute, or suggest a revision or addition to the CMO configurations.

4 Controlled interrupted time series study

Interrupted time series studies provide a robust method of assessing the effect of an intervention and have been used to assess effectiveness of a variety of complex interventions [52]. In a CITS, the addition of a control group enhances causal inference because the presence of seasonal trends and other potential time-varying confounders can be assessed [53]. Data will be collected across the five Trusts, with two control Trusts per intervention Trust, providing a total of 10 control Trusts. Control Trusts will be matched according to their size and outcomes pre-intervention. Having more than one control site per intervention site increases power but, as the number of control sites per intervention site increases, guality of matching decreases. Therefore, we have chosen to have two control Trusts per intervention Trust to increase power while maintaining quality of the matching.

Given the study intention to determine the feasibility of and inform the design of a trial, a range of measures will be considered. Initially, we selected two process measures, one for MINAP and one for PICANet. For MINAP, we selected the composite process measure Cumulative Missed Opportunities for Care (CMOC). This has nine components (pre-hospital ECG, acute use of aspirin, timely perfusion, referral for cardiac rehabilitation, and prescription at hospital discharge of what are considered to be the gold standard drugs – aspirin, thienopyridine inhibitor, ACE-inhibitor, HMG-CoA reductase inhibitor, and beta blockers) and is inversely associated with mortality [54]. As some of these components, such as pre-hospital ECG, are outside the direct control of the Trust, we will also explore the impact of QualDash on the individual measures that make up CMOC. On the basis of the measures that cardiology clinicians described in the interviews as being important for measuring care quality, we will also look at the percentage of patients who receive an angiogram within 72 hours from first admission to hospital, which is part of the Best Practice Tariff financial incentive scheme, and, for those hospitals that provide percutaneous coronary intervention (PCI), the proportion of patients who have a door-to-balloon time (the time from arrival at the hospital to PCI) of less than 60 minutes. Our CMO configurations (Additional file 2) suggest improvement will be seen in measures if: clinical teams perceive them as being important indicators of care and/or they relate to financial incentives;

performance is not in line with expectations; they perceive the measure as being within their control;
 and the team is resourced to introduce QI initiatives in relation to these measures.

For PICANet, we selected use of non-invasive ventilation first for patients requiring ventilation, which has been shown to be associated with reduced mortality [55]. However, this was not raised as an area of concern in our interviews with PICU clinicians. On the basis of this and two additional considerations - it would require loading additional data into QualDash which would reduce the performance of QualDash in terms of speed and it requires computation of the data, while the focus of QualDash is on visualising the data - a QualCard has not been created for this metric. Therefore, while we will still include this measure in the CITS, we do not hypothesise that it will change, unless other sources of information, such as the PICANet annual report, draw a PICU team's attention to it. However, accidental extubation and unplanned readmission within 48 hours were identified in our interviews with PICU clinicians as being important indicators of care quality, so we will include these two measures in the CITS. On the basis of our CMO configurations (Additional file 2), we would expect to see an improvement in these measures in sites where performance is not in line with expectations, if the team is resourced to introduce QI initiatives in relation to these measures.

18 Sample size considerations

A CITS study requires data for a minimum of three time points pre-intervention and three time points post-intervention and must also allow for any seasonal effect on the outcomes [56]. Monthly data will be obtained for 24 months pre-intervention and 12 months post-intervention. Consequently, for each intervention Trust, there will be 72 data points prior to introduction (24 for the intervention Trust and 48 for the control Trusts) and 36 data points post intervention (12 for the intervention Trust and 24 for the control Trusts). Sample size calculations were undertaken based on our two initial measures, CMOC for MINAP and use of non-invasive ventilation first for patients requiring ventilation for PICANet; full details are provided in Additional file 3.

28 Analysis

Monthly MINAP and PICANet data will be extracted to spreadsheets for analysis with R software [57].
For both NCAs, each outcome will be regressed upon time and the intervention. The time component

BMJ Open

will include a seasonal effect (quarterly effect) and will allow for a (linear) time trend. To account for clustering of monthly observations within hospitals, a random intercept will be fitted, although a fixed effect for hospital as a sensitivity analysis will be explored. Although the intervention is abrupt, its impact may well be 'phased in' over a few months, perhaps three. The timing of the bedding in of the intervention will be reported from the multi-site case study. Then a partial effect can be considered for this period with the interaction effect stepping up in a linear fashion.

8 Results of the CITS analysis will be incorporated into the biography of QualDash, the analysis of the
9 data from the multi-site case study describing how contextual factors shape the evolution of practices
10 around QualDash and how this leads to the resulting outcome pattern.

12 Trial feasibility assessment and design

Our trial progression criteria are: (i) the number of people who engage with either MINAP or PICANet data (via QualDash or some other means) is the same or higher than the number of people who engaged with either MINAP or PICANet data prior to QualDash's introduction; (ii) data completeness in the national audit improves or remains the same; (iii) 50% or more of participants in the questionnaire survey perceive QualDash to be useful and express the intention to continue using it after the study period. Criteria (i) and (ii) are concerned with ensuring the intervention does not have unintended negative consequences which would affect success of the intervention. Criterion (ii) is also concerned with feasibility of outcome assessment. Criterion (iii) is concerned with acceptability and uptake of the intervention, and therefore has implications for recruitment to a trial, as well as being concerned with participants' perceptions of the impact of QualDash on care. While not formally assessed as part of the progression criteria, the impact of QualDash on care as identified in the CITS will be considered in determining whether a future trial is justified. A traffic light system will be used to determine if a trial is feasible (green), feasible with modifications to QualDash (amber), or not feasible (red) [58 59].

If the results show a trial of QualDash is feasible, we will design a stepped wedge cluster randomised
trial. Data from the CITS will be used to inform the selection of NCAs to be included in the trial (MINAP
and/or PICANet) and will provide information about variability of outcomes and about how long a trial
intervention period would need to be. Findings from the multi-site case study will be used to inform the

selection of categories of user to be included in the trial and, associated with this, the level of randomisation (Trust, hospital, or ward). Using the understanding of the relationship between contexts, mechanisms, and outcomes provided by the study, we will identify QualDash components associated with mechanisms that produce the desired outcomes in order for them to be preserved in the trial, while other components can be adapted to suit the local context.

ETHICS AND DISSEMINATION

Ethics approval has been received from the University of Leeds School of Healthcare Research Ethics Committee (Approval no.HREC16-044). Written consent will be obtained from participants for interviews and for meeting observations.

> Study results will provide initial understanding of how and in what contexts quality dashboards may lead to improvements in care quality. We will disseminate these results to academic audiences, study participants, hospital IT departments, and NCAs. If we progress to a trial, in addition to providing further understanding of the impact of quality dashboards on care quality, this will result in wider dissemination of the QualDash software. 4.0

Acknowledgements

This research is funded by the National Institute for Health Research (NIHR) Health Services and Delivery Research (HS&DR) Programme (project number 16/04/06). The views and opinions expressed are those of the presenter and do not necessarily reflect those of the HS&DR programme, NIHR, NHS or the Department of Health.

Data statement

The qualitative data gathered during the course of this evaluation will be kept until June 2030 and can be accessed by other researchers during this time, subject to the necessary ethical approvals being obtained. Requests for access to this data should be addressed to the corresponding author.

Ζ.		
- 3 4	1	Authors' contributions
5	2	RR is Principal Investigator for the study. She conceived, designed, and secured funding for the study
7	3	in collaboration with JG, RW, AF, CPG, RP, JK, RAR, JL, MM, and DD. NA and LM led the qualitative
8 9	4	data collection and analysis that informed the design of QualDash and the design of evaluation. ME
10 11	5	developed the QualDash software and contributed to the design of the evaluation. RP and RF provided
12 13	6	data for the testing of QualDash and provided significant feedback on its design. All authors provided
14 15	7	input into various aspects of the evaluation design and revised drafts of the protocol. RR led the writing
16 17	8	of this protocol manuscript. All authors read and approved the final manuscript.
18 19	9	
20 21	10	Funding statement
22 23	11	This research is funded by the National Institute for Health Research (NIHR) Health Services and
24 25	12	Delivery Research (HS&DR) Programme (project number 16/04/06).
26	13	
27 28	14	Competing interests statement
29 30	15	Chris Gale is a member of the MINAP Academic and Steering Groups. Richard Feltbower is Principal
31 32	16	Investigator for PICANet and Roger Parslow was previously Principal Investigator for PICANet. The
33 34	17	authors have no other competing interests to declare.
35 36	18	
37 38	19	Additional files
39 40	20	Additional file 1: Checklist of RAMESES II reporting standards for realist evaluations (PDF)
41 42	21	Additional file 2: Context Mechanism Outcome configurations to be tested in the realist feasibility
43 44	22	evaluation (PDF)
45 46	23	Additional file 3: Sample size calculations for controlled interrupted time series (PDF)
47 48	24	
49 50	25	REFERENCES
51	26	1. Phekoo KJ, Clements J, Bell D. National Clinical Audit Quality Assessment - Overview of the self-
52	27	assessment survey: "audit of audits". London: Healthcare Quality Improvement Partnership,
53	28	2014.
54		
55	29	2. Miller T, Leatherman S. The National Quality Forum: a'me-too'or a breakthrough in quality
56	30	measurement and reporting? Health Aff. (Millwood) 1999; 18 (6):233-37.
57	31	3. Birkhead JS, Walker L, Pearson M, Weston C, Cunningham AD, Rickards AF. Improving care for
58	32	patients with acute coronary syndromes: initial results from the National Audit of Myocardial
59	33	Infarction Project (MINAP). Heart 2004; 90 (9):1004-09.
60		

Page 18 of 33

BMJ Open

1 2

2		
3	1	4. Bridgewater B, Grayson AD, Brooks N, et al. Has the publication of cardiac surgery outcome data
4	2	been associated with changes in practice in northwest England: an analysis of 25 730 patients
5	3	undergoing CABG surgery under 30 surgeons over eight years. Heart 2007; 93 (6):744-48.
6 7	4	5. Neuburger J, Currie C, Wakeman R, et al. The Impact of a National Clinician-led Audit Initiative on
8	5	Care and Mortality after Hip Fracture in England: An External Evaluation using Time Trends in
9	6	Non-audit Data. Med. Care 2015; 53 (8):686-91.
10	7	6. Allwood D. Engaging Clinicians in Quality Improvement through National Clinical Audit. London:
11	8	Healthcare Quality Improvement Partnership, 2014.
12	9	7. Taylor A, Neuburger J, Walker K, Cromwell D, Groene O. How is feedback from national clinical
13	10	audits used? Views from English National Health Service trust audit leads. J. Health Serv. Res.
14	11	Policy 2016; 21 (2):91-100.
15	12	8. Pauwels K, Ambler T, Clark BH, et al. Dashboards as a Service Why, What, How, and What Research
16	13	Is Needed? Journal of Service Research 2009; 12 (2):175-89.
17	14	9. Weiss D, Dunn SI, Sprague AE, et al. Effect of a population-level performance dashboard
18 19	15	intervention on maternal-newborn outcomes: an interrupted time series study. BMJ Quality
20	16	& amp; Safety 2018; 27 (6):425-36.
20	10	10. Keen J, Nicklin E, Long A, et al. Quality and safety between ward and board: a biography of artefacts
22	18	study. Health Services and Delivery Research 2018;6(22).
23		11. Weggelaar-Jansen AMJWM, Broekharst DSE, de Bruijne M. Developing a hospital-wide quality and
24	19 20	safety dashboard: a qualitative research study. BMJ Quality & amp; Safety 2018.
25	20	
26	21	12. Dowding D, Randell R, Gardner P, et al. Dashboards for improving patient care: Review of the
27	22	literature. International Journal of Medical Informatics 2015; 84 (2):87-100.
28	23	13. Wong G, Westhorp G, Manzano A, Greenhalgh J, Jagosh J, Greenhalgh T. RAMESES II reporting
29 30	24	standards for realist evaluations. BMC Med. 2016; 14 (1):96.
31	25	14. Foy R, Eccles MP, Jamtvedt G, Young J, Grimshaw JM, Baker R. What do we know about how to do
32	26	audit and feedback? Pitfalls in applying evidence from a systematic review. BMC Health Serv.
33	27	Res. 2005; 5 :50.
34	28	15. Ivers NM, Grimshaw JM, Jamtvedt G, et al. Growing Literature, Stagnant Science? Systematic
35	29	Review, Meta-Regression and Cumulative Analysis of Audit and Feedback Interventions in
36	30	Health Care. J. Gen. Intern. Med. 2014; 29 (11):1534-41.
37	31	16. Ivers NM, Sales A, Colquhoun H, et al. No more 'business as usual' with audit and feedback
38	32	interventions: towards an agenda for a reinvigorated intervention. Implementation Science
39 40	33	2014; 9 (1):1-8.
40	34	17. Grol RPTM, Bosch MC, Hulscher MEJL, Eccles MP, Wensing M. Planning and Studying Improvement
42	35	in Patient Care: The Use of Theoretical Perspectives. Milbank Q. 2007; 85 (1):93-138.
43	36	18. Davidoff F, Dixon-Woods M, Leviton L, Michie S. Demystifying theory and its use in improvement.
44	37	BMJ Quality & Safety 2015.
45	38	19. Dixon-Woods M, Bosk CL, Aveling EL, Goeschel CA, Pronovost PJ. Explaining Michigan: Developing
46	39	an Ex Post Theory of a Quality Improvement Program. Milbank Q. 2011; 89 (2):167-205.
47	40	20. Pawson R, Tilley N. <i>Realistic Evaluation</i> . London: SAGE Publications, 1997.
48	41	21. Dalkin S, Greenhalgh J, Jones D, Cunningham B, Lhussier M. What's in a mechanism? Development
49 50	42	of a key concept in realist evaluation. Implementation Science 2015; 10 (1):49.
50 51	43	22. Pawson R. The science of evaluation: a realist manifesto. London: SAGE, 2013.
52	44	23. Robert G, Fulop N. The role of context in successful improvement. Perspectives on context. A
53	45	selection of essays considering the role of context in successful quality improvement. London:
54	46	Health Foundation 2014; 31 .
55	47	24. Greenhalgh T, Humphrey C, Hughes J, Macfarlane F, Butler C, Pawson R. How Do You Modernize a
56	48	Health Service? A Realist Evaluation of Whole-Scale Transformation in London. Milbank Q.
57	49	2009; 87 (2):391-416.
58		
59		
60		

17

¢

2		
3	1	25. Fletcher A, Jamal F, Moore G, Evans RE, Murphy S, Bonell C. Realist complex intervention science:
4	2	Applying realist principles across all phases of the Medical Research Council framework for
5	3	developing and evaluating complex interventions. Evaluation 2016; 22 (3):286-303.
6	4	26. Brand SL, Quinn C, Pearson M, et al. Building programme theory to develop more adaptable and
7	5	scalable complex interventions: Realist formative process evaluation prior to full trial.
8 9	6	Evaluation 2019; 25 (2):149-70.
9 10	7	27. Randell R, Honey S, Hindmarsh J, et al. A realist process evaluation of robot-assisted surgery:
11	8	integration into routine practice and impacts on communication, collaboration and decision-
12	° 9	
13		making. Health Services and Delivery Research 2017;5(20).
14	10	28. Andrienko N, Andrienko G. <i>Exploratory analysis of spatial and temporal data: a systematic</i>
15	11	approach: Springer Science & Business Media, 2006.
16	12	29. Brehmer M, Munzner T. A multi-level typology of abstract visualization tasks. IEEE transactions on
17	13	visualization and computer graphics 2013; 19 (12):2376-85.
18	14	30. Hysong SJ, Best RG, Pugh JA. Audit and feedback and clinical practice guideline adherence: Making
19	15	feedback actionable. Implementation Science 2006; 1 (1):1-10.
20	16	31. Sapyta J, Riemer M, Bickman L. Feedback to clinicians: Theory, research, and practice. J. Clin.
21	17	Psychol. 2005; 61 (2):145-53.
22	18	32. Van Helden GJ, Tillema S. In Search of a Benchmarking Theory for the Public Sector. Financial
23	19	Accountability & Management 2005; 21 (3):337-61.
24 25	20	33. Scott RW. Institutions and Organizations. 2nd Edition ed. London: Sage, 2001.
25	21	34. Furusten S. Institutional Theory and Organizational Change. Cheltenham, UK: Edward Elgar, 2013.
20	22	35. Yin RK. Case study research: design and methods. 3rd ed. Thousand Oaks, California: SAGE, 2003.
28	23	36. Øvretveit J, Gustafson D. Evaluation of quality improvement programmes. Quality and Safety in
29	24	Health Care 2002; 11 (3):270-75.
30	25	37. Ramsay AIG, Turner S, Cavell G, et al. Governing patient safety: lessons learned from a mixed
31	26	methods evaluation of implementing a ward-level medication safety scorecard in two English
32	27	NHS hospitals. BMJ Quality & Safety 2013; 23 :136-46.
33	28	38. Benn J, Burnett S, Parand A, Pinto A, Iskander S, Vincent C. Studying large-scale programmes to
34	28	improve patient safety in whole care systems: Challenges for research. Soc. Sci. Med.
35		
36	30	2009; 69 (12):1767-76.
37	31	39. Hyysalo S. Health technology development and use: from practice-bound imagination to evolving
38	32	impacts. New York: Routledge, 2010.
39 40	33	40. Greenhalgh T, Swinglehurst D. Studying technology use as social practice: the untapped potential
40 41	34	of ethnography. BMC Med. 2011; 9 (1):45.
42	35	41. Dainty KN, Golden BR, Hannam R, et al. A realist evaluation of value-based care delivery in home
43	36	care: The influence of actors, autonomy and accountability. Soc. Sci. Med. 2018; 206 :100-09.
44	37	42. Pollock N, Williams R. Software and organisations: The biography of the enterprise-wide system or
45	38	how SAP conquered the world. New York: Routledge, 2008.
46	39	43. Pollock N, Williams R. e-Infrastructures: How Do We Know and Understand Them? Strategic
47	40	Ethnography and the Biography of Artefacts. Computer Supported Cooperative Work (CSCW)
48	41	2010; 19 (6):521-56.
49	42	44. Hammersley M, Atkinson P. Ethnography: principles in practice. London: Routledge, 1995.
50	43	45. Waring J. Adaptive regulation or governmentality: patient safety and the changing regulation of
51	44	medicine. Sociol. Health Illn. 2007; 29 (2):163-79.
52 53	45	46. Goodwin D, Pope C, Mort M, Smith A. Access, boundaries and their effects: legitimate participation
53 54	46	in anaesthesia. Sociol. Health Illn. 2005; 27 (6):855-71.
54 55	47	47. Pawson R. Theorizing the Interview. The British Journal of Sociology 1996;47(2):295-314.
56	48	48. Harrison DG, Efford ND, Fisher QJ, Ruddle RA. PETMiner—A Visual Analysis Tool for Petrophysical
57	49	Properties of Core Sample Data. IEEE transactions on visualization and computer graphics
58	50	2017; 24 (5):1728-41.
59	20	
60		

c

- 49. Holden RJ, Karsh B-T. The Technology Acceptance Model: Its past and its future in health care.
 Journal of Biomedical Informatics 2010;43(1):159-72.
 - 50. Lee K, Jung SY, Hwang H, et al. A novel concept for integrating and delivering health information
 using a comprehensive digital dashboard: An analysis of healthcare professionals' intention to
 adopt a new system and the trend of its real usage. Int. J. Med. Inform. 2017;97:98-108.

6 51. Maxwell JA. *A realist approach for qualitative research*. London: SAGE Publications, 2012.

- 52. Hu Y. Stepped wedge, natural experiments and interrupted time series analysis designs. In:
 Richards DA, Hallberg IR, eds. Complex interventions in health: An overview of research
 methods. Abingdon: Routledge, 2015:200-12.
- 53. Handley MA, Lyles CR, McCulloch C, Cattamanchi A. Selecting and Improving Quasi-Experimental
 Designs in Effectiveness and Implementation Research. Annu. Rev. Public Health 2018;**39**(1):5 25.
- 54. Simms AD, Baxter PD, Cattle BA, et al. An assessment of composite measures of hospital
 performance and associated mortality for patients with acute myocardial infarction. Analysis
 of individual hospital performance and outcome for the National Institute for Cardiovascular
 Outcomes Research (NICOR). European Heart Journal: Acute Cardiovascular Care 2013;2(1):9 18.
 - 55. Morris JV, Ramnarayan P, Parslow RC, Fleming SJ. Outcomes for Children Receiving Noninvasive
 Ventilation as the First-Line Mode of Mechanical Ventilation at Intensive Care Admission: A
 Propensity Score-Matched Cohort Study. Crit. Care Med. 2017.
 - 56. Cochrane Effective Practice and Organisation of Care Group (EPOC). What study designs should be
 inlcuded in an EPOC review and what should they be called? Oslo: Norwegian Knowledge
 Centre for the Health Services, 2013.
 - 57. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014.
 - 58. Bugge C, Williams B, Hagen S, et al. A process for Decision-making after Pilot and feasibility Trials
 (ADePT): development following a feasibility study of a complex intervention for pelvic organ
 prolapse. Trials 2013;14(1):353.
 - 59. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res.
 Methodol. 2010;10(1):1-10.




Fig. 1: Prototype of main dashboard view for the Paediatric Intensive Care Audit Network (using simulated data).

161x74mm (300 x 300 DPI)

BMJ Open: first published as 10.1136/bmjopen-2019-033208 on 25 February 2020. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright.






Fig. 2: Prototype of main dashboard view for the Paediatric Intensive Care Audit Network with the Mortality QualCard expanded (using simulated data).

161x85mm (300 x 300 DPI)

Page 23	of 33
---------	-------

AMESES II reporting	standards for realist evaluations		omjopen-2019-033208 o	
lead to improv	contexts, and why do quality dashboards rements in care quality in acute hospitals? realist feasibility evaluation	Reported in document Y/N/NA	Page(s) in document	Comment
1	In the title, identify the document as a	Y	1 2020	
	realist evaluation		D	
SUMMARY OR A	ABSTRACT		wnlo	
2	Journal articles will usually require an abstract, while reports and other forms of publication will usually benefit from a short summary. The abstract or summary should include brief details on: the policy, programme or initiative under evaluation; programme setting; purpose of the evaluation; evaluation question(s) and/or objective(s); evaluation strategy; data collection, documentation and analysis methods; key findings and conclusions Where journals require it and the nature of the study is appropriate, brief details of respondents to the	Y	wnloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected b ຕາ	

		BMJ Open		omjopen-20	
		evaluation and recruitment and sampling processes may also be included Sufficient detail should be provided to identify that a realist approach was used and that realist programme theory was developed and/or refined		omjopen-2019-033208 on 25 February 2020. Downloade	
	FRODUCTION		X7	<u>a</u>	
3	Rationale for evaluation	Explain the purpose of the evaluation and the implications for its focus and design	Y	from http://t	
4	Programme theory	Describe the initial programme theory (or theories) that underpin the programme, policy or initiative	Y	8 and by Additional file 2 h	Placed in body of article, rather than Introduction, as more appropriate fo protocol
5	Evaluation questions, objectives and focus	State the evaluation question(s) and specify the objectives for the evaluation. Describe whether and how the programme theory was used to define the scope and focus of the evaluation	Y	n April 16, 2024 by guest. I	
6	Ethical approval	State whether the realist evaluation required and has gained ethical approval from the relevant	Y	15 Protected by copyright	

Page	25	of	33
------	----	----	----

		BMJ Open		lopen-z	5
				mjopen-zurie-usazue	
		authorities, providing details as appropriate. If ethical approval was deemed unnecessary, explain why		on 25 re	
ME	THODS			brua	
7	Rationale for using realist evaluation	Explain why a realist evaluation approach was chosen and (if relevant) adapted	Y	7-8 2020. Dow	
8	Environment surrounding the evaluation	Describe the environment in which the evaluation took place	Y	8-9 Red from	
9	Describe the programme policy, initiative or product evaluated	Provide relevant details on the programme, policy or initiative evaluated	Y	5-7 -14 April 16	Description of intervention placed in Introduction as this seemed more appropriate in providing the conte for the protocol
10	Describe and justify the evaluation design	A description and justification of the evaluation design (i.e. the account of what was planned, done and why) should be included, at least in summary form or as an appendix, in the document which presents the main findings. If this is not done, the omission should be justified and a reference or link to the evaluation	Y	7-14 Pril 16, 2024 by guest. Protected by copyright.	

		BMJ Open		omjopen-2	
		design given. It may also be useful to publish or make freely available (e.g. online on a website) any original evaluation design document or		omjopen-2019-033208 on 25 February 2020. Downloaded from http://bmjopen.tcmj.com/ on April 16. 9-11 9-11 8-9	
		protocol, where they exist	\$7	ary 202	
11	Data collection methods	Describe and justify the data collection methods – which ones were used, why and how they fed into developing, supporting, refuting or refining programme theory	Y	9-11 20. Downloaded from ht	
		Provide details of the steps taken to enhance the trustworthiness of data collection and documentation		tp://bmjopen.t	
12	Recruitment process and sampling strategy	Describe how respondents to the evaluation were recruited or engaged and how the sample contributed to the development, support, refutation or refinement of programme theory	Ŷ	2024	Sampling of sites, rather than individuals, is described; Recruitment will be described when reporting the results of the study
13	Data analysis	Describe in detail how data were analysed. This section should include information on the constructs that were identified, the process of	Y	by galactic by gal	
				/ copyright.	

Page	27	of	33
------	----	----	----

	BMJ Open		mjopen-2019-033208 on	
RESULTS	analysis, how the programme theory was further developed, supported, refuted and refined, and (where relevant) how analysis changed as the evaluation unfolded		25 February 2020.	
14 Details of participants	Report (if applicable) who took part in the evaluation, the details of the data they provided and how the data was used to develop, support, refute or refine programme theory	NA	Downloaded from http:/	Protocol so no results to report
15 Main findings	Present the key findings, linking them to contexts, mechanisms and outcome configurations. Show how they were used to further develop, test or refine the programme theory	NA	/bmjopen.bmj.com/ on	Protocol so no results to report
DISCUSSION		0)	Apri	
16 Summary of findings	Summarise the main findings with attention to the evaluation questions, purpose of the evaluation, programme theory and intended audience	NA	ii 16, 2024 by guest.	Protocol so no results to report
17 Strengths, limitations and future directions	Discuss both the strengths of the evaluation and its limitations. These should include (but need not be	4	t. Protected by copyright	Strengths and limitations of study design

3 4

	BMJ Open		njopen-2(
			019-03	
	 limited to): (1) consideration of all the steps in the evaluation processes; and (2) comment on the adequacy, trustworthiness and value of the explanatory insights which emerged In many evaluations, there will be an expectation to provide guidance on future directions for the programme, policy or initiative, its implementation and/or design. The particular implications arising from the realist 		omjopen-2019-033208 on 25 February 2020. Downloaded from http://bmjopen.t	
	nature of the findings should be reflected in these discussions			
18 Comparison with existing literature	Where appropriate, compare and contrast the evaluation's findings with the existing literature on similar programmes, policies or initiatives	NA	mj.com/ on April ,	Protocol so no results to compare with existing literature
19 Conclusion and recommendations	List the main conclusions that are justified by the analyses of the data. If appropriate, offer recommendations consistent with a realist approach	NA	16, 2024 by guest.	Protocol so no results on which to base recommendations
20 Funding and conflict	State the funding source (if any) for the evaluation, the role played by the	Y	16 Protected	

Page 29 of 33	BMJ Open	omiopen
1 2		miopen-2019-033
3 4	funder (if any) and any conflicts of	32008
5		<u>o</u>
6 7		
8		3brua
9 10		arv 2
11		0200.
12 13		Dow
13		
15		aded
16 17		from
18		from http://bmiopen.bmi.com/ on April 16. 2024 by au
19 20		5.//bn
21		
22 23		
24		<u>B</u>
25 26		om/
27		on A
28 29		
30		6. N
31		024
32 33		
34		uest.
35 36		Pro
37		
38 39		
40		Protected by copyright.
41 42		
42 43		h t
44	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	
45		
46		

BMJ Open How, in what contexts, and why do quality dashboards lead to improvements in care quality in acute hospitals? Protocol for a realist feasibility evaluation

#	Context	+	M	echanism 25	=	Outcome
			Resource	Response g		
1.	Teams previously constrained in their	+	QualDash offers easy access to	Teams are able to see whether the	=	Improvement in data
	ability to use NCA data for monitoring		key metrics	data displayed are timely, $a_{\rm gc}^{ m N}$ curate,		quality in terms of
	service performance because data not			and/or complete and, where they are		timeliness, accuracy
	considered to be timely, accurate, and/or			not, adjust their data collection		completeness – as c
	complete			processes in order to benet from		quality improves, us
				QualDash T		QualDash increases
				Teams use QualDash to endbed NCA	=	Increased routine us
				data within their monitoring processes		NCA data in perform
				e.g. in clinical governance		monitoring, providing
				where data is presented visually via		opportunities for its
				screens.		quality improvement
2.	Teams previously using NCA data to	+	QualDash visualises key	Teams use QualDash to fagilitate their	=	Reduced time spent
	monitor service performance routinely by		metrics in ways that clearly	existing processes for mone		accessing, and prep
	extracting raw data and producing		show whether service	service performance using ACA data		visualisations of, NC
	reports for review in meetings and by		performance is within an	116,		data
	individuals		expected range and provides	2024 by		
			functions to interrogate that data	4 by		
				gue		
				st. P		
				rotec		
				cted		
				by o		
				guest. Protected by copyright.		
				ight.		
	For pee	er rev	view only - http://bmjopen.bmj.com/s	ite/about/guidelines.xhtml		

44 45

#	Context	+	Me	echanism	=	Outcome
			Resource	Response မ္မ်		
3.	Teams who want to use NCA data but	+	QualDash provides functions	Teams will use these functions to	=	Introduction of QI
	were previously constrained by data		that enable users to interact	interrogate anomalies in the data,		initiatives in relation to
	quality and existing systems did not		with NCA data and explore	which will help them to und grstand		metrics that teams
	provide functions to easily access and		relationships between variables	what has impacted performence,		consider important and
	interact with the data			thereby enabling them to identify		where performance is no
				appropriate strategies for inproving		in line with expectations
				performance		
				penomance Downloaded		Over time, improvement
				oad		metrics that QI initiatives
				ed fr		target
4.	Performance in key metrics, such as the	+	QualDash offers teams the	Teams add new QualCards to be able	. =	Introduction of QI
	Best Practice Tariff, is in line with		ability to quickly and easily add	to monitor and interrogate detrics the	у	initiatives in relation to
	expectations		new QualCards (within NCA	have chosen as important	-	metrics shown on new
			parameters)	ope		QualCards when
	Relevant audit/IT support staff have time					performance is not in line
	and willingness to support use of					with expectations
	QualDash			have chosen as important on April 16, 2		·
				Ap r		Over time, improvement
				ni 16		metrics that QI initiatives
				3, 2024		target
				n6 A		
				est.		
				Prot		
				ecte		
				by guest. Protected by copyright		
				op Op		
				ýrig		

Page 32 of 33

3 4

24

			BMJ Open		omjopen		Page 3
#	Context	+				=	Outcome
			Resource	Response	2019-03:		
5.	Teams who previously did not, or were	+	QualDash provides quick and	Teams will become aware	<u>ଝ</u>	=	Introduction of QI
	not able to, monitor key metrics routinely		easy access to key metrics	discrepancies between per	Bormance		initiatives in relation to key
				and targets in key metrics,			metrics
	Performance is not in line with			will take action to address	ebru		
	expectations in key metrics				lary		Over time, improvement in
				will take action to address	2020		those metrics
	Teams are resourced to make practice				Do		
	changes				wnlo		
6.	Teams are asked to produce reports and	+	QualDash offers easy access to	Teams will use QualDash	produce	=	Reduced time spent in
	recommendations for managers and		NCA data and visualisations	performance reports reque	Sted by		report preparation
	other groups about service performance,		that can be exported into	other groups	m ht		
	e.g. at the time of publication of NCA		reports		tp://t		Increased use of NCA
	annual report				mjo		data at divisional and
					pen.		corporate levels via
					bmj.		outputs produced by
					com/		QualDash
					http://bmjopen.bmj.com/ on April 16, 2024 by gu		
					April		Over time, use of
					16, 1		QualDash at divisional
					2024		and/or corporate levels,
					by		due to increased
					guest.		awareness of NCA data
					Protected by copyright.		
					ted b		
					e S		
					pyri		
					ght.		
	For peer	r rev	iew only - http://bmjopen.bmj.com/s	ite/about/guidelines.xhtml			

Page	33	of	33
------	----	----	----

3 of 33	33 BMJ Open g							
_	#	Context	+	Mechanism 01			=	Outcome
				Resource	Response	9-03		
_	7.	Teams receive data requests from	+	QualDash can be easily	Service managers will use	gualDash to	=	Streamlines the use of
		service managers		accessed via the web by	access the information they	gneed		NCA data for clinical
				multiple users	quickly and easily	25 Fel		managers
						25 February 2020. Down		Reduced time spent by
						2020		audit support staff/clinica
								team in producing data
						own		reports for managers
_	8.	Teams need to evidence their	+	QualDash visualises	Teams will use these functi	ans to	=	Other Trust groups, who
		performance to managers and other		performance metrics, which can	evidence service performa	≝ ≆e, in order		are able to offer additiona
		groups in order to support a case for		also be exported into reports	to convince other Trust gro	ps that		resource to teams, are
		practice change e.g. in business		and presentations	change is needed	tto://		convinced of the need fo
		meetings with managers or in the NCA				p://bmiopen.bmi.com/ on April 16. 2024 by quest		change based on the
		annual report summary				open		evidence provided.
					0,			However, this is likely to
								be where those outputs
						on		are clearly associated wi
						Apri		Trust priorities, e.g.
						116		relating to Trust reputation
						202		or avoiding
						4 5		penalties/gaining
					(que		incentives.
_								
						rote		
						cted		
					•	by c		
						Protected by copyright		
					(iaht.		
		For pe	er rev	iew only - http://bmjopen.bmj.com/s				

How, in what contexts, and why do quality dashboards lead to improvements in care quality in acute hospitals? Protocol for a realist feasibility evaluation (Randell et al.) Additional file 3

The average CMOC for patients on a ward will be averaged for each month, so that there are 36 observations clustered within each of 15 hospitals. Taking the intra-class correlation to be 0.15, this yields a design effect of 6.25. Hence the effective number of observations is 15*36/6.25=86.4. Using Cohen's approach to sample size calculation means an effect size of 0.17 can be estimated with 80% given that there are six parameters in the model (including the coefficient for QualDash). Converting this to the percentage of variation that can be explained by the model, this yields 20.5%. Translating this back to CMOC, currently 49.6% of patients are discharged from hospital without missing any of the nine opportunities for care, and we would be powered at the 80% level to detect an improvement from an average of 8.33 opportunities achieved to 8.46. Thus our study has good power to detect small but meaningful clinical improvements. For PICANet, 10% of the admitted population receive non-invasive ventilation first [1]. On average there are 5.25 ventilation cases per month per hospital. With a further design effect from patients clustered within hospitals, based on the reported intraclass correlation coefficient of 0.065 giving a design effect of 1.276, the actual anticipated number of patients is 1701 giving an effective number of 213: 71 exposed to QualDash and 142 controls. This yields 80% power to detect a change from 32% to 53%.

References

 Morris JV, Ramnarayan P, Parslow RC, Fleming SJ. Outcomes for Children Receiving Noninvasive Ventilation as the First-Line Mode of Mechanical Ventilation at Intensive Care Admission: A Propensity Score-Matched Cohort Study. Crit. Care Med. 2017.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

How, in what contexts, and why do quality dashboards lead to improvements in care quality in acute hospitals? Protocol for a realist feasibility evaluation

Journal:	BMJ Open
Manuscript ID	bmjopen-2019-033208.R3
Article Type:	Protocol
Date Submitted by the Author:	20-Jan-2020
Complete List of Authors:	Randell, Rebecca; University of Bradford, Faculty of Health Studies Alvarado, Natasha; University of Leeds, School of Healthcare McVey, Lynn; University of Leeds, School of Healthcare Greenhalgh, Joanne; University of Leeds, Sociology and Social Policy West, Robert; University of Leeds, Leeds Institute of Health Sciences Farrin, Amanda; University of Leeds, Clinical Trials Research Unit Gale, Chris; University of Leeds, Leeds Institute if Genetics, Health and Therapeutics Keen, Justin; University of Leeds, Leeds Institute of Health Sciences Elshehaly, Mai; University of Leeds, School of Computing Ruddle, Roy; University of Leeds, School of Computing Lake, Julia; Leeds Teaching Hospitals NHS Trust Mamas, Mamas; Royal Stoke University Hospital Feltbower, Richard; University of Leeds, Dowding, Dawn; University of Manchester
Primary Subject Heading :	Health informatics
Secondary Subject Heading:	Health services research
Keywords:	AUDIT, Health informatics < BIOTECHNOLOGY & BIOINFORMATICS, Clinical audit < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, QUALITATIVE RESEARCH

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

R. O.

2									
3 4	1	Title: How, in what contexts, and why do quality dashboards lead to improvements in care							
5 6	2	quality in acute hospitals? Protocol for a realist feasibility evaluation							
7	3								
8 9 10	4	Authors							
10 11 12	5	Corresponding author: Rebecca Randell, Faculty of Health Studies, University of Bradford, Bradford,							
13	6	UK, r.randell@bradford.ac.uk							
14 15	7	Natasha Alvarado, of Healthcare, University of Leeds, Leeds, UK, n.alvarado@leeds.ac.uk							
16 17	8	Lynn McVey, School of Healthcare, University of Leeds, Leeds, UK, I.mcvey@leeds.ac.uk							
18 19	9	Joanne Greenhalgh, School of Sociology and Social Policy, University of Leeds, Leeds, UK,							
20 21	10	j.greenhalgh@leeds.ac.uk							
22 23	11	Robert West, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK, r.m.west@leeds.ac.uk							
24 25	12	Amanda Farrin, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK,							
26 27	13	a.j.farrin@leeds.ac.uk							
28 29	14	Chris P. Gale, School of Medicine, University of Leeds, Leeds, UK, c.p.gale@leeds.ac.uk							
30 31	15	Roger Parslow, School of Medicine, University of Leeds, Leeds, UK, r.c.parslow@leeds.ac.uk							
32 33	16	Justin Keen, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK, j.keen@leeds.ac.uk							
34	17	Mai Elshehaly, School of Computing, University of Leeds, Leeds, UK, m.h.elshehaly@leeds.ac.uk							
35 36	18	Roy A. Ruddle, School of Computing, University of Leeds, Leeds, UK, r.a.ruddle@leeds.ac.uk							
37 38	19	Julia Lake, Leeds Teaching Hospitals NHS Trust, Leeds, UK, julia.lake3@nhs.net							
39 40	20	Mamas A. Mamas, Royal Stoke Hospital, Stoke on Trent, UK, mamasmamas1@yahoo.co.uk							
41 42	21	Richard Feltbower, School of Medicine, University of Leeds, Leeds, UK, r.g.feltbower@leeds.ac.uk							
43 44	22	Dawn Dowding, School of Health Sciences, University of Manchester, Manchester, UK,							
45 46	23	dawn.dowding@lmanchester.ac.uk							
47 48	24								
49 50	25								
51									
52									
53									
54									
55									
56									
57 50									
58 59									
60									
		1							

BMJ Open

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in our licence.

10 The Submitting Author accepts and understands that any supply made under these terms is made by 11 BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a 12 postgraduate student of an affiliated institution which is paying any applicable article publishing charge 13 ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on 14 an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access 15 shall be governed by a Creative Commons licence – details of these licences and which Creative 16 Commons licence will apply to this Work are set out in our licence referred to above.

ABSTRACT

Introduction: National audits are used to monitor care guality and safety and are anticipated to reduce unexplained variations in quality by stimulating quality improvement. However, variation within and between providers in the extent of engagement with national audits mean that the potential for national audit data to inform quality improvement is not being realised. This study will undertake a feasibility evaluation of QualDash, a quality dashboard designed to support clinical teams and managers to explore data from two national audits, the Myocardial Ischaemia National Audit Project (MINAP) and the Paediatric Intensive Care Audit Network (PICANet).

Methods and analysis: Realist evaluation, which involves building, testing, and refining theories of how an intervention works, provides an overall framework for this feasibility study. Realist hypotheses that describe how, in what contexts, and why QualDash is expected to provide benefit will be tested across five hospitals. A controlled interrupted time series analysis, using key MINAP and PICANet measures, will provide preliminary evidence of the impact of QualDash, while ethnographic observations and interviews over 12 months will provide initial insight into contexts and mechanisms that lead to those impacts. Feasibility outcomes include the extent to which MINAP and PICANet data are used, data completeness in the audits, and the extent to which participants perceive QualDash to be useful and express the intention to continue using it after the study period.

Ethics and dissemination: The study has been approved by University of Leeds School of Healthcare Research Ethics Committee. Study results will provide an initial understanding of how, in what contexts, and why quality dashboards lead to improvements in care quality. These will be disseminated to academic audiences, study participants, hospital IT departments, and national audits. If results show a trial is feasible, we will disseminate the QualDash software through a stepped wedge cluster randomised trial.

Keywords: Dashboard, audit and feedback, quality improvement, realist evaluation

- Trial registration: ISRCTN18289782

Word count: 4,218

2	
3 4	1
5 6	2
7	3
8 9	4
10 11	5
12 13	6
14 15	7
16 17	8
18 19	9
20 21	10
22 23	11
24	12
25 26	13
27 28	14
29 30	15
31 32	16
33 34	17
35 36	18
37 38	19
39	20
40 41	20
42 43	
44 45	22
46 47	23
48 49	24
50	25
51 52	26
53 54	27
55 56	28
57 58	29
59	30
60	

1 ARTICLE SUMMARY

2 Strengths and limitations of this study

This study will assess the feasibility of a trial of QualDash, a quality dashboard; if a trial is feasible,
 the findings will be used to inform the design of the definitive trial, determining the components of
 QualDash to be preserved, appropriate outcome measures, and the contexts in which the trial
 should be undertaken.

- Through a controlled interrupted time series study and qualitative multi-site case study, the study
 will also provide an initial understanding of whether use of a quality dashboard leads to quality
 improvement, how, in what contexts, and why.
 - The study will contribute to understanding of how realist methods can contribute to feasibility studies
 and the design of trials.
 - Issues of data quality may be a limitation of the controlled interrupted time series study; data
 completeness, and whether this changes over the course of the study, will be assessed.

15 INTRODUCTION

.6 National clinical audits (NCAs), which provide comparative data on the performance of healthcare .7 providers, are one means by which health systems around the world monitor care quality and safety. In .8 England, a programme of over 30 NCAs is managed by the Healthcare Quality Improvement 9 Partnership (HQIP) and all healthcare providers that contribute to delivery of the National Health Service 20 (NHS) are required to participate. Such audits are anticipated to reduce unexplained variations in 21 healthcare quality by stimulating quality improvement (QI) [1 2]. While there is evidence of positive 22 impacts of NCAs [3-5], variation within and between providers in the extent to which they engage with 23 NCAs mean the potential for NCA data to inform QI is not being realised [6 7].

Quality dashboards are a form of audit and feedback (A&F) that provide visualisations of audit data with the aim of informing QI efforts [8]. Healthcare providers are increasingly using quality dashboards. For example, quality dashboard use has been reported in Canada [9], the UK [10], and the Netherlands [11]. While quality dashboards have been shown to have positive effects on some performance indicators [9], empirical evidence regarding their impact remains limited [12].

1		
2 3	1	
4	T	
5 6 7	2	
8 9	3	QualDash
10 11 12	4	QualDash is an interactive web-based quality dashboard designed to support clinical teams and
13	5	managers to explore data from two national audits, the Myocardial Ischaemia National Audit Project
14 15 16	6	(MINAP) and the Paediatric Intensive Care Audit Network (PICANet), for the purpose of QI (Fig. 1).
17	7	Information used to inform design of QualDash was collected through interviews with 50 clinicians and
18 19 20	8	managers across five NHS Trusts (providers) and four healthcare commissioners, observations of
21	9	meetings where audit data are discussed, a workshop with NCA suppliers, and two co-design
22 23	10	workshops with clinicians and managers from one Trust.
24 25	11	
26 27	12	Fig. 1: Prototype of main dashboard view for the Paediatric Intensive Care Audit Network (using
28 29	13	simulated data).
30 31	14	[Figure 1 should go approximately here]
32 33	15	
34 35	16	The interviews revealed that use of NCA data is largely at the clinical team level, with more limited use
36 37	17	at divisional and corporate (Board and sub-committees that report to the Board, such as Quality and
38 39	18	Safety Committees) levels. At all levels, a key constraint in use of NCA data for QI is lack of access to
40 41	19	timely data; there was consensus among interviewees that data should not be more than three months
42 43	20	old. QualDash seeks to improve access to timely data, providing users with a means to visualise the
44	21	data they collect for the NCAs, without having to wait for data to be returned to them from the NCAs.
45 46	22	There is variation between Trusts in the extent to which NCA data are used, often related to resources,
47 48	23	which in turn impacts on timeliness of data; Trusts that make greater use of NCA data tend to have
49 50	24	local databases from which they can generate visualisations of the data (e.g. bar charts) and audit
51 52	25	support staff who have the time and skills to be able to generate such visualisations. In contrast, where
53 54	26	such resources are not available, Trusts rely on the NCA annual reports, where data may be 15 months
55 56	27	old (e.g. one annual report published in June 2017 reported data from April 2015 to March 2016).
57 58	28	QualDash provides visualisations of key metrics, each metric being represented within a 'QualCard'
59 60	29	(Fig. 2), enabling Trusts to use NCA data for QI, regardless of existing resources. QualCards for MINAP

1 2			
2 3 4	1	and PICANet are listed in Table 1; while there is only one set of QualCards for PICANet, for MINAP	Net, for MINAP an
5 6	2	additional QualCard is provided for teaching hospitals, as discussions with sites revealed that the	revealed that the
7 8	3	metrics of interest are different between teaching hospitals and District General Hospitals (DGHs). Sit	oitals (DGHs). Sites
9	4	are also able to create additional QualCards, to reflect local priorities.	
10 11	5		
12 13	6	Fig. 2: Prototype of main dashboard view for the Paediatric Intensive Care Audit Network with the	t Network with the
14 15	7	Mortality QualCard expanded (using simulated data).	
16 17	8	[Figure 2 should go approximately here]	
18 19	9		
20 21	10	Table 1: QualCards	
22		Metric]
23 24		MINAP – all Mortality	
24 25		sites Door (arrival in Accident and Emergency) to angiogram time	
26		Gold standard drugs on discharge Referral for cardiac rehabilitation	
27		Acute use of aspirin	
28		MINAP – Call (by patient/relative to emergency services) to balloon (percutaneous	n (percutaneous
29		teaching coronary intervention) time	
30		hospital specific	
31 32		PICANet – all Mortality	
33		sites 48 hour unplanned readmission Bed days and accidental extubation	
34		Specialty case mix	
35		Data quality (number of records with a missing value)	
36		Patient dependency	
37	11		
38 39	12		
40			
41	13	To load new data into QualDash, NCA data are either extracted from the site's database or download	ase or downloaded
42 43	14	from the NCA website and then fed to a small script (written in R), which in turn updates the dashboar	ites the dashboard.
44 45	15	Users can add new data as often as they want, but at a minimum they will load data into QualDash	a into QualDash at
46 47	16	the same time as uploading to the NCAs (typically every three months).	
48 49	17		
50 51	18	The benefits perceived from using QualDash may vary between sites, with under-resourced sites the	esourced sites that
52 53	19	previously made little use of NCA data for QI perceiving greater impact than those that already ha	that already have
54 55	20	the means to use NCA data for QI. There are also constraints on use of NCA data for QI that it may	or QI that it may be
56 57	21	difficult for QualDash to address. For example, in some Trusts, clinical team members perceive th	bers perceive that
58 59	22	relevant managers will not agree to provide the resources necessary for QI initiatives, which reduc	es, which reduces
60	23	motivation to engage with NCA data and may affect the extent to which QualDash is used. However	is used. However,

QualDash provides means for visualisations to be downloaded and incorporated into presentations and reports, which may support clinical teams in making a stronger case for QI initiatives. Another constraint on use of NCA data for QI relates to clinicians' trust in the quality of the data. Interviews revealed variations across sites in processes for ensuring data quality. However, some interviewees also suggested that having the means to make more use of NCA data via QualDash would motivate them to improve their processes for ensuring data quality, although this will be dependent on local resources.

8 In this paper, we describe the methods for a realist feasibility evaluation of QualDash. The study
9 objectives are:

To develop an initial understanding of how, in what contexts, and why use of QualDash leads to QI;
 and

12 2. To assess the feasibility of conducting a trial of QualDash.

As no checklists exist for reporting of realist evaluation protocols, in presenting this protocol we draw
on the RAMESES II reporting standards for realist evaluations [13] (Additional file 1).

16 METHODS AND ANALYSIS

17 Study design

Use of theory is needed for design and evaluation of A&F interventions [14-16], and QI initiatives more generally [17-19]. This project draws on Realist Evaluation (RE), which involves building, testing, and refining theories about how an intervention is supposed to work [20]. These theories are expressed in the form of Context Mechanism Outcome (CMO) configurations, where C+M=O, reflecting the realist understanding that it is recipients' responses to the resources that an intervention provides (the intervention mechanisms) that determine the impact of the intervention, and such responses are highly influenced by context [21]. Consequently, RE seeks to answer not only the question of 'what works?' but 'what works for whom, in what circumstances, and why?' [22]. It is concerned with both intended and unintended outcomes. RE is recommended for studying QI [23] and has been used for studying the implementation and impact of large-scale QI programmes [24]. There is increasing interest in use of realist methods in feasibility evaluations [25-27].

BMJ Open

We have drawn on a range of sources to develop CMO configurations which describe how, in what contexts, and why use of QualDash is anticipated to lead to QI (see Additional file 2). Data generated from the interviews, observations, and workshops described above have been essential to this, as have discussions with the designers of QualDash (ME and RAR) who, drawing on their expertise in information visualisation, have their own literature-informed theories regarding why certain features of QualDash will provide benefit to users [28 29]. We have also drawn on substantive theories regarding how A&F lead to QI at the micro [30 31], meso [32], and macro level [33 34].

Data collection is designed to enable testing of the CMO configurations. Outcome data, in the form of key MINAP and PICANet measures, will be collected and analysed in a controlled interrupted time series (CITS) study, while a multi-site case study [35] will provide an initial understanding of the contexts and mechanisms that lead to those outcomes, as well as providing data on intermediate outcomes such as increased use of NCA data. A&F interventions, and QI interventions more generally, require longitudinal evaluation to allow sufficient time for staff to implement changes and incorporate them into their practice [36-38]. Similarly, evaluation of health IT (HIT) should allow time for staff to integrate the technology into their practices and evolve those practices to take advantage of the functionality offered by the technology [39]. Therefore, data will be collected over a 12 month period, from August 2019.

Public and patient involvement

A Lay Advisory Group has been established, which has contributed to the design of QualDash by reviewing the topic guide for the interviews that were conducted, providing their perspective on the findings of the interview study, and participating in the usability evaluation of QualDash. For the realist feasibility evaluation, they have provided advice on aspects to pay attention to when undertaking observations. They will contribute to analysis of a sample of the qualitative data, to provide a patient perspective. They will advise on dissemination of findings to relevant interest groups and will review outputs for comprehensibility.

28 Setting/context

29 The feasibility study will be conducted in the five NHS acute Trusts in which the interview study that 30 informed the design of QualDash was undertaken. Three Trusts are teaching hospitals that participate in both MINAP and PICANet and have been selected to ensure variation in key outcome measures
(MINAP: 30-day mortality for patients hospitalised with ST-elevation myocardial infarction; PICANet:
risk adjusted standardised mortality ratio). Two Trusts are DGHs that participate in MINAP but do not
have a PICU and so do not participate in PICANet. These have been selected to ensure variation in the
same key MINAP measure.

7 Multi-site case study

In the multi-site case study, data will be collected through ethnographic observation and interviews. Ethnographic methods have been argued as essential for studying implementation of QI interventions [19] and introduction of HIT [40]. Ethnography is well suited to RE because it involves observing phenomena in context, supporting understanding of how context influences the response to an intervention [41]. We will follow the Biography of Artefacts approach [42], which is concerned with capturing how particular contexts and appropriations of a technology lead to different processes and generate different outcomes, a parallel to RE's concern with contexts, mechanisms, and outcomes [43]. It involves longitudinal 'strategic ethnography' [42], where data collection is guided by a provisional understanding of the moments and locales in which a technology and associated practices evolve [43].

18 Data collection

In the three teaching hospitals, we will undertake a minimum of 24 periods of observation per Trust, to be split across activities related to cardiology and the PICU, and in the two DGHs we will undertake a minimum of 12 periods of observation per Trust, to be spent observing activities related to cardiology. Each period of observation will be a minimum of four hours (total n=384 hours). While researchers will return to each Trust monthly, to understand how use of QualDash changes over time, more time will be spent in the first few months following the introduction of QualDash, because this is when users are most likely to engage with and explore the affordances of QualDash and establish new practices around it, generating information with implications for system enhancement [43]. Observations will be scheduled to take place at different times of day and on different days of the week, to ensure the account of what is observed is as complete and representative as possible [44].

BMJ Open

At each case site, an initial phase of general observation will provide an opportunity for researchers to become familiar with the setting and for those in the setting to become familiar with the presence of the researchers. Following a previous study of dashboards [10], observations will be undertaken in clinical areas to understand clinical teams' working practices and capture 'corridor committees' where issues of quality and safety are discussed more informally [45]. In the PICUs, initial observations will take place on the PICU, e.g. with the researchers positioning themselves by the nurses' station, as well as observing handovers, safety huddles, and ward rounds. Because activities related to cardiology tend to be more dispersed across hospitals, researchers will first shadow clinical team members (consultant cardiologists and acute chest pain nurses) to determine where it is most appropriate to conduct subsequent observations. These initial observations will also be used to record general details of the setting that may influence QualDash use, such as staffing levels and availability of computers.

After this initial phase, observation will be guided by the CMO configurations under investigation. In addition to observing formal meetings where quality and safety are discussed, predominantly at ward level but also at divisional and corporate level, observation will involve shadowing staff members as they undertake particular activities: collection and entry of NCA data, to see if and how this changes over time; accessing and interrogating NCA data, whether using QualDash or some other means; preparation of reports and/or presentations using NCA data, again whether using QualDash or some other means. Where visualisations from QualDash are incorporated into presentations and written reports, we will follow the path of those documents, to identify staff members who may not use QualDash directly but are receiving QualDash outputs. Attention will be paid to how, in what contexts, and why QualDash and QualDash outputs are used or not, understood in the context of broader practices and use of other sources of information for monitoring care quality, and how this changes over time. We will also follow local QI initiatives, recording data on, for example, when and how the need for the QI initiative was identified, contextual factors that appear to support and constrain its introduction, how the impact of the QI initiative is monitored, and other contextual factors that appear to influence the metric that the QI initiative is targeting. Researchers will record observations in fieldnotes, which will be written up in detail as soon after data collection as possible.

Brief interviews will be undertaken opportunistically during the course of conducting observations to clarify aspects of practice that are not immediately intelligible to an observer, with participant responses recorded in fieldnotes [46]. As data collection progresses, longer semi-structured interviews will be used to discuss revisions to our CMO configurations. These will be undertaken using a particular approach from RE, referred to as the teacher-learner cycle, whereby the theories under investigation are made explicit to the interviewee so that the interviewee can use their experiences to refine the researcher's understanding [47]. Being concerned with the reasoning of intervention recipients, mechanisms are often not observable [21], so these longer interviews will also provide the opportunity to explore staff reasoning about QualDash. These longer interviews will be audio recorded and transcribed verbatim.

Logfiles are widely used to evaluate visualisation tools [48]. QualDash logfiles will record information about the user (job title, etc.), data used (audit, year), overall time spent using QualDash, time spent interacting with different QualCards (including new QualCards that have been created), functionality used, and whether QualDash visualisations were downloaded. In addition to providing data regarding extent of QualDash use, how QualDash is used and by whom, and how this changes over time, information from logfiles will be used to inform qualitative data collection (e.g. asking in interviews why participants use particular QualCards and not others and the motivation behind the creation of new QualCards).

At the end of the data collection period, we will ask participants to complete a questionnaire based on the Technology Acceptance Model, using well validated items that have been used in numerous evaluations of HIT [49], including dashboards [50]. This will provide participants' perceptions of the usefulness of QualDash and data on whether they intend to continue using QualDash after the study period.

26 Analysis

An iterative approach to data collection and analysis will be taken, to enable: ongoing testing and refinement of the CMO configurations; gathering of further data in light of such revisions; and refinement of QualDash in response to participants' feedback. Fieldnotes and interview transcripts will be entered into NVivo 11. Narrative analysis will be undertaken to develop a 'biography' of QualDash, which will

Page 13 of 34

BMJ Open

describe use of QualDash and its outputs by a range of stakeholders at different levels (clinical team, divisional, and corporate) and the interconnections between them [10]. Narrative analysis is consistent with a realist approach due to its emphasis on preserving connections within the data, thereby helping to understand causality [51]. This analysis will be supplemented with analysis of the logfiles and questionnaire data. Findings will be compared with the CMO configurations, to determine whether they support, refute, or suggest a revision or addition to the CMO configurations.

8 Controlled interrupted time series study

Interrupted time series studies provide a robust method of assessing the effect of an intervention and have been used to assess effectiveness of a variety of complex interventions [52]. In a CITS, the addition of a control group enhances causal inference because the presence of seasonal trends and other potential time-varying confounders can be assessed [53]. Data will be collected across the five Trusts, with two control Trusts per intervention Trust, providing a total of 10 control Trusts. Control Trusts will be matched according to their size and outcomes pre-intervention. Having more than one control site per intervention site increases power but, as the number of control sites per intervention site increases, quality of matching decreases. Therefore, we have chosen to have two control Trusts per intervention Trust to increase power while maintaining quality of the matching.

;

Given the study intention to determine the feasibility of and inform the design of a trial, a range of measures will be considered. Initially, we selected two process measures, one for MINAP and one for PICANet. For MINAP, we selected the composite process measure Cumulative Missed Opportunities for Care (CMOC). This has nine components (pre-hospital ECG, acute use of aspirin, timely perfusion, referral for cardiac rehabilitation, and prescription at hospital discharge of what are considered to be the gold standard drugs – aspirin, thienopyridine inhibitor, ACE-inhibitor, HMG-CoA reductase inhibitor, and beta blockers) and is inversely associated with mortality [54]. As some of these components, such as pre-hospital ECG, are outside the direct control of the Trust, we will also explore the impact of QualDash on the individual measures that make up CMOC. On the basis of the measures that cardiology clinicians described in the interviews as being important for measuring care quality, we will also look at the percentage of patients who receive an angiogram within 72 hours from first admission to hospital, which is part of the Best Practice Tariff financial incentive scheme, and, for those hospitals

that provide percutaneous coronary intervention (PCI), the proportion of patients who have a door-toballoon time (the time from arrival at the hospital to PCI) of less than 60 minutes. Our CMO configurations (Additional file 2) suggest improvement will be seen in measures if: clinical teams perceive them as being important indicators of care and/or they relate to financial incentives; performance is not in line with expectations; they perceive the measure as being within their control; and the team is resourced to introduce QI initiatives in relation to these measures.

For PICANet, we selected use of non-invasive ventilation first for patients requiring ventilation, which has been shown to be associated with reduced mortality [55]. However, this was not raised as an area of concern in our interviews with PICU clinicians. On the basis of this and two additional considerations - it would require loading additional data into QualDash which would reduce the performance of QualDash in terms of speed and it requires computation of the data, while the focus of QualDash is on visualising the data - a QualCard has not been created for this metric. Therefore, while we will still include this measure in the CITS, we do not hypothesise that it will change, unless other sources of information, such as the PICANet annual report, draw a PICU team's attention to it. However, accidental extubation and unplanned readmission within 48 hours were identified in our interviews with PICU clinicians as being important indicators of care quality, so we will include these two measures in the CITS. On the basis of our CMO configurations (Additional file 2), we would expect to see an improvement in these measures in sites where performance is not in line with expectations, if the team is resourced to introduce QI initiatives in relation to these measures.

22 Sample size considerations

BMJ Open

A CITS study requires data for a minimum of three time points pre-intervention and three time points post-intervention and must also allow for any seasonal effect on the outcomes [56]. Monthly data will be obtained for 24 months pre-intervention and 12 months post-intervention. Consequently, for each intervention Trust, there will be 72 data points prior to introduction (24 for the intervention Trust and 48 for the control Trusts) and 36 data points post intervention (12 for the intervention Trust and 24 for the control Trusts). Sample size calculations were undertaken based on our two initial measures, CMOC for MINAP and use of non-invasive ventilation first for patients requiring ventilation for PICANet; full details are provided in Additional file 3.

10 Analysis

Monthly MINAP and PICANet data will be extracted to spreadsheets for analysis with R software [57]. For both NCAs, each outcome will be regressed upon time and the intervention. The time component will include a seasonal effect (quarterly effect) and will allow for a (linear) time trend. To account for clustering of monthly observations within hospitals, a random intercept will be fitted, although a fixed effect for hospital as a sensitivity analysis will be explored. Although the intervention is abrupt, its impact may well be 'phased in' over a few months, perhaps three. The timing of the bedding in of the intervention will be reported from the multi-site case study. Then a partial effect can be considered for this period with the interaction effect stepping up in a linear fashion.

Results of the CITS analysis will be incorporated into the biography of QualDash, the analysis of the
data from the multi-site case study describing how contextual factors shape the evolution of practices
around QualDash and how this leads to the resulting outcome pattern.

24 Trial feasibility assessment and design

Our trial progression criteria are: (i) the number of people who engage with either MINAP or PICANet
data (via QualDash or some other means) is the same or higher than the number of people who engaged
with either MINAP or PICANet data prior to QualDash's introduction; (ii) data completeness in the national
audit improves or remains the same; (iii) 50% or more of participants in the questionnaire survey perceive
QualDash to be useful and express the intention to continue using it after the study period. Criteria (i)
and (ii) are concerned with ensuring the intervention does not have unintended negative consequences

which would affect success of the intervention. Criterion (ii) is also concerned with feasibility of outcome assessment. Criterion (iii) is concerned with acceptability and uptake of the intervention, and therefore has implications for recruitment to a trial, as well as being concerned with participants' perceptions of the impact of QualDash on care. While not formally assessed as part of the progression criteria, the impact of QualDash on care as identified in the CITS will be considered in determining whether a future trial is justified. A traffic light system will be used to determine if a trial is feasible (green), feasible with modifications to QualDash (amber), or not feasible (red) [58 59].

If the results show a trial of QualDash is feasible, we will design a stepped wedge cluster randomised trial. Data from the CITS will be used to inform the selection of NCAs to be included in the trial (MINAP and/or PICANet) and will provide information about variability of outcomes and about how long a trial intervention period would need to be. Findings from the multi-site case study will be used to inform the selection of categories of user to be included in the trial and, associated with this, the level of randomisation (Trust, hospital, or ward). Using the understanding of the relationship between contexts, mechanisms, and outcomes provided by the study, we will identify QualDash components associated with mechanisms that produce the desired outcomes in order for them to be preserved in the trial, while other components can be adapted to suit the local context.

36 18

19 ETHICS AND DISSEMINATION

Ethics approval has been received from the University of Leeds School of Healthcare Research Ethics
Committee (Approval no.HREC16-044). Written consent will be obtained from participants for interviews
and for meeting observations.

Study results will provide initial understanding of how and in what contexts quality dashboards may lead to improvements in care quality. We will disseminate these results to academic audiences, study participants, hospital IT departments, and NCAs. If we progress to a trial, in addition to providing further understanding of the impact of quality dashboards on care quality, this will result in wider dissemination of the QualDash software.

30 Acknowledgements

BMJ Open

This research is funded by the National Institute for Health Research (NIHR) Health Services and Delivery Research (HS&DR) Programme (project number 16/04/06). The views and opinions expressed are those of the presenter and do not necessarily reflect those of the HS&DR programme, NIHR, NHS or the Department of Health.

Data statement

<text> The qualitative data gathered during the course of this evaluation will be kept until June 2030 and can be accessed by other researchers during this time, subject to the necessary ethical approvals being obtained. Requests for access to this data should be addressed to the corresponding author.

1 Authors' contributions

RR is Principal Investigator for the study. She conceived, designed, and secured funding for the study in collaboration with JG, RW, AF, CPG, RP, JK, RAR, JL, MM, and DD. NA and LM led the qualitative data collection and analysis that informed the design of QualDash and the design of evaluation. ME developed the QualDash software and contributed to the design of the evaluation. RP and RF provided data for the testing of QualDash and provided significant feedback on its design. All authors provided input into various aspects of the evaluation design and revised drafts of the protocol. RR led the writing of this protocol manuscript. All authors read and approved the final manuscript.

10 Funding statement

This research is funded by the National Institute for Health Research (NIHR) Health Services and
Delivery Research (HS&DR) Programme (project number 16/04/06).

14 Competing interests statement

15 Chris Gale is a member of the MINAP Academic and Steering Groups. Richard Feltbower is Principal

16 Investigator for PICANet and Roger Parslow was previously Principal Investigator for PICANet. The

17 authors have no other competing interests to declare.

19 Additional files

- 20 Additional file 1: Checklist of RAMESES II reporting standards for realist evaluations (PDF)
- 21 Additional file 2: Context Mechanism Outcome configurations to be tested in the realist feasibility
- 22 evaluation (PDF)
- 23 Additional file 3: Sample size calculations for controlled interrupted time series (PDF)
- ⁷ 24

REFERENCES

- Phekoo KJ, Clements J, Bell D. National Clinical Audit Quality Assessment Overview of the self assessment survey: "audit of audits". London: Healthcare Quality Improvement Partnership,
 2014.
- Miller T, Leatherman S. The National Quality Forum: a'me-too'or a breakthrough in quality
 measurement and reporting? Health Aff. (Millwood) 1999;**18**(6):233-37.
- 3. Birkhead JS, Walker L, Pearson M, Weston C, Cunningham AD, Rickards AF. Improving care for
 patients with acute coronary syndromes: initial results from the National Audit of Myocardial
 Infarction Project (MINAP). Heart 2004;**90**(9):1004-09.

Page 19 of 34

1

BMJ Open

2		
3	1	4. Bridgewater B, Grayson AD, Brooks N, et al. Has the publication of cardiac surgery outcome data
4	2	been associated with changes in practice in northwest England: an analysis of 25 730 patients
5	3	undergoing CABG surgery under 30 surgeons over eight years. Heart 2007; 93 (6):744-48.
6	4	5. Neuburger J, Currie C, Wakeman R, et al. The Impact of a National Clinician-led Audit Initiative on
7	5	Care and Mortality after Hip Fracture in England: An External Evaluation using Time Trends in
8 9	6	Non-audit Data. Med. Care 2015; 53 (8):686-91.
9 10	7	6. Allwood D. Engaging Clinicians in Quality Improvement through National Clinical Audit. London:
11	8	Healthcare Quality Improvement Partnership, 2014.
12	° 9	7. Taylor A, Neuburger J, Walker K, Cromwell D, Groene O. How is feedback from national clinical
13	9 10	
14		audits used? Views from English National Health Service trust audit leads. J. Health Serv. Res.
15	11	Policy 2016; 21 (2):91-100.
16	12	8. Pauwels K, Ambler T, Clark BH, et al. Dashboards as a Service Why, What, How, and What Research
17	13	Is Needed? Journal of Service Research 2009; 12 (2):175-89.
18	14	9. Weiss D, Dunn SI, Sprague AE, et al. Effect of a population-level performance dashboard
19	15	intervention on maternal-newborn outcomes: an interrupted time series study. BMJ Quality
20	16	& Safety 2018; 27 (6):425-36.
21 22	17	10. Keen J, Nicklin E, Long A, et al. Quality and safety between ward and board: a biography of artefacts
22	18	study. Health Services and Delivery Research 2018;6(22).
24	19	11. Weggelaar-Jansen AMJWM, Broekharst DSE, de Bruijne M. Developing a hospital-wide quality and
25	20	safety dashboard: a qualitative research study. BMJ Quality & amp; Safety 2018.
26	21	12. Dowding D, Randell R, Gardner P, et al. Dashboards for improving patient care: Review of the
27	22	literature. International Journal of Medical Informatics 2015;84(2):87-100.
28	23	13. Wong G, Westhorp G, Manzano A, Greenhalgh J, Jagosh J, Greenhalgh T. RAMESES II reporting
29	24	standards for realist evaluations. BMC Med. 2016; 14 (1):96.
30	25	14. Foy R, Eccles MP, Jamtvedt G, Young J, Grimshaw JM, Baker R. What do we know about how to do
31	26	audit and feedback? Pitfalls in applying evidence from a systematic review. BMC Health Serv.
32	27	Res. 2005; 5 :50.
33	28	15. Ivers NM, Grimshaw JM, Jamtvedt G, et al. Growing Literature, Stagnant Science? Systematic
34 35	29	Review, Meta-Regression and Cumulative Analysis of Audit and Feedback Interventions in
36	30	Health Care. J. Gen. Intern. Med. 2014; 29 (11):1534-41.
37	31	16. Ivers NM, Sales A, Colquhoun H, et al. No more 'business as usual' with audit and feedback
38	32	interventions: towards an agenda for a reinvigorated intervention. Implementation Science
39	33	2014; 9 (1):1-8.
40	34	17. Grol RPTM, Bosch MC, Hulscher MEJL, Eccles MP, Wensing M. Planning and Studying Improvement
41	35	in Patient Care: The Use of Theoretical Perspectives. Milbank Q. 2007;85(1):93-138.
42	36	18. Davidoff F, Dixon-Woods M, Leviton L, Michie S. Demystifying theory and its use in improvement.
43	37	BMJ Quality & Safety 2015.
44	38	19. Dixon-Woods M, Bosk CL, Aveling EL, Goeschel CA, Pronovost PJ. Explaining Michigan: Developing
45 46	39	an Ex Post Theory of a Quality Improvement Program. Milbank Q. 2011; 89 (2):167-205.
46 47	40	20. Pawson R, Tilley N. <i>Realistic Evaluation</i> . London: SAGE Publications, 1997.
48	41	21. Dalkin S, Greenhalgh J, Jones D, Cunningham B, Lhussier M. What's in a mechanism? Development
49	42	of a key concept in realist evaluation. Implementation Science 2015; 10 (1):49.
50	43	22. Pawson R. The science of evaluation: a realist manifesto. London: SAGE, 2013.
51	45 44	23. Robert G, Fulop N. The role of context in successful improvement. Perspectives on context. A
52	44 45	
53		selection of essays considering the role of context in successful quality improvement. London:
54	46	Health Foundation 2014; 31 .
55	47	24. Greenhalgh T, Humphrey C, Hughes J, Macfarlane F, Butler C, Pawson R. How Do You Modernize a
56	48	Health Service? A Realist Evaluation of Whole-Scale Transformation in London. Milbank Q.
57 58	49	2009; 87 (2):391-416.
58 59		
60		

c


3	4	25 Flather Allowed Fl Marcol C. Flather DFL March, C. Barrello, Barlin, and the state state state
4	1	25. Fletcher A, Jamal F, Moore G, Evans RE, Murphy S, Bonell C. Realist complex intervention science:
5	2	Applying realist principles across all phases of the Medical Research Council framework for
6	3	developing and evaluating complex interventions. Evaluation 2016; 22 (3):286-303.
7	4	26. Brand SL, Quinn C, Pearson M, et al. Building programme theory to develop more adaptable and
8	5	scalable complex interventions: Realist formative process evaluation prior to full trial.
9	6	Evaluation 2019; 25 (2):149-70.
10 11	7	27. Randell R, Honey S, Hindmarsh J, et al. A realist process evaluation of robot-assisted surgery:
12	8	integration into routine practice and impacts on communication, collaboration and decision-
13	9	making. Health Services and Delivery Research 2017;5(20).
14	10	28. Andrienko N, Andrienko G. Exploratory analysis of spatial and temporal data: a systematic
15	11 12	<i>approach</i> : Springer Science & Business Media, 2006. 29. Brehmer M, Munzner T. A multi-level typology of abstract visualization tasks. IEEE transactions on
16	12	visualization and computer graphics 2013; 19 (12):2376-85.
17	15	30. Hysong SJ, Best RG, Pugh JA. Audit and feedback and clinical practice guideline adherence: Making
18 19	14	feedback actionable. Implementation Science 2006; 1 (1):1-10.
20	16	31. Sapyta J, Riemer M, Bickman L. Feedback to clinicians: Theory, research, and practice. J. Clin.
21	10	Psychol. 2005; 61 (2):145-53.
22	18	32. Van Helden GJ, Tillema S. In Search of a Benchmarking Theory for the Public Sector. Financial
23	19	Accountability & Management 2005; 21 (3):337-61.
24	20	33. Scott RW. Institutions and Organizations. 2nd Edition ed. London: Sage, 2001.
25	21	34. Furusten S. <i>Institutional Theory and Organizational Change</i> . Cheltenham, UK: Edward Elgar, 2013.
26 27	22	35. Yin RK. <i>Case study research: design and methods</i> . 3rd ed. Thousand Oaks, California: SAGE, 2003.
27	23	36. Øvretveit J, Gustafson D. Evaluation of quality improvement programmes. Quality and Safety in
29	24	Health Care 2002; 11 (3):270-75.
30	25	37. Ramsay AIG, Turner S, Cavell G, et al. Governing patient safety: lessons learned from a mixed
31	26	methods evaluation of implementing a ward-level medication safety scorecard in two English
32	27	NHS hospitals. BMJ Quality & Safety 2013; 23 :136-46.
33	28	38. Benn J, Burnett S, Parand A, Pinto A, Iskander S, Vincent C. Studying large-scale programmes to
34 35	29	improve patient safety in whole care systems: Challenges for research. Soc. Sci. Med.
36	30	2009; 69 (12):1767-76.
37	31	39. Hyysalo S. Health technology development and use: from practice-bound imagination to evolving
38	32	impacts. New York: Routledge, 2010.
39	33	40. Greenhalgh T, Swinglehurst D. Studying technology use as social practice: the untapped potential
40	34	of ethnography. BMC Med. 2011; 9 (1):45.
41	35	41. Dainty KN, Golden BR, Hannam R, et al. A realist evaluation of value-based care delivery in home
42 43	36	care: The influence of actors, autonomy and accountability. Soc. Sci. Med. 2018; 206 :100-09.
44	37	42. Pollock N, Williams R. Software and organisations: The biography of the enterprise-wide system or
45	38	how SAP conquered the world. New York: Routledge, 2008.
46	39	43. Pollock N, Williams R. e-Infrastructures: How Do We Know and Understand Them? Strategic
47	40	Ethnography and the Biography of Artefacts. Computer Supported Cooperative Work (CSCW)
48	41	2010; 19 (6):521-56.
49 50	42	44. Hammersley M, Atkinson P. <i>Ethnography: principles in practice</i> . London: Routledge, 1995.
50 51	43	45. Waring J. Adaptive regulation or governmentality: patient safety and the changing regulation of
52	44	medicine. Sociol. Health Illn. 2007; 29 (2):163-79.
53	45	46. Goodwin D, Pope C, Mort M, Smith A. Access, boundaries and their effects: legitimate participation
54	46	in anaesthesia. Sociol. Health IIIn. 2005; 27 (6):855-71.
55	47	47. Pawson R. Theorizing the Interview. The British Journal of Sociology 1996; 47 (2):295-314.
56	48	48. Harrison DG, Efford ND, Fisher QJ, Ruddle RA. PETMiner—A Visual Analysis Tool for Petrophysical
57 58	49 50	Properties of Core Sample Data. IEEE transactions on visualization and computer graphics
58 59	50	2017; 24 (5):1728-41.

1 2

c

 49. Holden RJ, Karsh B-T. The Technology Acceptance Model: its past and its future in health care. Journal of Biomedical Informatics 2010;43(1):159-72. 50. Lee K. Jung SY, Hwang H, et al. A novel concept for integrating and delivering health information using a comprehensive digital dashboard: An analysis of healthcare professionals, intention to adopt a new system and the trend of its real usage. Int. J. Med. Inform. 2017;97:98-108. 51. Maxwell JA. <i>A realist approach for qualitative research.</i> London: SAGE Publications, 2012. 72. Hu Y. Stepped wedge, natural experiments and interrupted time series analysis designs. In: Richards DA, Hallberg IR, eds. Complex interventions in health: An overview of research methods. Abingdon: Routledge, 2015;200-12. 53. Handley MA, Lybes CM, McCulloch C, Cattamanchi A. Selecting and Improving Quasi-Experimental Designs in Effectiveness and Implementation Research. Annu. Rev. Public Health 2018;39(1):5- 25. 54. Simms AD, Baxter PD, Cattle BA, et al. An assessment of composite measures of hospital performance and associated mortality for patients with acute myocardial infarction. Analysis of individual hospital performance and outcome for the National Institute for Cardiovascular Outcomes Research (NICOR). European Heart Journal: Acute Cardiovascular Care 2013;2(1):9- 18. 55. Morris JV, Ramnarayan P, Parslow RC, Fleming SJ. Outcomes for Children Receiving Noninvasive Ventilation as the First-Line Mode of Mechanical Ventilation at Intensive Care Admission: A Propensity Score-Matthed Cohort Study. Crit. Care Med. 2017. 56. Cochrane Effective Practice and Organisation of Care Group (EPOC). What study designs should be included in an EPOC review and Mytus tholud they be called? Oslo: Norwegian Knowledge Centre for the Health Services, 2013. 57. Roore Team. R: A language and environment for statistical computing, Vienna, Austria: Ruber J. Alex J. Chu, R. et al. A turori	1		
 42. Holdell ID, Kasting MC, Barton MC, Hang MC, Hang	2 3	1	10. Helden DL Kersh D.T. The Technology Accountered Medal, the next and its future in health same
 50. Lee K, Jung SY, Hwang H, et al. A novel concept for integrating and delivering health information to adopt a new system and the trend of its real usage. Int. J. Med. Inform. 2017;97:98-108. 51. Maxwell JA. A realist approach for qualitative research. London: SAGE Publications, 2012. 52. Hu Y. Stepped wedge, natural experiments and interrupted time series analysis designs. In: Richards DA, Hallberg IR, eds. Complex interventions in health: An overview of research methods. Abingdon: Routledge, 2015:200-12. 53. Handley MA, Lyles CR, McCulloch C, Cattamanchi A. Selecting and Improving Quasi-Experimental Designs in Effectiveness and Implementation Research. Annu. Rev. Public Health 2018;39(1):5- 25. 54. Simms AD, Baxter PD, Cattle BA, et al. An assessment of composite measures of hospital performance and associated mortality for patients with acute Cardiovascular Care 2013;2(1):9- 18. 55. Morris JV, Ramnarayan P, Parslow RC, Fleming SJ. Outcomes for Children Receiving Noninvasive Ventilation as the First-Line Mode of Mechanical Ventilation at Intensive Care Admission: A Propensity Score-Matched Cohort Study. Crit. Care Med. 2017. 56. Cochrane Effective Practice and Organisation of Care Group (EPOC). What study designs should be included in an EPOC review and what should they be called? Colic. Norwegian Knowledge Centre for the Health Services, 2013. 57. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014. 58. Bugge C, Williams B, Hagen S, et al. A process for Decision-making after Pilot and feasibility Trials (ADe/Pil): evelopment following a feasibility study of a complex intervention for pelvic organ prolapse. Trials 2013;14(1):353. 59. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res. Methodol. 2010;10(1):1-10. 			
 using a comprehensive digital dashboard: An analysis of healthcare professionals' intention to adopt a new system and the trend of its real usage. Int. J. Med. Inform. 2017;97:98-108. S1. Maxwell JA. A <i>realist approach for qualitative research</i>. London: SAGE Publications, 2012. S2. Hu Y. Stepped wedge, natural experiments and interrupted time series analysis designs. In: Richards DA, Hallberg IR, eds. Complex interventions in health: An overview of research methods. Abingdon: Routledge, 2015;200-12. S3. Handley MA, Lyles CR, McCulloch C, Cattamanchi A. Selecting and Improving Quasi-Experimental Designs in Effectiveness and implementation Research. Annu. Rev. Public Health 2018;39(1):5- 25. S4. Simms AD, Baxter PD, Cattle BA, et al. An assessment of composite measures of hospital performance and associated mortality for patients with acute myocardial infarction. Analysis of individual hospital performance and outcome for the National Institute for Cardiovascular Outcomes Research (NICOR). European Heart Journal: Acute Cardiovascular Care 2013;2(1):9- 18. S5. Morris JV, Ramnarayan P, Parslow RC, Fleming SJ. Outcomes for Children Receiving Noninvasive Ventilation as the First-Line Mode of Mechanical Ventilation at Intensive Care Admission: A Propensity Score-Matched Cohort Study. Crit. Care Med. 2017. S6. Cochrane Effective Practice and Organisation of Care Group (EPOC). What study designs should be included in an EPOC review and what should they be called? Osio: Norwegian Knowledge Centre for the Health Services, 2013. S8. Bugge C, Williams B, Hagen S, et al. A process for Decision-making after Pilot and feasibility Trials (ADePT): development following a feasibility study of a complex intervention for pelvic organ prolapse. Trials 2013;14(1):353. S9. Thabane L, Ma J, Chu A, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res. Methodol. 2010;10(1):1-10. 			
 adopt a new system and the trend of its real usage. Int. J. Med. Inform. 2017, 97:98-108. 51. Maxwell JA. A realist approach for qualitative research. London: SAGE Publications, 2012. 52. Hu Y. Stepped wedge, natural experiments and interrupted time series analysis designs. In: Richards DA, Hallberg IR, eds. Complex Interventions in health: An overview of research methods. Abingdon: Routledge, 2015:200-12. 53. Handley MA, Lyles CR, McCulloch C, Cattamanchi A. Selecting and Improving Quasi-Experimental Designs in Effectiveness and Implementation Research. Annu. Rev. Public Health 2018;39(1):5- 25. 54. Simms AD, Baxter PD, Cattle BA, et al. An assessment of composite measures of hospital performance and associated mortality for patients with acute myocardial infarction. Analysis of individual hospital performance and outcome for the National Institute for Cardiovascular Outcomes Research (NICOR). European Heart Journal: Acute Cardiovascular Care 2013;2(1):9- 18. 55. Morris JV, Ramnarayan P, Parslow RC, Fleming SJ. Outcomes for Children Receiving Noninvasive Ventilation as the First Line Mode of Mechanical Ventilation at Intensive Care Admission: A Propensity Score-Matched Cohort Study. Crit. Care Med. 2017. 56. Cochrane Effective Practice and Organisation of Care Group (EPOC). What study designs should be included in an EPOC review and what should they be called? Oslo: Norwegian Knowledge Centre for the Health Services, 2013. 57. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014. 58. Bugge C, Williams B, Hagen S, et al. A process for Decision-making after Pilot and feasibility Trials (ADePT): development following a feasibility study of a complex intervention for pelvic organ prolapse. Trials 2013;14(1):35. 59. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res. Methodol. 2010;10(1):1-10. 			
 51. Maxwell JA. A realist approach for qualitative research. London: SAGE Publications, 2012. 52. Hu Y. Stepped wedge, natural experiments and interrupted time series analysis designs. In: Richards DA, Hallberg IR, eds. Complex interventions in health: An overview of research methods. Abingdon: Routledge, 2015;200-12. 53. Handley MA, Lyles CR, McCulloch C, Cattamanchi A. Selecting and Improving Quasi-Experimental Designs in Effectiveness and Implementation Research. Annu. Rev. Public Health 2018;39(1):5- 25. 54. Simms AD, Baxter PD, Cattle BA, et al. An assessment of composite measures of hospital performance and associated mortality for patients with acute myocardial infarction. Analysis of individual hospital performance and outcome for the National Institute for Cardiovascular Outcomes Research (NICOR). European Heart Journal: Acute Cardiovascular Care 2013;2(1):9- 18. 55. Morris JV, Ramnarayan P, Parslow RC, Fleming SJ. Outcomes for Children Receiving Noninvasive Ventilation as the First-Line Mode of Mechanical Ventilation at Intensive Care Admission: A Propensity Score-Matched Cohort Study. Crit. Care Med. 2017. 56. Cochrane Effective Practice and Organisation of Care Group (EPOC). What study designs should be included in an EPOC review and what should they be called? Oslo: Norwegian Knowledge Centre for the Health Services, 2013. 57. R. Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014. 58. Buggee C, Williams B, Hagen S, et al. A process for Decision-making after Pilot and feasibility Trials (ADePT): development following a feasibility study of a complex intervention for pekic organ prolapse. Trials 2013;14(1):353. 59. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res. Methodol. 2010;10(1):1-10. 			
 52. Hu Y. Stepped wedge, natural experiments and interrupted time series analysis designs. In: Richards DA, Hallberg IR, eds. Complex interventions in health: An overview of research methods. Abingdon: Routledge, 2015:200-12. 53. Handley MA, Lyles CR, McCulloch C, Cattamanchi A. Selecting and Improving Quasi-Experimental Designs in Effectiveness and Implementation Research. Annu. Rev. Public Health 2018;39(1):5- 25. 54. Simms AD, Baxter PD, Cattle BA, et al. An assessment of composite measures of hospital performance and associated mortality for patients with acute myocardial infarction. Analysis of individual hospital performance and outcome for the National Institute for Cardiovascular Outcomes Research (NICOR). European Heart Journal: Acute Cardiovascular Care 2013;2(1):5- 18. 55. Morris JV, Ramnarayan P, Parslow RC, Fleming SJ. Outcomes for Children Receiving Noninvasive Ventilation as the First-Line Mode of Mechanical Ventilation at Intensive Care Admission: A Propensity Score-Matched Cohort Study. Crit. Care Med. 2017. 56. Cochrane Effective Practice and Organisation of Care Group (EPOC). What study designs should be inicuded in an EPOC review and what should they be called? Oslo: Norwegian Knowledge Centre for the Health Services, 2013. 57. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014. 58. Bugge C, Williams B, Hagen S, et al. A process for Decision-making after Pilot and feasibility Trials (ADEPT): development following a feasibility study of a complex intervention for pelvic organ prolapse. Trials 2013;14(1):353. 59. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies; the what, why and how. BMC Med. Res. Methodol. 2010;10(1):1-10. 			
 methods. Abingdon: Routledge, 2015:200-12. 33. Handley MA, Lyles CR, McCulloch C, Cattamanchi A. Selecting and Improving Quasi-Experimental Designs in Effectiveness and Implementation Research. Annu. Rev. Public Health 2018;39(1):5- 25. 44. Simms AD, Baxter PD, Cattle BA, et al. An assessment of composite measures of hospital performance and associated mortality for patients with acute myocardial infarction. Analysis of individual hospital performance and outcome for the National Institute for Cardiovascular Outcomes Research (NICOR). European Heart Journal: Acute Cardiovascular Care 2013;2(1):9- 18. 55. Morris JV, Ramnarayan P, Parslow RC, Fleming SJ. Outcomes for Children Receiving Noninvasive Ventilation as the First-Line Mode of Mechanical Ventilation at Intensive Care Admission: A Propensity Score-Matched Cohort Study. Crit. Care Med. 2017. 56. Cochrane Effective Practice and Organisation of Care Group (EPOC). What study designs should be inlcuded in an EPOC review and what should they be called? Oslo: Norwegian Knowledge Centre for the Health Services, 2013. 57. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014. 58. Bugge C, Williams B, Hagen S, et al. A process for Decision-making after Pilot and feasibility Trials (ADEPT): development following a feasibility study of a complex intervention for pelvic organ prolapes. Trials 2013;14(1):353. 59. Thabane L, Ma J, Chu R, et al. A turorial on pilot studies: the what, why and how. BMC Med. Res. Methodol. 2010;10(1):1-10. 			
 S. Handley MA, Lyles CR, McCulloch C, Cattamanchi A. Selecting and Improving Quasi-Experimental Designs in Effectiveness and Implementation Research. Annu. Rev. Public Health 2018;39(1):5- 25. S. Simms AD, Baxter PD, Cattle BA, et al. An assessment of composite measures of hospital performance and associated mortality for patients with acute myocardial infarction. Analysis of individual hospital performance and outcome for the National Institute for Cardiovascular Outcomes Research (NICOR). European Heart Journal: Acute Cardiovascular Cardiovascular Ventilation as the First-Line Mode of Mechanical Ventilation at Intensive Care Admission: A Propensity Score-Matched Cohort Study. Crit. Care Med. 2017. Cochrane Effective Practice and Organisation of Care Group (EPOC). What study designs should be included in an EPOC review and what should they be called? Oslo: Norwegian Knowledge Centre for the Health Services, 2013. R. Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014. B. Bugge C, Williams B, Hagen S, et al. A process for Decision-making after Pilot and feasibility Trials (ADePT): development following a feasibility study of a complex intervention for pelvic organ prolapse. Trials 2013;14(1):353. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies; the what, why and how. BMC Med. Res. Methodol. 2010;10(1):1-10. 		8	
 Josh Handrey MP, Spes CR, McCallour P, Jandardy MP. Beecking and implying Quasi-Cyper Interted Designs in Effectiveness and implementation Research. Annu. Rev. Public Health 2018;39(1):5- 25. Simms AD, Baxter PD, Cattle BA, et al. An assessment of composite measures of hospital performance and associated mortality for patients with acute myocardial infarction. Analysis of individual hospital performance and outcome for the National Institute for Cardiovascular Outcomes Research (NICOR). European Heart Journal: Acute Cardiovascular Care 2013;2(1):9- 18. Morris JV, Ramnarayan P, Parslow RC, Fleming SJ. Outcomes for Children Receiving Noninvasive Ventilation as the First-Line Mode of Mechanical Ventilation at Intensive Care Admission: A Propensity Score-Matched Cohort Study. Crit. Care Med. 2017. Cochrane Effective Practice and Organisation of Care Group (EPOC). What study designs should be included in an EPOC review and what should they be called? Oslo: Norwegian Knowledge Centre for the Health Services, 2013. Sr. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014. S8. Bugge C, Williams B, Hagen S, et al. A process for Decision-making after Pilot and feasibility Trials (ADerT): development following a feasibility study of a complex intervention for pelvic organ prolapes. Trials 2013;14(1):53. S9. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res. Methodol. 2010;10(1):1-10. 		9	methods. Abingdon: Routledge, 2015:200-12.
 Designs in Effectiveness and implementation Research. AnNU. Rev. Public Health 2018;39(1):5-25. Simms AD, Baxter PD, Cattle BA, et al. An assessment of composite measures of hospital performance and associated mortality for patients with acute myocardial infarction. Analysis of individual hospital performance and outcome for the National Institute for Cardiovascular Outcomes Research (NICOR). European Heart Journal: Acute Cardiovascular Care 2013;2(1):9-18. Si. Morris JV, Ramnarayan P, Parslow RC, Fleming SJ. Outcomes for Children Receiving Noninvasive Ventilation as the First-Line Mode of Mechanical Ventilation at Intensive Care Admission: A Propensity Score-Matched Cohort Study. Crit. Care Med. 2017. Sc. Cochrane Effective Practice and Organisation of Care Group (FPCO). What study designs should be inlcuded in an EPOC review and what should they be called? Oslo: Norwegian Knowledge Centre for the Health Services, 2013. R. Core Team, R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014. Sa. Bugge C, Williams B, Hagen S, et al. A process for Decision-making after Pilot and feasibility Trials (ADePT): development following a feasibility study of a complex intervention for pelvic organ prolapse. Trials 2013;14(1):353. St. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res. Methodol. 2010;10(1):1-10. 		10	53. Handley MA, Lyles CR, McCulloch C, Cattamanchi A. Selecting and Improving Quasi-Experimental
 12 25. 54. Simms AD, Baxter PD, Cattle BA, et al. An assessment of composite measures of hospital performance and associated mortality for patients with acute myocardial infarction. Analysis of individual hospital performance and outcome for the National Institute for Cardiovascular Outcomes Research (NICOR). European Heart Journal: Acute Cardiovascular Care 2013;2(1):9- 18. 55. Morris JV, Ramnarayan P, Parslow RC, Fleming SJ. Outcomes for Children Receiving Noninvasive Ventilation as the First-Line Mode of Mechanical Ventilation at Intensive Care Admission: A Propensity Score-Matched Cohort Study. Crit. Care Med. 2017. 56. Cochrane Effective Practice and Organisation of Care Group (EPOC). What study designs should be included in an EPOC review and what should they be called? Osio: Norwegian Knowledge Centre for the Health Services, 2013. 57. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014. 58. Bugge C, Williams B, Hagen S, et al. A process for Decision-making after Pilot and feasibility Trials (ADePT): development following a feasibility study of a complex intervention for pelvic organ prolapse. Trials 2013;14(1):353. 59. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies; the what, why and how. BMC Med. Res. Methodol. 2010;10(1):1-10. 			
 performance and associated mortality for patients with acute myocardial infarction. Analysis of individual hospital performance and outcome for the National Institute for Cardiovascular Care 2013;2(1):9-18. 55. Morris JV, Ramnarayan P, Parslow RC, Fleming SJ. Outcomes for Children Receiving Noninvasive Ventilation as the First-line Mode of Mechanical Ventilation at Intensive Care Admission: A Propensity Score-Matched Cohort Study. Crit. Care Med. 2017. 56. Cochrane Effective Practice and Organisation of Care Group (EPOC). What study designs should be included in an EPOC review and what should they be called? Oslo: Norwegian Knowledge Centre for the Health Services, 2013. 57. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014. 58. Bugge C, Williams B, Hagen S, et al. A process for Decision-making after Pilot and feasibility Trials (ADePT): development following a feasibility study of a complex intervention for pelvic organ prolapse. Trials 2013;14(1):353. 59. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res. Methodol. 2010;10(1):1-10. 			
 of individual hospital performance and outcome for the National Institute for Cardiovascular Outcomes Research (NICOR). European Heart Journal: Acute Cardiovascular Care 2013;2(1):9- 18. 55. Morris JV, Ramnarayan P, Parslow RC, Fleming SJ. Outcomes for Children Receiving Noninvasive Ventilation as the First-Line Mode of Mechanical Ventilation at Intensive Care Admission: A Propensity Score-Matched Cohort Study. Crit. Care Med. 2017. 56. Cochrane Effective Practice and Organisation of Care Group (EPOC). What study designs should be included in an EPOC review and what should they be called? Oslo: Norwegian Knowledge Centre for the Health Services, 2013. 57. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014. 58. Bugge C, Williams B, Hagen S, et al. A process for Decision-making after Pilot and feasibility Trials (ADEPT): development following a feasibility study of a complex intervention for pelvic organ prolapse. Trials 2013;14(1):353. 59. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res. Methodol. 2010;10(1):1-10. 	17		
 Outcomes Research (NICOR). European Heart Journal: Acute Cardiovascular Care 2013;2(1):9-18. St. Morris JV, Ramnarayan P, Parslow RC, Fleming SJ. Outcomes for Children Receiving Noninvasive Ventilation as the First-Line Mode of Mechanical Ventilation at Intensive Care Admission: A Propensity Score-Matched Cohort Study. Crit. Care Med. 2017. Sc. Cochrane Effective Practice and Organisation of Care Group (EPOC). What study designs should be influeded in an EPOC review and what should they be called? Oslo: Norwegian Knowledge Centre for the Health Services, 2013. Sr. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014. Sa. Bugge C, Williams B, Hagen S, et al. A process for Decision-making after Pilot and feasibility Trials (ADePT): development following a feasibility study of a complex intervention for pelvic organ prolayse. Trials 2013;14(1):353. Sp. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res. Methodol. 2010;10(1):1-10. 			
 17 18. 18. S5. Morris JV, Ramnarayan P, Parslow RC, Fleming SJ. Outcomes for Children Receiving Noninvasive Ventilation as the First-Line Mode of Mechanical Ventilation at Intensive Care Admission: A Propensity Score-Matched Cohort Study. Crit. Care Med. 2017. 15. Cochrane Effective Practice and Organisation of Care Group (EPOC). What study designs should be included in an EPOC review and what should they be called? Oslo: Norwegian Knowledge Centre for the Health Services, 2013. 17. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014. 18. Bugge C, Williams B, Hagen S, et al. A process for Decision-making after Pilot and feasibility Trials (ADePT): development following a feasibility study of a complex intervention for pelvic organ prolapse. Trials 2013;14(1):353. 19. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res. Methodol. 2010;10(1):1-10. 			
 55. Moris IV, Ramnarayan P, Parslow RC, Fleming SJ. Outcomes for Children Receiving Noninvasive Ventilation as the First-Line Mode of Mechanical Ventilation at Intensive Care Admission: A Propensity Score-Matched Cohort Study. Crit. Care Med. 2017. 56. Cochrane Effective Practice and Organisation of Care Group (EPOC). What study designs should be included in an EPOC review and what should they be called? Oslo: Norwegian Knowledge Centre for the Health Services, 2013. 57. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014. 58. Bugge C, Williams B, Hagen S, et al. A process for Decision-making after Pilot and feasibility Trials (ADerT): development following a feasibility study of a complex intervention for pelvic organ prolapse. Trials 2013;14(1):353. 59. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res. Methodol. 2010;10(1):1-10. 			
 18 John Marins JP, Kamina ayain P, Ya Sino McC, Treimag JJ. Outcomes D. Control Clinicating Kominizasian A Propensity Score-Matched Cohort Study. Crit. Care Med. 2017. 19 56. Cochrane Effective Practice and Organisation of Care Group (EPOC). What study designs should be included in an EPOC review and what should they be called? Oslo: Norwegian Knowledge Centre for the Health Services, 2013. 10 57. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014. 12 58. Bugge C, Williams B, Hagen S, et al. A process for Decision-making after Pilot and feasibility Trials (ADePT): development following a feasibility study of a complex intervention for pelvic organ prolapse. Trials 2013;14(1):353. 13 59. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res. Methodol. 2010;10(1):1-10. 14 59. 			
 Propensity Score-Matched Cohort Study. Crit. Care Med. 2017. 56. Cochrane Effective Practice and Organisation of Care Group (EPOC). What study designs should be inlcuded in an EPOC review and what should they be called? Oslo: Norwegian Knowledge Centre for the Health Services, 2013. 57. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014. 58. Bugge C, Williams B, Hagen S, et al. A process for Decision-making after Pilot and feasibility Trials (ADePT): development following a feasibility study of a complex intervention for pelvic organ prolapse. Trials 2013;14(1):353. 59. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res. Methodol. 2010;10(1):1-10. 			
 56. Cochrane Effective Practice and Organisation of Care Group (EPOC). What study designs should be inlcuded in an EPOC review and what should they be called? Oslo: Norwegian Knowledge Centre for the Health Services, 2013. 57. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014. 58. Bugge C, Williams B, Hagen S, et al. A process for Decision-making after Pilot and feasibility Trials (ADePT): development following a feasibility study of a complex intervention for pelvic organ prolapse. Trials 2013;14(1):353. 59. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res. Methodol. 2010;10(1):1-10. 31 			
 inlcuded in an EPOC review and what should they be called? Oslo: Norwegian Knowledge Centre for the Health Services, 2013. Sr. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014. Sa. Bugge C, Williams B, Hagen S, et al. A process for Decision-making after Pilot and feasibility Trials (ADePT): development following a feasibility study of a complex intervention for pelvic organ prolapse. Trials 2013;14(1):353. Sb. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res. Methodol. 2010;10(1):1-10. 			
 23 Centre for the Health Services, 2013. 24 57. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014. 26 58. Bugge C, Williams B, Hagen S, et al. A process for Decision-making after Pilot and feasibility Trials (ADePT): development following a feasibility study of a complex intervention for pelvic organ prolapse. Trials 2013;14(1):353. 29 59. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res. Methodol. 2010;10(1):1-10. 31 31 			
 29 24 57. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014. 31 26 58. Bugge C, Williams B, Hagen S, et al. A process for Decision-making after Pilot and feasibility Trials (ADePT): development following a feasibility study of a complex intervention for pelvic organ prolapse. Trials 2013;14(1):353. 39 59. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res. Methodol. 2010;10(1):1-10. 31 			
 Foundation for Statistical Computing, 2014. 58. Bugge C, Williams B, Hagen S, et al. A process for Decision-making after Pilot and feasibility Trials (ADePT): development following a feasibility study of a complex intervention for pelvic organ prolapse. Trials 2013;14(1):353. 59. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res. Methodol. 2010;10(1):1-10. 31 			
 26 50. bugge c, winding of hegen s, et al. A process to breast intervention for pelvic organ (ADePT): development following a feasibility study of a complex intervention for pelvic organ prolapse. Trials 2013;14(1):353. 29 59. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res. Methodol. 2010;10(1):1-10. 31 31 44 45 46 47 48 49 59 50 50 50 51 52 53 54 55 56 57 58 59 			
 27 (ADEPT), development biolowing a teasibility study of a complex intervention for period organ 28 prolapse. Trials 2013;14(1):353. 29 59. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res. 30 Methodol. 2010;10(1):1-10. 31 		26	
34 28 protapse. Irrais 2013;14(1):353. 35 29 59. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res. 36 30 Methodol. 2010;10(1):1-10. 37 31 38 31 40		27	(ADePT): development following a feasibility study of a complex intervention for pelvic organ
35 29 59. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res. 30 Methodol. 2010;10(1):1-10. 37 31 39 40 40 41 42 43 43 44 44 45 46 47 47 48 48 49 50 51 51 52 53 54 54 55 56 57 58 59		28	prolapse. Trials 2013; 14 (1):353.
30 Methodol. 2010;10(1):1-10. 37 31 39		29	59. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med. Res.
31 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59		30	Methodol. 2010; 10 (1):1-10.
39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59		21	
40 41 42 43 43 44 44 45 46 46 47 48 49 50 50 51 52 53 53 54 56 56 57 58 59 59		51	
41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59			
45 46 47 48 49 50 51 52 53 54 55 56 57 58 59			
45 46 47 48 49 50 51 52 53 54 55 56 57 58 59			
45 46 47 48 49 50 51 52 53 54 55 56 57 58 59			
46 47 48 49 50 51 52 53 54 55 56 57 58 59			
47 48 49 50 51 52 53 54 55 56 57 58 59			
 48 49 50 51 52 53 54 55 56 57 58 59 			
50 51 52 53 54 55 56 57 58 59			
51 52 53 54 55 56 57 58 59			
52 53 54 55 56 57 58 59			
53 54 55 56 57 58 59			
54 55 56 57 58 59			
56 57 58 59			
57 58 59			
58 59			
59			

c



60




Fig. 1: Prototype of main dashboard view for the Paediatric Intensive Care Audit Network (using simulated data).

161x74mm (300 x 300 DPI)

BMJ Open: first published as 10.1136/bmjopen-2019-033208 on 25 February 2020. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright.



Fig. 2: Prototype of main dashboard view for the Paediatric Intensive Care Audit Network with the Mortality QualCard expanded (using simulated data).

161x85mm (300 x 300 DPI)

BMJ Open: first published as 10.1136/bmjopen-2019-033208 on 25 February 2020. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright.

Page	24	of	34
------	----	----	----

	ng standards for realist evaluations t contexts, and why do quality dashboards ovements in care quality in acute hospitals?	Reported in	Page(\$) in document	Comment
-	a realist feasibility evaluation	document Y/N/NA	sbruary	
L	In the title, identify the document as a	Y	1 2020.	
	realist evaluation		Do	
SUMMARY OI	R ABSTRACT		wnlo	
2	Journal articles will usually require an	Y	wnloaded from http://bmjopen.bmj.com/ on April 16, 2024 by gu ຕ	
	abstract, while reports and other		from	
	forms of publication will usually		http://	
	benefit from a short summary. The		o://br	
	abstract or summary should include		njope	
	brief details on: the policy,		en.br	
	programme or initiative under		nj.co	
	evaluation; programme setting;		m/ o	
	purpose of the evaluation; evaluation		n Ap	
	<pre>question(s) and/or objective(s);</pre>		ril 16	
	evaluation strategy; data collection,		5, 20	
	documentation and analysis methods;		24 b	
	key findings and conclusions			
	Where journals require it and the		est. Protected b	
	nature of the study is appropriate,		otect	
	brief details of respondents to the		ed b	

		BMJ Open		pen-2019	
		evaluation and recruitment and		omjopen-2019-033208 on 25	
		sampling processes may also be included		n 25 Febi	
		Sufficient detail should be provided to		ruary	
		identify that a realist approach was		2020	
		used and that realist programme). Do	
		theory was developed and/or refined		wnlo	
IN	TRODUCTION	<u> </u>		aded	
3	Rationale for	Explain the purpose of the evaluation	Y	7 fron	
	evaluation	and the implications for its focus and design		February 2020. Downloaded from http://b	
4	Programme theory	Describe the initial programme theory	Y	8 and g	Placed in body of
		(or theories) that underpin the		Additional file 2	article, rather than Introduction, as
		programme, policy or initiative		file 2 bmj.com/ on April 16,	more appropriate protocol
5	Evaluation questions,	State the evaluation question(s) and	Y	7 Ap	
	objectives and focus	specify the objectives for the		oril 16	
		evaluation. Describe whether and how			
		the programme theory was used to		2024 by gu	
		define the scope and focus of the		/ gue	
		evaluation		lest. P	
6	Ethical approval	State whether the realist evaluation	Y	Protected by copyright	
		required and has gained ethical		ted k	
		approval from the relevant		by a	

	Page	26	of	34
--	------	----	----	----

		BMJ Open		mjopen-	
				2019-03	
		authorities, providing details as appropriate. If ethical approval was deemed unnecessary, explain why		omjopen-2019-033208 on 25 Fe	
ME	THODS			orua	
7	Rationale for using realist evaluation	Explain why a realist evaluation approach was chosen and (if relevant) adapted	Y	7-8 7-8 Down	
8	Environment surrounding the evaluation	Describe the environment in which the evaluation took place	Y	8-9 B-9	
9	Describe the programme policy, initiative or product evaluated	Provide relevant details on the programme, policy or initiative evaluated	Y	5-7 http://bmjopen.bmj.com/ on April 16, 7-14 7-14	Description of intervention placed in Introduction as this seemed more appropriate in providing the contex for the protocol
10	Describe and justify the evaluation design	A description and justification of the evaluation design (i.e. the account of what was planned, done and why) should be included, at least in summary form or as an appendix, in the document which presents the main findings. If this is not done, the omission should be justified and a reference or link to the evaluation	Y	April 16, 2024 by guest. Protected by copyright	

Page 2	27 of	34
--------	-------	----

		BMJ Open		njopen-2	
				2019-03	
		design given. It may also be useful to publish or make freely available (e.g. online on a website) any original evaluation design document or protocol, where they exist		omjopen-2019-033208 on 25 February 2020. 9-11	
	Data collection methods	Describe and justify the data collection methods – which ones were used, why and how they fed into developing, supporting, refuting or refining programme theory Provide details of the steps taken to enhance the trustworthiness of data collection and documentation	Y	9-11 9-11 9-20. Downloaded from http://bmjopen.bmj.com/ on April 16,	
	Recruitment process and sampling strategy	Describe how respondents to the evaluation were recruited or engaged and how the sample contributed to the development, support, refutation or refinement of programme theory	Ŷ	2024	Sampling of sites, rather than individuals, is described; Recruitment will t described when reporting the resu of the study
13	Data analysis	Describe in detail how data were analysed. This section should include information on the constructs that were identified, the process of	Y	by g8-14 11-12, g8-14	

Page	28	of	34
ruge	20	U,	54

		BMJ Open		mjopen-2019-	
		analysis, how the programme theory was further developed, supported, refuted and refined, and (where relevant) how analysis changed as the evaluation unfolded		omjopen-2019-033208 on 25 February 2020.	
RE	SULTS				
14	Details of participants	Report (if applicable) who took part in the evaluation, the details of the data they provided and how the data was used to develop, support, refute or refine programme theory	NA	Downloaded from http:/	Protocol so no results to report
15	Main findings	Present the key findings, linking them to contexts, mechanisms and outcome configurations. Show how they were used to further develop, test or refine the programme theory	NA	//bmjopen.bmj.com/ on	Protocol so no results to report
DIS	SCUSSION		0	n Apri	
16	Summary of findings	Summarise the main findings with attention to the evaluation questions, purpose of the evaluation, programme theory and intended audience	NA	16, 2024 by gu	Protocol so no results to report
17	Strengths, limitations and future directions	Discuss both the strengths of the evaluation and its limitations. These should include (but need not be	4	est. Protected by copyright	Strengths and limitations of study design

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

		BMJ Open			ven-2019-	
		limited to): (1) consideration of all the			omjopen-2019-033208 on 25	
		steps in the evaluation processes; and (2) comment on the adequacy,			25 Feb	
		trustworthiness and value of the explanatory insights which emerged			oruary 20	
		In many evaluations, there will be an			20. Dov	
		expectation to provide guidance on future directions for the programme,			vnloade	
		policy or initiative, its implementation and/or design. The particular			d from t	
		implications arising from the realist			http://br	
		nature of the findings should be reflected in these discussions			njopen.l	
18	Comparison with existing literature	Where appropriate, compare and contrast the evaluation's findings with the existing literature on similar programmes, policies or initiatives	NA	57	February 2020. Downloaded from http://bmjopen.bmj.com/ on April .	Protocol so no results to compar- with existing literature
19	Conclusion and recommendations	List the main conclusions that are justified by the analyses of the data. If appropriate, offer recommendations consistent with a realist approach	NA	7	16, 2024 by guest.	Protocol so no results on which t base recommendations
20	Funding and conflict of interest	State the funding source (if any) for the evaluation, the role played by the	Y	16	Protected	
	·	· · · · · · · · · · · · · · · · · · ·		·	d by copyright	

BMJ Open	omjopen-2	
funder (if any) and any conflicts of	omjopen-2019-033208 on]
interests of the evaluators	8 on 2	
For peer review only - http://bmjopen.bmj.com/	25 February 2020. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright.	

3 4

24

BMJ Open How, in what contexts, and why do quality dashboards lead to improvements in care quality in acute hospitals? Protocol for a realist feasibility evaluation (Randell et al.) Additional file 2

1.				echanism 25		=	Outcome
1.			Resource	Response			
	Teams previously constrained in their	+	QualDash offers easy access to	Teams are able to see whether	er the	=	Improvement in data
	ability to use NCA data for monitoring		key metrics	data displayed are timely, a	urate,		quality in terms of
	service performance because data not			and/or complete and, where the	ney are		timeliness, accuracy,
	considered to be timely, accurate, and/or			not, adjust their data collect	า		completeness – as da
	complete			processes in order to benet fi	rom		quality improves, use
				QualDash 5			QualDash increases
				Teams use QualDash to engle	ed NCA	=	Increased routine use
				data within their monitoring	ocesses		NCA data in performa
				e.g. in clinical governance	etings		monitoring, providing
				where data is presented visua	ally via		opportunities for its u
				screens.			quality improvement
2.	Teams previously using NCA data to	+	QualDash visualises key	Teams use QualDash to fagilit	tate their	=	Reduced time spent
	monitor service performance routinely by		metrics in ways that clearly	existing processes for monigor	ring		accessing, and prepa
	extracting raw data and producing		show whether service	service performance using	CA data		visualisations of, NC
	reports for review in meetings and by		performance is within an	16,			data
	individuals		expected range and provides	2024 by			
			functions to interrogate that data	4 by			
				guest.			
				t. Pr			
				otect			
				Protected by copyright			
				ý co			
				pyrig			
			/iew only - http://bmjopen.bmj.com/s	-			

Page 32 of 34

3 4

24

			BMJ Open		miopen-		Page 32
#	Context	+	M	echanism	2019	=	Outcome
			Resource	Response	9-03		
3.	Teams who want to use NCA data but	+	QualDash provides functions	Teams will use these funct	Bens to	=	Introduction of QI
	were previously constrained by data		that enable users to interact	interrogate anomalies in the	gdata,		initiatives in relation to
	quality and existing systems did not		with NCA data and explore	which will help them to und	erstand		metrics that teams
	provide functions to easily access and		relationships between variables	what has impacted perform	gince,		consider important and
	interact with the data			thereby enabling them to id	entify		where performance is not
				appropriate strategies for ir	proving		in line with expectations
				performance	0 0		
					Downloaded		Over time, improvement in
					oade		metrics that QI initiatives
					ed fro		target
4.	Performance in key metrics, such as the	+	QualDash offers teams the	Teams add new QualCards	to be able	=	Introduction of QI
	Best Practice Tariff, is in line with		ability to quickly and easily add	to monitor and interrogate	etrics they		initiatives in relation to
	expectations		new QualCards (within NCA	have chosen as important	/bmi		metrics shown on new
			parameters)		oper		QualCards when
	Relevant audit/IT support staff have time						performance is not in line
	and willingness to support use of						with expectations
	QualDash				n or		
				O_{h}	Ap		Over time, improvement in
							metrics that QI initiatives
					. 2024		target
					lest.		
					Pro		
					ecte		
					p D		
					by quest. Protected by copyright.		2
					-		

Page	33	of	34
------	----	----	----

3 4

33 34

44 45

BMJ Open

Resource Response Performance is not in line with expectations in key metrics AualDash provides quick and easy access to key metrics Teams will become aware of discrepancies between performance and targets in key metrics. Introduction of initiatives in remetrics 6. Teams are resourced to make practice changes + QualDash offers easy access to NCA annual report Teams will use QualDash to produce reports and other groups about service performance, e.g. at the time of publication of NCA annual report + QualDash offers easy access to the service output to produce reports and other groups + QualDash offers easy access to the groups Teams will use QualDash to produce reports requeated by other groups = Reduced time reports requeated by other groups = Reduced time reports requeated by other groups = Reduced time reports requeated by other groups = Increased use output produce reports requeated by other groups = Reduced time report prepara other groups = Increased use output produce reports requeated by other groups = Increased use output produce reports requeated by other groups = Increased use output produce reports requeated by other groups = Increased use output produce ou		Co	ntext	+	N	echanism	omjopen-201	=	Outcome
 5. Teams who previously did not, or were not able to, monitor key metrics routinely not able to, monitor key metrics routinely Performance is not in line with expectations in key metrics Teams are resourced to make practice changes 6. Teams are asked to produce reports and other groups about service performance, e.g. at the time of publication of NCA annual report Can the time of publication of NCA annual report Can the time of publication of NCA annual report Can the time of publication of NCA annual report 					Resource	Response	9		
 and targets in key metrics, which they metrics Performance is not in line with expectations in key metrics Teams are resourced to make practice changes Teams are asked to produce reports and recommendations for managers and other groups about service performance, e.g. at the time of publication of NCA annual report Teams are not in time of publication of NCA annual report Teams are resourced to make practice changes Teams are asked to produce reports and recommendations for managers and other groups about service performance, e.g. at the time of publication of NCA annual report Teams are of the time of publication of NCA annual report Teams are of the time of publication of NCA annual report Teams are of the time of publication of NCA annual report Teams are of the time of publication of NCA annual report 	Feams who pr	ns who previo	isly did not, or were	+	QualDash provides quick and		()	=	Introduction of QI
Performance is not in line with expectations in key metrics Teams are resourced to make practice changes 6. Teams are asked to produce reports and other groups about service performance, e.g. at the time of publication of NCA annual report	not able to, mo	ble to, monito	key metrics routinely		easy access to key metrics	discrepancies between per	rgermance		initiatives in relation to ke
6. Teams are asked to produce reports and recommendations for managers and other groups about service performance, e.g. at the time of publication of NCA annual report reports and annual report reports and that can be exported into that can be exported into the groups and the time of publication of NCA annual report reports and annual report annual r									metrics
 Teams are asked to produce reports and recommendations for managers and other groups about service performance, e.g. at the time of publication of NCA annual report Annual report Comparison of NCA annual rep	Performance i	rmance is not	in line with			will take action to address	ebru		
6. Teams are asked to produce reports and recommendations for managers and other groups about service performance, e.g. at the time of publication of NCA annual report reports and annual report reports and that can be exported into that can be exported into the groups annual report reports and annual report annual report reports annual report reports and and/or corporate leve outputs produce annual report reports and the time of publication of NCA are annual report reports annual report reports annual report reports and annual report reports reports annual report reports repo	expectations in	ctations in key	metrics				lary :		Over time, improvement
 6. Teams are asked to produce reports and recommendations for managers and other groups about service performance, e.g. at the time of publication of NCA annual report 6. Teams will use QualDash to produce reports and other groups about service performance, e.g. at the time of publication of NCA are ports 6. Teams will use QualDash to produce reports requested by other groups about service performance, reports 6. Teams will use QualDash to produce reports requested by other groups 6. Teams will use QualDash to produce reports requested by other groups 6. Teams will use QualDash to produce reports requested by other groups 6. Teams will use QualDash to produce reports requested by other groups 6. Teams will use QualDash to produce reports requested by other groups 6. Teams will use QualDash to produce reports requested by other groups 6. Teams will use QualDash to produce reports requested by other groups 6. Teams will use QualDash to produce reports requested by other groups 6. Teams will use QualDash to produce reports requested by other groups 6. Teams will use QualDash to produce reports requested by other groups 6. Teams will use QualDash to produce reports 							2020		those metrics
6. Teams are asked to produce reports and recommendations for managers and other groups about service performance, e.g. at the time of publication of NCA annual report reports and annual report reports and that can be exported into that can be exported into the groups and the time of publication of NCA annual report reports and annual report annual r	Feams are res	ns are resourc	ed to make practice				 Do		
recommendations for managers and other groups about service performance, e.g. at the time of publication of NCA annual report	changes	ges							
other groups about service performance, that can be exported into other groups e.g. at the time of publication of NCA annual report annual report Over time, use QualDash at d and/or corporat due to increase awareness of l awareness	Feams are asl	ns are asked t	produce reports and	+	QualDash offers easy access to	Teams will use QualDash	to produce	=	Reduced time spent in
e.g. at the time of publication of NCA reports Increased use annual report data at division corporate leve outputs produc QualDash due to increase awareness of l	ecommendati	nmendations	or managers and		NCA data and visualisations	performance reports reque	sted by		report preparation
			-		that can be exported into	other groups	n htt		
	a.g. at the time	it the time of p	ublication of NCA		reports		:р://b		Increased use of NCA
	annual report	al report					mjor		data at divisional and
							ben.t		corporate levels via
							omj.o		outputs produced by
							iom/		QualDash
							on /		
							April		
							16, 2		QualDash at divisional
							2024		and/or corporate levels,
							by g		
							Jues		awareness of NCA data
by by									
ed by							otect		
× ×							ed b		
							V CO		
pyriq							pyrię		

Page 34 of 34

3 4

24

			BMJ Open				Pag
#	Context +	+	Me	echanism	2001	=	Outcome
			Resource	Response	0-03		
7.	Teams receive data requests from +	. C	aualDash can be easily	Service managers will use	gualDash to	=	Streamlines the use of
	service managers	а	ccessed via the web by	access the information they	gneed		NCA data for clinical
		n	nultiple users	quickly and easily	о л П		managers
							Reduced time spent by
					2002r		audit support staff/clinica
				ç	<u>,</u>		team in producing data
							reports for managers
8.	Teams need to evidence their +	. C	ualDash visualises	Teams will use these function	ans to	=	Other Trust groups, who
	performance to managers and other	р	erformance metrics, which can	evidence service performan	€e, in order		are able to offer addition
	groups in order to support a case for	а	lso be exported into reports	to convince other Trust grou	ps that		resource to teams, are
	practice change e.g. in business	а	nd presentations	change is needed	# 		convinced of the need for
	meetings with managers or in the NCA		evie		n//honionen honi nom/ on April 16 2021 hv nue		change based on the
	annual report summary						evidence provided.
					7		However, this is likely to
							be where those outputs
							are clearly associated w
							Trust priorities, e.g.
				=	<u>ר</u> בי		relating to Trust reputati
					202		or avoiding
				4			penalties/gaining
					2		incentives.

How, in what contexts, and why do quality dashboards lead to improvements in care quality in acute hospitals? Protocol for a realist feasibility evaluation (Randell et al.) Additional file 3

The average CMOC for patients on a ward will be averaged for each month, so that there are 36 observations clustered within each of 15 hospitals. Taking the intra-class correlation to be 0.15, this yields a design effect of 6.25. Hence the effective number of observations is 15*36/6.25=86.4. Using Cohen's approach to sample size calculation means an effect size of 0.17 can be estimated with 80% given that there are six parameters in the model (including the coefficient for QualDash). Converting this to the percentage of variation that can be explained by the model, this yields 20.5%. Translating this back to CMOC, currently 49.6% of patients are discharged from hospital without missing any of the nine opportunities for care, and we would be powered at the 80% level to detect an improvement from an average of 8.33 opportunities achieved to 8.46. Thus our study has good power to detect small but meaningful clinical improvements. For PICANet, 10% of the admitted population receive non-invasive ventilation first [1]. On average there are 5.25 ventilation cases per month per hospital. With a further design effect from patients clustered within hospitals, based on the reported intraclass correlation coefficient of 0.065 giving a design effect of 1.276, the actual anticipated number of patients is 1701 giving an effective number of 213: 71 exposed to QualDash and 142 controls. This yields 80% power to detect a change from 32% to 53%.

References

 Morris JV, Ramnarayan P, Parslow RC, Fleming SJ. Outcomes for Children Receiving Noninvasive Ventilation as the First-Line Mode of Mechanical Ventilation at Intensive Care Admission: A Propensity Score-Matched Cohort Study. Crit. Care Med. 2017.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml